<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cik0002079109="http://cik0002079109/20251231"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cik0002079109-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-25</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-24_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <context id="AsOf2025-06-24_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <context id="AsOf2025-06-24_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <context id="From2025-06-252025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-25</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-06-252025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-25</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-06-252025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-25</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-24_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <context id="AsOf2026-02-27_custom_VeraxaBiotechHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-27</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:CapitalReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:OCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:CapitalReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:OCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:CapitalReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:OCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:CapitalReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:OCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:SubscribedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:CapitalReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:OCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:RetainedEarningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">cik0002079109:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FurnitureAndFixturesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ITSystemsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:ITSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:LeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_IndustrialPropertyRightsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:IndustrialPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CapitalizedDevelopmentCostsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:CapitalizedDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TechnologyMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:MachinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:AssetsUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:LeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:MachinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:AssetsUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:LeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:MachinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:AssetsUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:LeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:MachinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:AssetsUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:MachinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:AssetsUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cik0002079109:LeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:GoodwillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:InProcessRAndDFlysinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:TrademarkRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:GoodwillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:InProcessRAndDFlysinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:TrademarkRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:GoodwillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:InProcessRAndDFlysinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:TrademarkRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:GoodwillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:InProcessRAndDFlysinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:TrademarkRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:GoodwillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:InProcessRAndDFlysinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:TrademarkRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cik0002079109:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">cik0002079109:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">cik0002079109:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">cik0002079109:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">cik0002079109:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-01_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-01</instant>
        </period>
    </context>
    <context id="AsOf2025-09-15_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-15</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:SARsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:SARsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:SARsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:SARsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:SARsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:ContingentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:ContingentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:ContingentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:ContingentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">cik0002079109:ContingentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">cik0002079109:Level3OfFairValuesHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_VeraxaBiotechAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002079109</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002079109:VeraxaBiotechAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="CHFShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000004">Veraxa Biotech Holding AG</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0002079109</dei:EntityCentralIndexKey>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-24_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0075"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-24_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0076"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-24_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0077"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareOutstanding
      contextRef="AsOf2025-06-24_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0079"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002079109:InitialContributionOfCapital
      contextRef="From2025-06-252025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0082"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2025-06-252025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0087"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-24_custom_VeraxaBiotechHoldingAGMember"
      id="xdx2ixbrl0119"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0206"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:NotesPayableRelatedParties
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0275"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0290"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0293"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0296"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0368"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0369"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0370"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2025-01-012025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0374"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2025-01-012025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0375"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2025-01-012025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0377"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2025-01-012025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0380"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2025-01-012025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0382"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2025-01-012025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0383"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2025-01-012025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0388"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2025-01-012025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0389"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2025-01-012025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0392"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2025-01-012025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0394"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2025-01-012025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0395"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0410"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0411"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0412"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0416"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0417"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0419"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0424"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0425"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0428"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0430"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0431"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions
      contextRef="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0436"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions
      contextRef="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0437"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions
      contextRef="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0438"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0440"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0442"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0443"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:NonCashLeaseExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0462"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0465"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OthersAssets
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0495"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:DeferredTaxes
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0498"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:ProceedsFromIssuanceOfNotesPayableRelatedParties
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0516"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:PaymentOfPrincipalPortionOfLeaseLiabilities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0519"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:NumberOfVsopSharesCommitments
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0641"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002079109:NumberOfVsopSharesForfeited
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0645"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002079109:NumberOfVsopSharesCancelled
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0647"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0682"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0690"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0692"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0694"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:TransferPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0702"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:TransferPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0704"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:TransferPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0706"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:TransferPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0708"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0714"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0716"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0718"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0728"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0730"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0742"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0750"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0752"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0764"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0790"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0800"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0802"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0814"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2025-01-012025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0824"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0848"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0850"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0860"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0880"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0882"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0884"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0890"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0892"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0896"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0910"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0912"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0914"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0916"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AdditionsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0918"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0920"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0922"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0940"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0942"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0950"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0952"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationDisposals
      contextRef="From2024-01-012024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0960"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationDisposals
      contextRef="From2024-01-012024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0962"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationDisposals
      contextRef="From2024-01-012024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0964"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0970"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0972"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0980"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0982"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0990"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl0992"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1016"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1085"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1086"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AmortizationOfDeferredTaxAssetsDueToDerecognition
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1102"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:AmortizationOfDeferredTaxAssetsDueToDerecognition
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1103"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:EffectsOfLossesForWhichDeferredTaxAssetsWereRecognized
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1111"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:EffectsOfLossesForWhichDeferredTaxAssetsWereRecognized
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1112"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1143"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1144"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1204"
      unitRef="CHF"
      xsi:nil="true"/>
    <cik0002079109:OtherReceivablesRelatedPartyVeraxaBiotechHoldingAg
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1207"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CurrentInterestPayable
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1210"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CurrentPrepayments
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1212"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1264"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1268"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1314"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1317"
      unitRef="CHF"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="xdx2ixbrl1320"
      unitRef="CHF"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000014">F-1</dei:DocumentType>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000015">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000017">Talacker 35</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000018">8001 Zurich</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000019">Switzerland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000020">00000</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000021">+41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000022">44 385 84 50</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000023">Cogency Global Inc.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000024">122 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000025">18th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000026">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000027">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000028">10168</dei:EntityAddressPostalZipCode>
    <dei:CountryRegion
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000029">1</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000030">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000031">221-0102</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000032">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000033">false</dei:EntityExTransitionPeriod>
    <ifrs-full:Cash
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000037"
      unitRef="CHF">101000</ifrs-full:Cash>
    <ifrs-full:Assets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000039"
      unitRef="CHF">101000</ifrs-full:Assets>
    <cik0002079109:AccruedExpenses
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000043"
      unitRef="CHF">18000</cik0002079109:AccruedExpenses>
    <cik0002079109:DueToRelatedParty
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000045"
      unitRef="CHF">8856</cik0002079109:DueToRelatedParty>
    <cik0002079109:AdvancesrelatedParties
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000047"
      unitRef="CHF">1000</cik0002079109:AdvancesrelatedParties>
    <ifrs-full:Liabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000049"
      unitRef="CHF">27856</ifrs-full:Liabilities>
    <cik0002079109:SubscribedCapital
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000053"
      unitRef="CHF">100000</cik0002079109:SubscribedCapital>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000055"
      unitRef="CHF">-26856</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000057"
      unitRef="CHF">73144</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000059"
      unitRef="CHF">101000</ifrs-full:EquityAndLiabilities>
    <cik0002079109:FormationExpenses
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000061"
      unitRef="CHF">18000</cik0002079109:FormationExpenses>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000063"
      unitRef="CHF">8856</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLoss
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000065"
      unitRef="CHF">-26856</ifrs-full:ProfitLoss>
    <cik0002079109:WeightedaverageSharesOutstandingBasic
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000067"
      unitRef="Shares">100000</cik0002079109:WeightedaverageSharesOutstandingBasic>
    <cik0002079109:WeightedaverageSharesOutstandingDiluted
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000069"
      unitRef="Shares">100000</cik0002079109:WeightedaverageSharesOutstandingDiluted>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000071"
      unitRef="CHFShares">-0.27</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000073"
      unitRef="CHFShares">-0.27</ifrs-full:DilutedEarningsLossPerShare>
    <cik0002079109:InitialContributionOfCapitalShares
      contextRef="From2025-06-252025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000085"
      unitRef="Shares">100000</cik0002079109:InitialContributionOfCapitalShares>
    <cik0002079109:InitialContributionOfCapital
      contextRef="From2025-06-252025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000081"
      unitRef="CHF">100000</cik0002079109:InitialContributionOfCapital>
    <cik0002079109:InitialContributionOfCapital
      contextRef="From2025-06-252025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000083"
      unitRef="CHF">100000</cik0002079109:InitialContributionOfCapital>
    <ifrs-full:ProfitLoss
      contextRef="From2025-06-252025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000088"
      unitRef="CHF">-26856</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2025-06-252025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000089"
      unitRef="CHF">-26856</ifrs-full:ProfitLoss>
    <cik0002079109:ShareOutstanding
      contextRef="AsOf2025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">100000</cik0002079109:ShareOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000091"
      unitRef="CHF">100000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000092"
      unitRef="CHF">-26856</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000093"
      unitRef="CHF">73144</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000099"
      unitRef="CHF">-26856</ifrs-full:ProfitLoss>
    <cik0002079109:IncreaseDecreaseInAccruedExpenses
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000103"
      unitRef="CHF">18000</cik0002079109:IncreaseDecreaseInAccruedExpenses>
    <cik0002079109:IncreaseDecreaseInDueToRelatedParty
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000105"
      unitRef="CHF">8856</cik0002079109:IncreaseDecreaseInDueToRelatedParty>
    <cik0002079109:IncreaseDecreaseInAdvancesrelatedParties
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000107"
      unitRef="CHF">1000</cik0002079109:IncreaseDecreaseInAdvancesrelatedParties>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000109"
      unitRef="CHF">1000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <cik0002079109:ProceedsFromInitialCapitalContribution
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000113"
      unitRef="CHF">100000</cik0002079109:ProceedsFromInitialCapitalContribution>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000115"
      unitRef="CHF">100000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000117"
      unitRef="CHF">101000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000121"
      unitRef="CHF">101000</ifrs-full:CashAndCashEquivalents>
    <cik0002079109:DescriptionOfOrganizationAndBusinessOperationsTextBlock
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000123">&lt;p id="xdx_80F_ecustom--DescriptionOfOrganizationAndBusinessOperationsTextBlock_z5tbNVNK2GX" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Note 1 &#x2014; &lt;span id="xdx_827_ziDiDMNp7oJ5"&gt;Description of Organization and Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Business Operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Veraxa Biotech Holding AG (the &#x201c;PubCo&#x201d;) is a Swiss Company formed by Voyager Acquisition Corp., a Cayman Islands exempted company (&#x201c;SPAC&#x201d;) on June&#160;25, 2025 (inception). The PubCo has adopted a fiscal year-end of December&#160;31. The PubCo was formed to be the surviving company in connection with a contemplated business combination between Veraxa Biotech AG (the &#x201c;Company&#x201d; or &#x201c;Veraxa&#x201d;) and SPAC, (see Note 3). The PubCo has no principal operations or revenue producing activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DescriptionOfOrganizationAndBusinessOperationsTextBlock>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000125">&lt;p id="xdx_804_eifrs-full--DisclosureOfMaterialAccountingPolicyInformationExplanatory_zjDTEioZI4Y5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Note 2 &#x2014; &lt;span id="xdx_829_zqMDeZ7I98Dh"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84B_ecustom--BasisOfConsolidationExplanatory_zlteNRecnQra" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_869_zesNDmkEQTXl"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These financial statements have been prepared in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), and in the presentation currency CHF, the Company&#x2019;s functional currency. All amounts are in actual CHF unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_840_ecustom--DisclosureUseOfEstimatesExplanatory_ztlJ0BGUCx8i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The preparation of the accompanying financial statements in conformity with IFRS requires management to make certain estimates and assumptions that affect the reported amounts and disclosures of assets during the reporting period. Estimates are adjusted to reflect actual experience when necessary. There were no significant estimates for the period from June&#160;25, 2025 (Inception) to December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_zG0AouXuq9t5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_863_znA2qzj4OYOg"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Cash is comprised of cash on hand and demand deposits which are subject to an insignificant risk of change in value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_zy6toBQ9ukya" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_86A_zEtsKbJB2FLl"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company currently does have any deferred tax assets. The PubCo&#x2019;s management determined that Switzerland is the PubCo&#x2019;s only major tax jurisdiction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84F_ecustom--DisclosureOrdinarySharesExplanatory_zKsHCdSLuIng" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_86C_zn1jvNb0rcsd"&gt;Ordinary shares&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Ordinary shares are classified as equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84B_ecustom--DisclosureLossPerShareExplanatory_zgENg7eSbje8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_861_zpNxDNuwHeNg"&gt;Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The PubCo computes basic loss per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of ordinary shares outstanding for the reporting period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of ordinary share equivalents outstanding. During the periods when they are anti-dilutive, ordinary share equivalents, if any, are not considered in the computation. As of December&#160;31, 2025, there were no anti-dilutive ordinary shares or ordinary share equivalents outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

&lt;p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zv4msLtxgS14" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_866_zE6hexovLki9"&gt;Fair Value measurement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s financial instruments include cash and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_842_ecustom--RecentlyIssuedAccountingStandards_z5zakwv6uN57" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_86E_zLWJtSbbff6j"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Standards, amendments to published standards and interpretations that are not yet effective and have not been early adopted by the Company&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Annual improvements to IFRS Accounting Standards, Volume 11&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Contract Referencing Nature-Dependent Electricity - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 19 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The amendments listed above have been published but are not mandatory and have not been early adopted by the Company. These amendments are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <cik0002079109:BasisOfConsolidationExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000127">&lt;p id="xdx_84B_ecustom--BasisOfConsolidationExplanatory_zlteNRecnQra" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_869_zesNDmkEQTXl"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These financial statements have been prepared in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), and in the presentation currency CHF, the Company&#x2019;s functional currency. All amounts are in actual CHF unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:BasisOfConsolidationExplanatory>
    <cik0002079109:DisclosureUseOfEstimatesExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000129">&lt;p id="xdx_840_ecustom--DisclosureUseOfEstimatesExplanatory_ztlJ0BGUCx8i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The preparation of the accompanying financial statements in conformity with IFRS requires management to make certain estimates and assumptions that affect the reported amounts and disclosures of assets during the reporting period. Estimates are adjusted to reflect actual experience when necessary. There were no significant estimates for the period from June&#160;25, 2025 (Inception) to December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DisclosureUseOfEstimatesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000131">&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_zG0AouXuq9t5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_863_znA2qzj4OYOg"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Cash is comprised of cash on hand and demand deposits which are subject to an insignificant risk of change in value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000133">&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_zy6toBQ9ukya" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_86A_zEtsKbJB2FLl"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company currently does have any deferred tax assets. The PubCo&#x2019;s management determined that Switzerland is the PubCo&#x2019;s only major tax jurisdiction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <cik0002079109:DisclosureOrdinarySharesExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000135">&lt;p id="xdx_84F_ecustom--DisclosureOrdinarySharesExplanatory_zKsHCdSLuIng" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_86C_zn1jvNb0rcsd"&gt;Ordinary shares&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Ordinary shares are classified as equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DisclosureOrdinarySharesExplanatory>
    <cik0002079109:DisclosureLossPerShareExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000137">&lt;p id="xdx_84B_ecustom--DisclosureLossPerShareExplanatory_zgENg7eSbje8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_861_zpNxDNuwHeNg"&gt;Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The PubCo computes basic loss per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of ordinary shares outstanding for the reporting period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of ordinary share equivalents outstanding. During the periods when they are anti-dilutive, ordinary share equivalents, if any, are not considered in the computation. As of December&#160;31, 2025, there were no anti-dilutive ordinary shares or ordinary share equivalents outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</cik0002079109:DisclosureLossPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000140">&lt;p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zv4msLtxgS14" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_866_zE6hexovLki9"&gt;Fair Value measurement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s financial instruments include cash and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <cik0002079109:RecentlyIssuedAccountingStandards
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000142">&lt;p id="xdx_842_ecustom--RecentlyIssuedAccountingStandards_z5zakwv6uN57" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span id="xdx_86E_zLWJtSbbff6j"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Standards, amendments to published standards and interpretations that are not yet effective and have not been early adopted by the Company&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Annual improvements to IFRS Accounting Standards, Volume 11&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Contract Referencing Nature-Dependent Electricity - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 19 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The amendments listed above have been published but are not mandatory and have not been early adopted by the Company. These amendments are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:RecentlyIssuedAccountingStandards>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000144">&lt;p id="xdx_80A_eifrs-full--DisclosureOfRelatedPartyExplanatory_zvyuYhZOIQz6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Note 3 &#x2014; &lt;span id="xdx_823_zcgKVThrDIoj"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Due to related party&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;During 2025, the Company incurred CHF &lt;span id="xdx_90F_eifrs-full--GeneralAndAdministrativeExpense_pp0d_c20250625__20251231_zrBzGtMy7vdg" title="General and administrative expenses"&gt;8,856&lt;/span&gt; of expenses that were paid for by a related party. These expenses were for general operating expenses of the entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Advances &#x2013; Related party&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Since inception, the PubCo has received advances from its sole member of CHF &lt;span id="xdx_90E_ecustom--OverpaymentOfInitialCapitalContribution_iI_c20250625__20251231_zkBEztEdGTKl" title="Overpayment of the initial capital contribution"&gt;1,000&lt;/span&gt; as an overpayment of the initial capital contribution. These amounts are interest free and due on demand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Business Combination&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On April&#160;22, 2025, Voyager Acquisition Corp., a Cayman Islands exempted company (&#x201c;SPAC&#x201d;), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#x201c;Business Combination Agreement&#x201d;), with the &#x201c;Company and Oliver Baumann, an individual, solely in his capacity as representative for the Company Shareholders. Pursuant to the terms of the Business Combination Agreement, Voyager Acquisition Sponsor Holdco LLC, a Delaware limited liability company (&#x201c;Sponsor&#x201d;), will form a public limited company organized under the Laws of Switzerland (&#x201c;PubCo&#x201d;), and PubCo will form an exempted company limited by shares incorporated under the laws of the Cayman Islands, to be a direct wholly owned subsidiary of PubCo (&#x201c;Merger Sub&#x201d; and, together with PubCo each, individually, an &#x201c;Acquisition Entity&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Business Combination Agreement provides for, among other things, the following transactions: (i) SPAC will merge with and into Merger Sub, with Merger Sub as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly owned subsidiary of PubCo (the &#x201c;Initial Merger&#x201d;), (ii) as soon as practicable, but not less than twenty-four hours following the completion of the Initial Merger, the Company will merge with and into PubCo, with PubCo as the surviving entity in the merger (the &#x201c;Acquisition Merger&#x201d;). The Initial Merger, the Acquisition Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the &#x201c;Business Combination&#x201d;. The Business Combination was consummated on June 10, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000146"
      unitRef="CHF">8856</ifrs-full:GeneralAndAdministrativeExpense>
    <cik0002079109:OverpaymentOfInitialCapitalContribution
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000149"
      unitRef="CHF">1000</cik0002079109:OverpaymentOfInitialCapitalContribution>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000151">&lt;p id="xdx_806_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zIZURos60HT9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span id="xdx_829_zTE6LjOqBkNk"&gt;Share Capital&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Holders of the PubCo&#x2019;s ordinary shares are entitled to one vote for each share. On June&#160;25, 2025, the PubCo issued &lt;span id="xdx_90F_ecustom--PubcoSharesIssued_c20250625__20251231_zDIjvAzww10j" title="PubCo shares issued"&gt;100,000&lt;/span&gt; ordinary shares, CHF &lt;span id="xdx_901_ecustom--PubcoParValue_c20250625__20251231_zt0sONmp15Ee" title="PubCo par value"&gt;1.00&lt;/span&gt; par value for CHF &lt;span id="xdx_904_ecustom--PubcoValueIssued_c20250625__20251231_zZeQ6aY7oqqd" title="PubCo value issued"&gt;100,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <cik0002079109:PubcoSharesIssued
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">100000</cik0002079109:PubcoSharesIssued>
    <cik0002079109:PubcoParValue
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000155"
      unitRef="CHFShares">1.00</cik0002079109:PubcoParValue>
    <cik0002079109:PubcoValueIssued
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000157"
      unitRef="CHF">100000</cik0002079109:PubcoValueIssued>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      id="Fact000159">&lt;p id="xdx_803_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_zv9BlaDD8Df2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span id="xdx_821_zGEiapVfEDc5"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Subsequent events have been evaluated through June 16, 2026, which represents the date the financial statements were available to be issued, and no events, other than those discussed below, have occurred through that date that would impact the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Corporate Restructuring and Merger&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On February&#160;27, 2026, an Extraordinary General Meeting (EGM) unanimously approved the corporate merger by absorption of Veraxa Biotech AG (VBAG) into Veraxa Biotech Holding AG (VHAG). The merger became effective upon registration in the Zurich commercial register, with retroactive accounting and tax effectiveness from January&#160;1, 2026. Following the merger, VBAG ceased to exist without liquidation, and the surviving entity (VHAG) officially changed its name to Veraxa Biotech AG.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As a result of the absorption, all of VBAG&#x2019;s assets, totaling CHF &lt;span id="xdx_90C_ecustom--AssetsTotaling_iI_c20260227_zu6DJ9wniZag" title="Assets totaling"&gt;73,783,861&lt;/span&gt;, and liabilities, totaling CHF &lt;span id="xdx_90E_ecustom--LiabilitiesTotaling_iI_c20260227_zTSHyNa6CDej" title="Liabilities totaling"&gt;20,108,070&lt;/span&gt;, were transferred to the Company. Independent auditors (BDO AG) confirmed the fairness of the valuation, which was determined using risk-adjusted net present value (DCF), market comparables, and transaction methods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In conjunction with the merger, the Company&#x2019;s statutes were completely revised to reflect a new capital structure and approved option plans. The following capital adjustments were executed:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Share Split:&lt;/b&gt; The Company&#x2019;s initial share capital of CHF &lt;span id="xdx_900_ecustom--InitialShareCapital_c20250625__20251231_zmVFvrlInKT5" title="Initial share capital"&gt;100,000&lt;/span&gt;, previously representing &lt;span id="xdx_905_ecustom--PreviouslyShares_c20250625__20251231_zzeRNYMMPiNd" title="Previously shares"&gt;100,000&lt;/span&gt; shares, was split into &lt;span id="xdx_903_ecustom--ShareSplit_c20250625__20251231_z5efm6JZLbsk" title="Share split"&gt;11,325,000&lt;/span&gt; shares.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Ordinary Capital Increase:&lt;/b&gt; The share capital was further increased by CHF &lt;span id="xdx_905_ecustom--OrdinaryCapitalIncrease_c20250625__20251231_zQGgdRnDYvv4" title="Ordinary capital increase"&gt;1,147,904&lt;/span&gt;, bringing the new total share capital to CHF &lt;span id="xdx_90A_ecustom--NewTotalShareCapital_c20250625__20251231_zTgOKwx4AMRa" title="New total share capital"&gt;1,247,904&lt;/span&gt;.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Share Exchange:&lt;/b&gt; The Company issued &lt;span id="xdx_90D_ecustom--IssuedOfExchangeShares_c20250625__20251231_z0T3JQ1OQG71" title="Issued of exchange shares"&gt;130,000,128&lt;/span&gt; new shares to VBAG shareholders in exchange for &lt;span id="xdx_906_ecustom--ShareholdersInExchangeShares_c20250625__20251231_zpLEA9c9LnPc" title="Shareholders in exchange shares"&gt;14,751,067&lt;/span&gt; VBAG shares, establishing an exchange ratio of &lt;span id="xdx_903_ecustom--ExchangeRatio_c20250625__20251231_zoXtB0S7D1hi" title="Exchange ratio"&gt;8.81293&lt;/span&gt; new shares per VBAG share. No cash compensation or special advantages were granted in this exchange.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Maximum Capital Increase:&lt;/b&gt; Authorization was granted for a maximum capital increase of up to CHF &lt;span id="xdx_90D_ecustom--MaximumCapitalIncrease_c20250625__20251231_z8NVlEZ1JqU4" title="Maximum capital increase"&gt;223,400&lt;/span&gt; through the issuance of up to &lt;span id="xdx_907_ecustom--IssuanceOfNewShares_c20250625__20251231_z89KsKWQvkGc" title="Issuance of new shares"&gt;25,300,050&lt;/span&gt; new shares.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Conditional Capital:&lt;/b&gt; Several tranches totaling over 40 million shares were approved as conditional capital to support future option exercises for shareholders, employees, and advisors. Existing employee option plans (VSOP) from prior to the merger will continue post-merger.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Capital Band:&lt;/b&gt; The Board of Directors is authorized to increase capital up to an additional CHF &lt;span id="xdx_905_ecustom--CapitalBand_iI_c20250625__20251231_zMLn5rj8zQu7" title="Capital Band"&gt;623,952&lt;/span&gt; (maximum &lt;span id="xdx_90C_ecustom--AdditionalShares_iI_c20250625__20251231_zyCNN0fCc3bk" title="Additional shares"&gt;70,662,564&lt;/span&gt; shares) until December&#160;31, 2030.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Concurrent with the restructuring, a new Board of Directors was elected, consisting of Oliver Baumann (Chairman), Warren Hosseinion, Dr. Christoph Antz, Christoph Ziegler, and Marc Gr&#xfc;ninger. BDO AG was elected as the statutory auditor.&lt;/p&gt; 

</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <cik0002079109:AssetsTotaling
      contextRef="AsOf2026-02-27_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000161"
      unitRef="CHF">73783861</cik0002079109:AssetsTotaling>
    <cik0002079109:LiabilitiesTotaling
      contextRef="AsOf2026-02-27_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000163"
      unitRef="CHF">20108070</cik0002079109:LiabilitiesTotaling>
    <cik0002079109:InitialShareCapital
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000166"
      unitRef="CHF">100000</cik0002079109:InitialShareCapital>
    <cik0002079109:PreviouslyShares
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">100000</cik0002079109:PreviouslyShares>
    <cik0002079109:ShareSplit
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">11325000</cik0002079109:ShareSplit>
    <cik0002079109:OrdinaryCapitalIncrease
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000172"
      unitRef="CHF">1147904</cik0002079109:OrdinaryCapitalIncrease>
    <cik0002079109:NewTotalShareCapital
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000174"
      unitRef="CHF">1247904</cik0002079109:NewTotalShareCapital>
    <cik0002079109:IssuedOfExchangeShares
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">130000128</cik0002079109:IssuedOfExchangeShares>
    <cik0002079109:ShareholdersInExchangeShares
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000178"
      unitRef="CHF">14751067</cik0002079109:ShareholdersInExchangeShares>
    <cik0002079109:ExchangeRatio
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000180"
      unitRef="CHFShares">8.81293</cik0002079109:ExchangeRatio>
    <cik0002079109:MaximumCapitalIncrease
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000182"
      unitRef="CHF">223400</cik0002079109:MaximumCapitalIncrease>
    <cik0002079109:IssuanceOfNewShares
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">25300050</cik0002079109:IssuanceOfNewShares>
    <cik0002079109:CapitalBand
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="0"
      id="Fact000186"
      unitRef="CHF">623952</cik0002079109:CapitalBand>
    <cik0002079109:AdditionalShares
      contextRef="From2025-06-252025-12-31_custom_VeraxaBiotechHoldingAGMember"
      decimals="INF"
      id="Fact000188"
      unitRef="Shares">70662564</cik0002079109:AdditionalShares>
    <ifrs-full:OtherPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000193"
      unitRef="CHF">1984977</ifrs-full:OtherPropertyPlantAndEquipment>
    <ifrs-full:OtherPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000194"
      unitRef="CHF">1961792</ifrs-full:OtherPropertyPlantAndEquipment>
    <ifrs-full:Goodwill
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000196"
      unitRef="CHF">22848728</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000197"
      unitRef="CHF">22848728</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000199"
      unitRef="CHF">51907963</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000200"
      unitRef="CHF">53485292</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000202"
      unitRef="CHF">1123395</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000203"
      unitRef="CHF">864486</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000205"
      unitRef="CHF">70718</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000208"
      unitRef="CHF">77935781</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000209"
      unitRef="CHF">79160298</ifrs-full:NoncurrentAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000211"
      unitRef="CHF">1111424</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000212"
      unitRef="CHF">153606</ifrs-full:OtherCurrentFinancialAssets>
    <cik0002079109:OtherReceivablesRelatedParty
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000214"
      unitRef="CHF">58927</cik0002079109:OtherReceivablesRelatedParty>
    <cik0002079109:OtherReceivablesRelatedParty
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000215"
      unitRef="CHF">21268</cik0002079109:OtherReceivablesRelatedParty>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000217"
      unitRef="CHF">100243</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000218"
      unitRef="CHF">68814</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000220"
      unitRef="CHF">1613989</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000221"
      unitRef="CHF">5362638</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000223"
      unitRef="CHF">2884583</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000224"
      unitRef="CHF">5606326</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000226"
      unitRef="CHF">80820364</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000227"
      unitRef="CHF">84766624</ifrs-full:Assets>
    <cik0002079109:ShareCapital
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000235"
      unitRef="CHF">14751067</cik0002079109:ShareCapital>
    <cik0002079109:ShareCapital
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000236"
      unitRef="CHF">14182189</cik0002079109:ShareCapital>
    <ifrs-full:CapitalReserve
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000238"
      unitRef="CHF">68252651</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000239"
      unitRef="CHF">48959480</ifrs-full:CapitalReserve>
    <cik0002079109:OtherReserve
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000241"
      unitRef="CHF">-291525</cik0002079109:OtherReserve>
    <cik0002079109:OtherReserve
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000242"
      unitRef="CHF">-222503</cik0002079109:OtherReserve>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000244"
      unitRef="CHF">-98478340</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000245"
      unitRef="CHF">-31864350</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000247"
      unitRef="CHF">-15766147</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000248"
      unitRef="CHF">31054816</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000250"
      unitRef="CHF">883553</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000251"
      unitRef="CHF">708082</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000253"
      unitRef="CHF">14440732</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000254"
      unitRef="CHF">15165086</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000256"
      unitRef="CHF">2898873</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000257"
      unitRef="CHF">2099705</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <cik0002079109:RemunerationCommitmentsSars
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000259"
      unitRef="CHF">71749543</cik0002079109:RemunerationCommitmentsSars>
    <cik0002079109:RemunerationCommitmentsSars
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000260"
      unitRef="CHF">33192793</cik0002079109:RemunerationCommitmentsSars>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000262"
      unitRef="CHF">89972701</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000263"
      unitRef="CHF">51165666</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000265"
      unitRef="CHF">1390932</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000266"
      unitRef="CHF">488543</ifrs-full:TradeAndOtherCurrentPayables>
    <cik0002079109:AccruedExpenses
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000268"
      unitRef="CHF">2675623</cik0002079109:AccruedExpenses>
    <cik0002079109:AccruedExpenses
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000269"
      unitRef="CHF">1802350</cik0002079109:AccruedExpenses>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000271"
      unitRef="CHF">257095</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000272"
      unitRef="CHF">156403</ifrs-full:CurrentLeaseLiabilities>
    <cik0002079109:NotesPayableRelatedParties
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000274"
      unitRef="CHF">1000000</cik0002079109:NotesPayableRelatedParties>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000277"
      unitRef="CHF">1290160</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000278"
      unitRef="CHF">98846</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000280"
      unitRef="CHF">6613810</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000281"
      unitRef="CHF">2546142</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000283"
      unitRef="CHF">96586511</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000284"
      unitRef="CHF">53711808</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000286"
      unitRef="CHF">80820364</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000287"
      unitRef="CHF">84766624</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000289"
      unitRef="CHF">23426</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000292"
      unitRef="CHF">7965</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000295"
      unitRef="CHF">15461</ifrs-full:GrossProfit>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000298"
      unitRef="CHF">46922232</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000299"
      unitRef="CHF">17095133</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000301"
      unitRef="CHF">10264123</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000302"
      unitRef="CHF">6310608</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000304"
      unitRef="CHF">6948456</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000305"
      unitRef="CHF">3635658</ifrs-full:SalesAndMarketingExpense>
    <cik0002079109:DepreciationAndAmortizationExpenses
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000307"
      unitRef="CHF">2097225</cik0002079109:DepreciationAndAmortizationExpenses>
    <cik0002079109:DepreciationAndAmortizationExpenses
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000308"
      unitRef="CHF">1876482</cik0002079109:DepreciationAndAmortizationExpenses>
    <cik0002079109:OperatingLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000310"
      unitRef="CHF">-66216575</cik0002079109:OperatingLoss>
    <cik0002079109:OperatingLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000311"
      unitRef="CHF">-28917881</cik0002079109:OperatingLoss>
    <cik0002079109:ChangeInFairValueOfContingentLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000313"
      unitRef="CHF">799168</cik0002079109:ChangeInFairValueOfContingentLiabilities>
    <cik0002079109:ChangeInFairValueOfContingentLiabilities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000314"
      unitRef="CHF">474538</cik0002079109:ChangeInFairValueOfContingentLiabilities>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000316"
      unitRef="CHF">-41545</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000317"
      unitRef="CHF">624154</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000319"
      unitRef="CHF">54247</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000320"
      unitRef="CHF">14811</ifrs-full:OtherOperatingIncomeExpense>
    <cik0002079109:FinanceExpenses
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000322"
      unitRef="CHF">3552</cik0002079109:FinanceExpenses>
    <cik0002079109:FinanceExpenses
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000323"
      unitRef="CHF">291</cik0002079109:FinanceExpenses>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000325"
      unitRef="CHF">-67006593</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000326"
      unitRef="CHF">-28753745</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000328"
      unitRef="CHF">-392603</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000329"
      unitRef="CHF">-620774</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000331"
      unitRef="CHF">-66613990</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000332"
      unitRef="CHF">-28132971</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000334"
      unitRef="CHFShares">-4.60</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000336"
      unitRef="CHFShares">-4.60</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000338"
      unitRef="CHFShares">-2.00</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000340"
      unitRef="CHFShares">-2.00</ifrs-full:DilutedEarningsLossPerShare>
    <cik0002079109:WeightedaverageSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000342"
      unitRef="Shares">14474974</cik0002079109:WeightedaverageSharesOutstandingBasic>
    <cik0002079109:WeightedaverageSharesOutstandingDiluted
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000344"
      unitRef="Shares">14474974</cik0002079109:WeightedaverageSharesOutstandingDiluted>
    <cik0002079109:WeightedaverageSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">14051547</cik0002079109:WeightedaverageSharesOutstandingBasic>
    <cik0002079109:WeightedaverageSharesOutstandingDiluted
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">14051547</cik0002079109:WeightedaverageSharesOutstandingDiluted>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000350"
      unitRef="CHF">-66613990</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000351"
      unitRef="CHF">-28132971</ifrs-full:ProfitLoss>
    <cik0002079109:ForeignOperationsCurrencyTranslationDifferences
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000353"
      unitRef="CHF">-69022</cik0002079109:ForeignOperationsCurrencyTranslationDifferences>
    <cik0002079109:ForeignOperationsCurrencyTranslationDifferences
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000354"
      unitRef="CHF">-222503</cik0002079109:ForeignOperationsCurrencyTranslationDifferences>
    <cik0002079109:TotalReclassifiableAmounts
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000356"
      unitRef="CHF">-69022</cik0002079109:TotalReclassifiableAmounts>
    <cik0002079109:TotalReclassifiableAmounts
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000357"
      unitRef="CHF">-222503</cik0002079109:TotalReclassifiableAmounts>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000359"
      unitRef="CHF">-66683012</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000360"
      unitRef="CHF">-28355474</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000362"
      unitRef="CHF">14182189</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000363"
      unitRef="CHF">48959480</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000364"
      unitRef="CHF">-222503</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000365"
      unitRef="CHF">-31864350</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000366"
      unitRef="CHF">31054816</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000371"
      unitRef="CHF">-66613990</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000372"
      unitRef="CHF">-66613990</ifrs-full:ProfitLoss>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2025-01-012025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000376"
      unitRef="CHF">-69022</cik0002079109:OtherResultCurrencyConversion>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2025-01-012025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000378"
      unitRef="CHF">-69022</cik0002079109:OtherResultCurrencyConversion>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2025-01-012025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000381"
      unitRef="CHF">14106551</cik0002079109:ShareBasedCompensationInRelationToEsop>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2025-01-012025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000384"
      unitRef="CHF">14106551</cik0002079109:ShareBasedCompensationInRelationToEsop>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2025-01-012025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000386"
      unitRef="CHF">568878</ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2025-01-012025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000387"
      unitRef="CHF">6288524</ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2025-01-012025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000390"
      unitRef="CHF">6857402</ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2025-01-012025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000393"
      unitRef="CHF">1101904</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2025-01-012025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000396"
      unitRef="CHF">1101904</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000398"
      unitRef="CHF">14751067</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000399"
      unitRef="CHF">68252651</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000400"
      unitRef="CHF">-291525</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000401"
      unitRef="CHF">-98478340</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000402"
      unitRef="CHF">-15766147</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000404"
      unitRef="CHF">13409213</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000405"
      unitRef="CHF">44960451</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000406"
      unitRef="CHF">489459</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000407"
      unitRef="CHF">-3731379</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000408"
      unitRef="CHF">55127744</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000413"
      unitRef="CHF">-28132971</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000414"
      unitRef="CHF">-28132971</ifrs-full:ProfitLoss>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2024-01-012024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000418"
      unitRef="CHF">-711962</cik0002079109:OtherResultCurrencyConversion>
    <cik0002079109:OtherResultCurrencyConversion
      contextRef="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000420"
      unitRef="CHF">-711962</cik0002079109:OtherResultCurrencyConversion>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000422"
      unitRef="CHF">244433</ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000423"
      unitRef="CHF">2398325</ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity>
    <ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity
      contextRef="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000426"
      unitRef="CHF">2642758</ifrs-full:ProceedsFromIssueOfRegulatoryCapitalEquity>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000429"
      unitRef="CHF">2930321</cik0002079109:ShareBasedCompensationInRelationToEsop>
    <cik0002079109:ShareBasedCompensationInRelationToEsop
      contextRef="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000432"
      unitRef="CHF">2930321</cik0002079109:ShareBasedCompensationInRelationToEsop>
    <cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions
      contextRef="From2024-01-012024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000434"
      unitRef="CHF">528543</cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions>
    <cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions
      contextRef="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000435"
      unitRef="CHF">-528543</cik0002079109:ShareCapitalIssuedInConnectionWithAcquisitions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2024-01-012024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000441"
      unitRef="CHF">801074</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2024-01-012024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000444"
      unitRef="CHF">801074</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_SubscribedCapitalMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000446"
      unitRef="CHF">14182189</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_CapitalReservesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000447"
      unitRef="CHF">48959480</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_OCIMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000448"
      unitRef="CHF">-222503</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_RetainedEarningMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000449"
      unitRef="CHF">-31864350</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-12-31_custom_TotalEquityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000450"
      unitRef="CHF">31054816</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000452"
      unitRef="CHF">-66613990</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000453"
      unitRef="CHF">-28132971</ifrs-full:ProfitLoss>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000455"
      unitRef="CHF">1972554</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000456"
      unitRef="CHF">1876482</ifrs-full:DepreciationAndAmortisationExpense>
    <cik0002079109:SharesbasedCompensation
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000458"
      unitRef="CHF">52663301</cik0002079109:SharesbasedCompensation>
    <cik0002079109:SharesbasedCompensation
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000459"
      unitRef="CHF">18328192</cik0002079109:SharesbasedCompensation>
    <cik0002079109:NonCashLeaseExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000461"
      unitRef="CHF">181893</cik0002079109:NonCashLeaseExpense>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000464"
      unitRef="CHF">24105</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <cik0002079109:ChangeInFairValueOfContingentLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000467"
      unitRef="CHF">799168</cik0002079109:ChangeInFairValueOfContingentLiabilities>
    <cik0002079109:ChangeInFairValueOfContingentLiabilities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000468"
      unitRef="CHF">474538</cik0002079109:ChangeInFairValueOfContingentLiabilities>
    <cik0002079109:LossOnDisposalOfAssets
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000470"
      unitRef="CHF">17449</cik0002079109:LossOnDisposalOfAssets>
    <cik0002079109:LossOnDisposalOfAssets
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000471"
      unitRef="CHF">27599</cik0002079109:LossOnDisposalOfAssets>
    <cik0002079109:UnrealizedLossgainOnForeignCurrencyTranslation
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000473"
      unitRef="CHF">76700</cik0002079109:UnrealizedLossgainOnForeignCurrencyTranslation>
    <cik0002079109:UnrealizedLossgainOnForeignCurrencyTranslation
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000474"
      unitRef="CHF">732328</cik0002079109:UnrealizedLossgainOnForeignCurrencyTranslation>
    <cik0002079109:AccountsPayable
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000479"
      unitRef="CHF">-902389</cik0002079109:AccountsPayable>
    <cik0002079109:AccountsPayable
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000480"
      unitRef="CHF">123032</cik0002079109:AccountsPayable>
    <cik0002079109:AccruedExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000482"
      unitRef="CHF">873273</cik0002079109:AccruedExpense>
    <cik0002079109:AccruedExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000483"
      unitRef="CHF">907859</cik0002079109:AccruedExpense>
    <cik0002079109:PrepaidExpensesAndOtherCurrentAssets
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000485"
      unitRef="CHF">31429</cik0002079109:PrepaidExpensesAndOtherCurrentAssets>
    <cik0002079109:PrepaidExpensesAndOtherCurrentAssets
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000486"
      unitRef="CHF">-199459</cik0002079109:PrepaidExpensesAndOtherCurrentAssets>
    <cik0002079109:OtherReceivable
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000488"
      unitRef="CHF">957817</cik0002079109:OtherReceivable>
    <cik0002079109:OtherReceivable
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000489"
      unitRef="CHF">-104155</cik0002079109:OtherReceivable>
    <cik0002079109:OtherReceivableRelatedParty
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000491"
      unitRef="CHF">37659</cik0002079109:OtherReceivableRelatedParty>
    <cik0002079109:OtherReceivableRelatedParty
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000492"
      unitRef="CHF">21268</cik0002079109:OtherReceivableRelatedParty>
    <cik0002079109:OthersAssets
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000494"
      unitRef="CHF">70718</cik0002079109:OthersAssets>
    <cik0002079109:DeferredTaxes
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000497"
      unitRef="CHF">724354</cik0002079109:DeferredTaxes>
    <cik0002079109:OthersCurrentLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000500"
      unitRef="CHF">-1224416</cik0002079109:OthersCurrentLiabilities>
    <cik0002079109:OthersCurrentLiabilities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000501"
      unitRef="CHF">629078</cik0002079109:OthersCurrentLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000503"
      unitRef="CHF">-9902331</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000504"
      unitRef="CHF">-7720393</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000506"
      unitRef="CHF">437176</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000507"
      unitRef="CHF">120877</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000509"
      unitRef="CHF">-437176</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000510"
      unitRef="CHF">-120877</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <cik0002079109:ProceedsFromIssueOfEquityInstrumentsOfCompanyNetOfTransactionCosts
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000512"
      unitRef="CHF">5755498</cik0002079109:ProceedsFromIssueOfEquityInstrumentsOfCompanyNetOfTransactionCosts>
    <cik0002079109:ProceedsFromIssueOfEquityInstrumentsOfCompanyNetOfTransactionCosts
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000513"
      unitRef="CHF">1851685</cik0002079109:ProceedsFromIssueOfEquityInstrumentsOfCompanyNetOfTransactionCosts>
    <cik0002079109:ProceedsFromIssuanceOfNotesPayableRelatedParties
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000515"
      unitRef="CHF">1000000</cik0002079109:ProceedsFromIssuanceOfNotesPayableRelatedParties>
    <cik0002079109:PaymentOfPrincipalPortionOfLeaseLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000518"
      unitRef="CHF">164640</cik0002079109:PaymentOfPrincipalPortionOfLeaseLiabilities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000521"
      unitRef="CHF">6590858</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000522"
      unitRef="CHF">1851685</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000524"
      unitRef="CHF">-3748649</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000525"
      unitRef="CHF">-5989585</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000527"
      unitRef="CHF">5362638</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000528"
      unitRef="CHF">11352223</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000530"
      unitRef="CHF">1613989</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000531"
      unitRef="CHF">5362638</ifrs-full:CashAndCashEquivalents>
    <cik0002079109:InitialRecognitionOfLeaseLiabilityAndRightofuseAsset
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000536"
      unitRef="CHF">440802</cik0002079109:InitialRecognitionOfLeaseLiabilityAndRightofuseAsset>
    <cik0002079109:InitialRecognitionOfLeaseLiabilityAndRightofuseAsset
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000537"
      unitRef="CHF">864486</cik0002079109:InitialRecognitionOfLeaseLiabilityAndRightofuseAsset>
    <cik0002079109:GeneralInformationFunctionalAndPresentationCurrencyTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000539">&lt;p id="xdx_809_ecustom--GeneralInformationFunctionalAndPresentationCurrencyTextBlock_zhAfneLdVULh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;1. &lt;span id="xdx_822_ztzVCaQoPb9k"&gt;General information, functional and presentation currency&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Veraxa Biotech AG (the &#x201c;Company&#x201d;), is a Swiss Company, based in Zurich with a focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (&#x201c;ADC&#x201d;s) and T cell engagers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On February&#160;15, 2021, Araxa Bioscience AG and VeLabs Therapeutics GmbH completed a contribution and merger agreement whereby the technology of ARAXA (technology for the modulation and development of antibodies) was combined with the technology of VeLabs (droplet-based microfluidic screening technology). As part of the contribution, 100% of the shares in both VeLabs and ARAXA were contributed in exchange for 11.5 million shares of the Company. In accordance with IFRS 3 VeLabs was identified as the accounting acquirer based on its activity and size.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On December&#160;29, 2023, the Company acquired all shares in Synimmune GmbH. Synimmune is a spin-off of the Department of Immunology at the University of T&#xfc;bingen, which active in the field of innovative and effective anti-tumor antibodies for the treatment of patients with life-threatening diseases specializing in so-called rare hematopoietic malignancies. The &#x201c;drug candidate&#x201d; is the antibody FLYSIN, which had successfully completed a Phase I clinical trial for the treatment of acute myeloid leukemia (&#x201c;AML&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On April&#160;22, 2025, Voyager Acquisition Corp., a Cayman Islands exempted company (&#x201c;&lt;span style="text-decoration: underline"&gt;SPAC&lt;/span&gt;&#x201d;), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#x201c;&lt;span style="text-decoration: underline"&gt;Business Combination Agreement&lt;/span&gt;&#x201d;), with the &#x201c;&lt;span style="text-decoration: underline"&gt;Company&lt;/span&gt; and Oliver Baumann, an individual, solely in his capacity as representative for the Company Shareholders. Pursuant to the terms of the Business Combination Agreement, Voyager Acquisition Sponsor Holdco LLC, a Delaware limited liability company (&#x201c;&lt;span style="text-decoration: underline"&gt;Sponsor&lt;/span&gt;&#x201d;), will form a public limited company organized under the Laws of Switzerland (&#x201c;&lt;span style="text-decoration: underline"&gt;PubCo&lt;/span&gt;&#x201d;), and PubCo will form an exempted company limited by shares incorporated under the laws of the Cayman Islands, to be a direct wholly owned subsidiary of PubCo (&#x201c;&lt;span style="text-decoration: underline"&gt;Merger Sub&lt;/span&gt;&#x201d; and, together with PubCo each, individually, an &#x201c;&lt;span style="text-decoration: underline"&gt;Acquisition Entity&lt;/span&gt;&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Business Combination Agreement provides for, among other things, the following transactions: (i) SPAC will merge with and into Merger Sub, with Merger Sub as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly owned subsidiary of PubCo (the &#x201c;&lt;span style="text-decoration: underline"&gt;Initial Merger&lt;/span&gt;&#x201d;), (ii) as soon as practicable, but not less than twenty-four hours following the completion of the Initial Merger, the Company will merge with and into PubCo, with PubCo as the surviving entity in the merger (the &#x201c;&lt;span style="text-decoration: underline"&gt;Acquisition Merger&lt;/span&gt;&#x201d;). The Initial Merger, the Acquisition Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the &#x201c;&lt;span style="text-decoration: underline"&gt;Business Combination&lt;/span&gt;&#x201d;. The Business Combination was consummated on June 10, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On May&#160;5, 2025, the Company and OmniAb entered a strategic joint venture to develop a novel bispecific antibody drug conjugate (&#x2018;bsADC&#x2019;) targeting solid tumors. The collaboration combines the Company&#x2019;s proprietary technology with OmniAb&#x2019;s platform to create next-generation cancer therapies. Both companies will jointly own and share future revenues from the resulting bsADC program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The material accounting policies adopted in the preparation of the consolidated financial statements are set out in Note 2. The policies have been consistently applied to all the years presented, unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These consolidated financial statements are presented in CHF, the Company&#x2019;s functional currency. The figures shown in the consolidated financial statements are rounded. As the calculations are made with a greater degree of accuracy, minor rounding errors may occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These financial statements have been prepared in accordance with International Financial Reporting Standards and International Accounting Standards as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;) and Interpretations (collectively IFRS).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The preparation of financial statements in compliance with adopted IFRS requires the use of certain critical accounting estimates. It also requires Company management to exercise judgment in applying the Company&#x2019;s accounting policies. The areas where significant judgments and estimates have been made in preparing the financial statements and their effects are disclosed in the &lt;i&gt;Critical Accounting Estimates and Judgments&lt;/i&gt; section of Note 2.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, which have been completed and authorized for issuance by the Board of Directors of the Company on June 16, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; 

</cik0002079109:GeneralInformationFunctionalAndPresentationCurrencyTextBlock>
    <cik0002079109:DescriptionOfNatureAndAmountOfChangesInAccountingEstimate
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000542">&lt;p id="xdx_804_ecustom--DescriptionOfNatureAndAmountOfChangesInAccountingEstimate_zRlW7lM7Jdb1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2. &lt;span id="xdx_828_za5XpAU5iTB7"&gt;Summary of material accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84F_ecustom--BasisOfConsolidationExplanatory_zuf68999Aj1d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_zMPqMi2x5dnl"&gt;Basis of consolidation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s consolidated financial statements consist of the financial statements of wholly owned subsidiaries Veraxa Biotech AG, Veraxa Biotech GmbH and Synimmune GmbH (the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company controls another Company if it:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;can exercise control over the investee,&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;is exposed to fluctuating returns from its investment, and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;can influence returns due to their power of disposal.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Control over subsidiaries is derived without exception from holding the majority of voting rights in the companies concerned. Subsidiaries are consolidated for the first time at the time of acquisition. This is the date on which the Company obtains control over the subsidiary. Subsidiaries are deconsolidated if control is lost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Subsidiaries are consolidated for the first time using the acquisition method. It involves measuring the assets acquired and liabilities assumed from the Company at their fair value at the time of acquisition. The acquisition costs of the acquisition correspond to the fair value of the consideration given. If the cost of the acquisition exceeds the fair value of the identified assets and liabilities, the Company recognizes goodwill.&lt;/p&gt; 

 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;All intra-group transactions, balances and unrealized gains on transactions between Company companies are eliminated on consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84C_ecustom--LiquidityAndGoingConcernExplanatory_zZPCrmbehwtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_z9AhlCueGAl9"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Historically, the Company&#x2019;s primary sources of liquidity have been cash flows from private fundraising offerings from related parties or other investors and other financing activities to fund operations. For the years ended December&#160;31, 2025 and 2024, the Company reported operating losses of CHF &lt;span id="xdx_901_eifrs-full--ProfitLoss_iN_di_c20250101__20251231_z7G8KiWqEyXk"&gt;66,613,990&lt;/span&gt; and CHF &lt;span id="xdx_905_eifrs-full--ProfitLoss_iN_di_c20240101__20241231_zSndc0LaT968"&gt;28,132,971&lt;/span&gt;, respectively, and negative cash flows used in operations of CHF &lt;span id="xdx_905_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_di_c20250101__20251231_z46E4twxL7uf"&gt;9,902,331&lt;/span&gt; and CHF &lt;span id="xdx_903_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_di_c20240101__20241231_zUhD1gdI9I6"&gt;7,720,393&lt;/span&gt;, respectively. As of December&#160;31, 2025, the Company had an aggregate unrestricted cash balance of CHF &lt;span id="xdx_909_eifrs-full--CashAndCashEquivalents_iI_c20251231_zbwtpN6gpOmh"&gt;1,613,989&lt;/span&gt; a net working capital deficit of CHF &lt;span id="xdx_908_ecustom--WorkingCapitalDeficit_iI_c20251231_z0iEMEOQTDl3" title="Working capital deficit"&gt;3,729,227&lt;/span&gt;, and accumulated deficit of CHF &lt;span id="xdx_906_eifrs-full--RetainedEarnings_iNI_di_c20251231_z87X2ZXj4Et1"&gt;98,478,340&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s future capital requirements will depend on many factors, including the timing and extent of spending to support further sales and marketing, and research and development efforts. In order to finance these opportunities, the Company will need to raise additional financing. While there can be no assurances, the Company intends to raise such capital through additional equity or debt fundraising activities. If additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to the Company or at all. If the Company is unable to raise additional capital when desired, the Company&#x2019;s business, results of operations and financial condition would be materially and adversely affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Subsequent to December 31, 2025, on May 27, 2026, PubCo and the Company entered into a senior secured financing arrangement with High Trail Capital (&#x201c;HTC&#x201d;), pursuant to which they issued a senior secured note in the aggregate principal amount of $27.5 million and a related warrant (the &#x201c;HTC Financing&#x201d;). The HTC Financing closed on June 15, 2026, and the Company received the related funding proceeds concurrently with the closing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Also on May 27, 2026, Voyager, PubCo and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a purchase agreement and related registration rights agreement (collectively, the &#x201c;LPC Agreements&#x201d;), pursuant to which Lincoln Park committed, subject to certain conditions and limitations, to purchase up to an aggregate of $50.0 million of PubCo Ordinary Shares over a 24-month period at market-based purchase prices (the &#x201c;LPC Financing&#x201d;). The LPC Financing provides PubCo with the ability to access additional capital at its discretion, subject to the terms of the LPC Agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the above, in connection with the Company&#x2019;s assessment of going concern considerations in accordance with IAS 1, management has considered the Company&#x2019;s liquidity condition together with the cash proceeds received from, and access to capital provided by, the HTC Financing described above, which closed subsequent to December 31, 2025. Based on this assessment, management has concluded that the Company has sufficient liquidity to fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zRzM5r0CnHK2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_868_zp3V7ohtEEV"&gt;Foreign Currency Transactions and Translation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The annual financial statements of the fully consolidated subsidiaries whose functional currency is not the Swiss franc are translated into the Company reporting currency, the Swiss franc, using the modified closing rate method. Assets and liabilities are translated at the exchange rate on the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income statement items are translated at the average exchange rate for the year. Equity components are translated at historical rates at the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The currency translation differences are recognized in other comprehensive income. The currency difference resulting from the translation is recognized in other comprehensive income. The cumulative currency translation differences recognized in other reserves are released to profit or loss when Company companies are deconsolidated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s reporting currency is CHF.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2025, the conversion rates between CHF and Euro used were 0.93703 Annual average exchange rate (translation of income and expenses) and 0.93050 Year-end exchange rate (translation of assets and liabilities).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2024, the conversion rates between CHF and Euro used were 0.95238 Annual average exchange rate (translation of income and expenses) and 0.93845 Year-end exchange rate (translation of assets and liabilities).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zqM0dOkBNZa9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86F_zhDYXl6mWI03"&gt;Fair value measurement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, other receivables, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

&lt;p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_zfKGIGJ41G8c" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_z9FCZ0Djhqf2"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Cash and cash equivalents comprise cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z9IvmxzGfvPj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zp8pfsprpfc8"&gt;Property, plant and equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The office and business equipment and IT systems recognized under property, plant and equipment are reported at acquisition or production cost less accumulated depreciation and recognized impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation is calculated using the straight-line method over a useful life of 3-20 years. The expected useful lives, residual values and depreciation methods are reviewed at each reporting date and all necessary changes in estimates are adjusted by account classification prospectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfStraightLineMethodOverAUsefulLifeTableTextBlock_zntqx7zbLHni" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of material accounting policies (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BF_z1fyrKZY0aDb" style="display: none"&gt;Schedule of straight-line method over a useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Fixed Asset Class&lt;/b&gt;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Applied Useful Life&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; width: 73%; padding-left: 0.125in; text-indent: -0.125in"&gt;Furniture and fixtures&lt;/td&gt;
    &lt;td style="width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; width: 25%"&gt;&lt;span id="xdx_90C_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixturesMember_zfcFxkuRjUFl" title="Amortization Useful life"&gt;3 &#x2013; 8&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IT systems&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITSystemsMember_z8u9NbONpW98" title="Amortization Useful life"&gt;3 &#x2013; 5&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Leasehold improvements (permanently installed laboratory equipment)&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_902_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zBSahEcHMXR8" title="Amortization Useful life"&gt;8 &#x2013; 20&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A0_zBuBCgecvpai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Property, plant and equipment are derecognized at the time of disposal or when they are no longer expected to generate any further economic benefit. The gain or loss resulting from the sale or retirement of an item of property, plant and equipment is determined as the difference between the proceeds from the sale and the carrying amount of the asset and is recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The carrying amount of the Company&#x2019;s plant and equipment are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset&#x2019;s recoverable amount is estimated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_zHMAVK1YDE1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_866_zNyn15AQdnwf"&gt;Intangible assets and Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other intangible assets that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation is calculated using the straight-line method over the estimated useful life. The expected useful lives, residual values and depreciation methods are reviewed at each reporting date and all necessary changes in estimates are taken into account prospectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zYz0JEYudJQ1" style="font: 10pt Times New Roman, Times, serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of material accounting policies (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8BA_zZgsGiwHTmY9" style="display: none"&gt;Schedule of estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Intangible asset class&lt;/b&gt;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Applied Useful Life&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top; width: 73%"&gt;Industrial property rights&lt;/td&gt;
    &lt;td style="width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; width: 25%"&gt;&lt;span id="xdx_901_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--IndustrialPropertyRightsMember_zjiLnHzIX8z5" title="Amortization Useful life"&gt;10 &#x2013; 20&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Capitalized development costs&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--CapitalizedDevelopmentCostsMember_zR6JVdrjwbzi" title="Amortization Useful life"&gt;3 &#x2013; 5 &lt;/span&gt;years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Technology &#x2013; patent protection rights&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TechnologyMember_zocu4V3Bs1U9" title="Amortization Useful life"&gt;20&lt;/span&gt; years, or patent protection period&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A6_zY5xQY3i3ATh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Goodwill is not amortized but is tested for impairment annually at the end of financial year and is allocated to the Company&#x2019;s cash generating units or groups of cash generating units, which represent the lowest level at which goodwill is monitored but where such a level is not larger than an operating segment. Gains and losses on the disposal of an entity include the carrying amount of goodwill related to the entity sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (a &#x201c;CGU&#x201d;). The goodwill acquired in a business combination, for the purpose of impairment testing, is allocated to a CGU that is expected to benefit from the synergies of the combination. If an indication of impairment or reversal of a previous impairment charge exists, an estimate of the recoverable amount of a CGU is calculated based on the greater of its value-in-use (&#x201c;VIU&#x201d;) and its fair value less costs of disposal (&#x201c;FVLCD&#x201d;). An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit (group of units) on a pro rata basis. An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&#x2019;s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Goodwill is carried at cost less any accumulated impairment losses. As of December&#160;31, 2025, and 2024, there is one CGU and there has been no impairment recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_zYrVHJ2sbCL5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_862_zuxp7husaJo9"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income tax expense represents the sum of current tax expense and deferred taxes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Current or deferred taxes are recognized in the consolidated statement of operations unless they relate to items that are recognized either in other comprehensive income or directly in equity. In this case, current and deferred taxes are also recognized in other comprehensive income or directly in equity. Deferred taxes resulting from the first-time recognition of a business combination are recognized as part of the revaluation of the net assets of the acquired Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The current tax expense is calculated on the basis of the taxable income for the year. Taxable income differs from the net loss for the year in the consolidated statement of operations due to expenses and income that are taxable or tax-deductible in later years or never. The Company&#x2019;s liability for current taxes is calculated on the basis of the tax rates applicable or soon to be applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred taxes are recognized for the differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred tax assets are generally recognized for all taxable temporary differences; deferred tax assets are recognized to the extent that it is probable that taxable profits will be available against which the losses from the reversal of deductible temporary differences can be offset. The Company does not recognize deferred tax assets and deferred tax liabilities for temporary differences arising from the initial recognition of goodwill or from a transaction that is not a business combination and, at the time of its initial recognition, affects neither the taxable result nor the result according to IFRS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The carrying amount of deferred tax assets is reviewed each year on the reporting date and reduced in value if it is no longer probable that sufficient taxable income will be available to realize the claim in full or in part.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred tax liabilities and tax assets are calculated on the basis of the expected tax rates and tax laws that are expected to apply at the time the liability is settled or the asset is realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

&lt;p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_zsJzt3VvgL31" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_zWjxSBcYvWub"&gt;Transactions with related parties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company has transactions with related parties (as noted in Note 1). The definition of related parties used is in accordance with IAS 24, Related Party Disclosures. The party which is considered a related party is a person or entity that is related to the entity that is preparing its consolidated financial statements. Key management personnel are identified as the key individuals having authority and responsibility for planning, directing, and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of the Company. The related party status extends to the key management of the subsidiaries to the extent they direct the operations of subsidiaries with minimal involvement from the Company&#x2019;s management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zCmYq2jroQua" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_861_z0Tcbr7EZll6"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Leases are accounted for in accordance with IFRS 16. At contract inception, the Company determines whether an arrangement is or contains a lease by assessing if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Leases include all contracts that transfer the right to use a specified asset for a period of time in exchange for consideration, even if the right-to-use such asset is not explicitly described in the contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company recognizes right-of-use assets as of the commencement date of the lease (i.e.; as of the date on which the underlying asset is available for use by a lessee). Right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment losses and adjusted for any remeasurement of the lease liability. The right-of-use asset corresponds to the amount of the initial measurement of the lease liability, the initial direct costs incurred and the lease payments made at or before the commencement date, less any lease incentives received and the estimate of costs for dismantling or removing the underlying asset or for restoring the underlying asset or the site on which it is located. The Company&#x2019;s leases primarily include real estate and vehicle contracts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Right-of-use assets are depreciated on a straight-line basis over the useful life of the underlying asset, adjusted for impairments. The useful life of the right-of-use asset is the shorter of the asset&#x2019;s economic useful life or the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;If ownership of the underlying asset transfers to the Company at the end of the lease term or a purchase option is exercised, the depreciation will be calculated based on the expected useful life of the underlying asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On the commencement date, the Company measures the lease liabilities at the present value of the future lease payments. In determining the lease term, extension and termination options are taken into account if it is reasonably certain that they will be exercised or not exercised. The lease payments include fixed payments (including in-substance fixed payments), less any lease incentives receivable, variable lease payments that depend on an index or rate and amounts expected to be payable under residual value guarantees. The lease payments further include the exercise price of a purchase option if the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease if the lease term reflects the Company exercising an option to terminate the lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Variable lease payments, that do not depend on an index or a rate, are recognized in profit or loss in the period in which the event or condition that triggers those payments occurs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As a practical expedient, the Company has elected not to separate non-lease components from lease components, and instead accounts for each lease component and any associated non-lease components as a single lease component.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;When calculating the present value of the lease payments, the Company uses its interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases, the lessee&#x2019;s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Following the commencement date, the amount of the lease liability is increased to reflect interest and reduced to reflect the lease payments made. In addition, the carrying amount of the lease liability is remeasured in the event of changes to the lease term, changes to the lease payments (e.g.; changes in future lease payments as a result of a change in an index or a rate used to determine those payments) or in the event of a change in the assessment of an option to purchase the underlying asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company applies the exemption for short-term leases (i.e.; leases whose term from the commencement date is a maximum of twelve months and which do not include a purchase option) for all asset classes. Lease payments for short- term leases are recognized as an expense on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84C_eifrs-full--DisclosureOfGeneralAndAdministrativeExpenseExplanatory_z5LNP58i6OXl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_865_zFWMROG3p4G2"&gt;General and Administrative expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;General and administrative expenses primarily consist of personnel expenses, professional fees, occupancy costs, depreciation expense, insurance expense, office expenses, security expenses, travel expenses, staff training expenses, utilities expenses, and subscription and dues expenses. Personnel-related costs include stock compensation expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_844_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zge3QDUdIvjd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zuvzVL1GOick"&gt;Research and development expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Research and development costs consist of salary and personnel related costs and third-party costs for the Company&#x2019;s research and development activities. Personnel-related costs include stock compensation expenses. The largest component of third-party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_842_ecustom--SalesAndMarketingExpensesExplanatory_zmnX6TVRmEug" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86E_z4JWQ0JE0jx3"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Sales and marketing expenses primarily consist of personnel expenses. Personnel-related costs include stock compensation expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_84D_ecustom--ShareBasedCompensationShareAppreciationRightsExplanatory_zvkU8uv2DuY" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zsMcVFgwWzN8"&gt;Share-Based Compensation &#x2013; Share Appreciation Rights (&#x201c;SARs&#x201d;)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash-settled share-based compensation benefits, including Virtual Stock Option Plans (VSOPs), Employee Stock Options (ESOPs) and Share Appreciation Rights (SARs), are provided to employees in exchange for the rendering of services. These awards entitle the holder to a future cash payment (or other Company assets) based on the value of the Company&#x2019;s equity instruments and are accounted for as liability-classified share-based payment transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The cost of these liability-classified transactions is recognized as an expense, with a corresponding liability, over the vesting period. The liability is remeasured at fair value at the end of each reporting period and at the date of settlement, with any changes in fair value recognized in profit or loss for the period. The cumulative charge to net loss is calculated based on the fair value of the award at each reporting date, the best estimate of the number of awards that are likely to vest, and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognized over the remaining vesting period, unless the award is forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

&lt;p id="xdx_847_ecustom--CriticalAccountingEstimatesAndJudgmentsExplanatory_zzzjCueTdJwb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_868_z97bHZfUyWFa"&gt;Critical Accounting Estimates and Judgments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;When applying the Company&#x2019;s accounting and valuation methods presented, management must assess facts, make estimates and judgements during the preparation of these consolidated financial statements regarding assumptions about current and future events affecting transactions and balances. These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates. The significant estimates and judgements made have been described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company measures the cost of liability classified share based payment transactions, including contingent liabilities, Virtual Stock Option Plans (VSOPs) and Employee Stock Options (ESOPs) and Employee Stock Options (ESOPs), by reference to the fair value of the equity instruments at the date at which they are granted and each subsequent reporting date. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 13.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zjmANlcFfBOj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86C_zzAGdo2zb07g"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, the Company has determined that it operates as one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;p id="xdx_840_ecustom--NewAndAmendedStandardsAndInterpretationsExplanatory_zeVMaFqpuwzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86F_ztj2EuHxnWS2"&gt;New and amended standards and interpretations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;New standards, amendments to published approved accounting and reporting standards and interpretations which are effective during the year&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company has applied the following standards and amendments for the first time for its annual reporting for the period commencing January&#160;1, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IAS 1, Presentation of Financial Statements - Classification of Liabilities as Current or Non-current&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendment to IFRS 16 Leases: Changes in the illustrative example related to Lease Liability in a Sale and Leaseback&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IAS 21 - Lack of exchangeability&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect the current or future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Standards, amendments to published standards and interpretations that are not yet effective and have not been early adopted by the Company&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Annual improvements to IFRS Accounting Standards, Volume 11&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Contract Referencing Nature-Dependent Electricity - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 19 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The amendments listed above have been published but are not mandatory and have not been early adopted by the Company. These amendments are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DescriptionOfNatureAndAmountOfChangesInAccountingEstimate>
    <cik0002079109:BasisOfConsolidationExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000544">&lt;p id="xdx_84F_ecustom--BasisOfConsolidationExplanatory_zuf68999Aj1d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_zMPqMi2x5dnl"&gt;Basis of consolidation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s consolidated financial statements consist of the financial statements of wholly owned subsidiaries Veraxa Biotech AG, Veraxa Biotech GmbH and Synimmune GmbH (the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company controls another Company if it:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;can exercise control over the investee,&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;is exposed to fluctuating returns from its investment, and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;can influence returns due to their power of disposal.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Control over subsidiaries is derived without exception from holding the majority of voting rights in the companies concerned. Subsidiaries are consolidated for the first time at the time of acquisition. This is the date on which the Company obtains control over the subsidiary. Subsidiaries are deconsolidated if control is lost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Subsidiaries are consolidated for the first time using the acquisition method. It involves measuring the assets acquired and liabilities assumed from the Company at their fair value at the time of acquisition. The acquisition costs of the acquisition correspond to the fair value of the consideration given. If the cost of the acquisition exceeds the fair value of the identified assets and liabilities, the Company recognizes goodwill.&lt;/p&gt; 

 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;All intra-group transactions, balances and unrealized gains on transactions between Company companies are eliminated on consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:BasisOfConsolidationExplanatory>
    <cik0002079109:LiquidityAndGoingConcernExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000548">&lt;p id="xdx_84C_ecustom--LiquidityAndGoingConcernExplanatory_zZPCrmbehwtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_z9AhlCueGAl9"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Historically, the Company&#x2019;s primary sources of liquidity have been cash flows from private fundraising offerings from related parties or other investors and other financing activities to fund operations. For the years ended December&#160;31, 2025 and 2024, the Company reported operating losses of CHF &lt;span id="xdx_901_eifrs-full--ProfitLoss_iN_di_c20250101__20251231_z7G8KiWqEyXk"&gt;66,613,990&lt;/span&gt; and CHF &lt;span id="xdx_905_eifrs-full--ProfitLoss_iN_di_c20240101__20241231_zSndc0LaT968"&gt;28,132,971&lt;/span&gt;, respectively, and negative cash flows used in operations of CHF &lt;span id="xdx_905_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_di_c20250101__20251231_z46E4twxL7uf"&gt;9,902,331&lt;/span&gt; and CHF &lt;span id="xdx_903_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_di_c20240101__20241231_zUhD1gdI9I6"&gt;7,720,393&lt;/span&gt;, respectively. As of December&#160;31, 2025, the Company had an aggregate unrestricted cash balance of CHF &lt;span id="xdx_909_eifrs-full--CashAndCashEquivalents_iI_c20251231_zbwtpN6gpOmh"&gt;1,613,989&lt;/span&gt; a net working capital deficit of CHF &lt;span id="xdx_908_ecustom--WorkingCapitalDeficit_iI_c20251231_z0iEMEOQTDl3" title="Working capital deficit"&gt;3,729,227&lt;/span&gt;, and accumulated deficit of CHF &lt;span id="xdx_906_eifrs-full--RetainedEarnings_iNI_di_c20251231_z87X2ZXj4Et1"&gt;98,478,340&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s future capital requirements will depend on many factors, including the timing and extent of spending to support further sales and marketing, and research and development efforts. In order to finance these opportunities, the Company will need to raise additional financing. While there can be no assurances, the Company intends to raise such capital through additional equity or debt fundraising activities. If additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to the Company or at all. If the Company is unable to raise additional capital when desired, the Company&#x2019;s business, results of operations and financial condition would be materially and adversely affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Subsequent to December 31, 2025, on May 27, 2026, PubCo and the Company entered into a senior secured financing arrangement with High Trail Capital (&#x201c;HTC&#x201d;), pursuant to which they issued a senior secured note in the aggregate principal amount of $27.5 million and a related warrant (the &#x201c;HTC Financing&#x201d;). The HTC Financing closed on June 15, 2026, and the Company received the related funding proceeds concurrently with the closing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Also on May 27, 2026, Voyager, PubCo and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a purchase agreement and related registration rights agreement (collectively, the &#x201c;LPC Agreements&#x201d;), pursuant to which Lincoln Park committed, subject to certain conditions and limitations, to purchase up to an aggregate of $50.0 million of PubCo Ordinary Shares over a 24-month period at market-based purchase prices (the &#x201c;LPC Financing&#x201d;). The LPC Financing provides PubCo with the ability to access additional capital at its discretion, subject to the terms of the LPC Agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the above, in connection with the Company&#x2019;s assessment of going concern considerations in accordance with IAS 1, management has considered the Company&#x2019;s liquidity condition together with the cash proceeds received from, and access to capital provided by, the HTC Financing described above, which closed subsequent to December 31, 2025. Based on this assessment, management has concluded that the Company has sufficient liquidity to fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</cik0002079109:LiquidityAndGoingConcernExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000549"
      unitRef="CHF">-66613990</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000550"
      unitRef="CHF">-28132971</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000551"
      unitRef="CHF">-9902331</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000552"
      unitRef="CHF">-7720393</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000553"
      unitRef="CHF">1613989</ifrs-full:CashAndCashEquivalents>
    <cik0002079109:WorkingCapitalDeficit
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000555"
      unitRef="CHF">3729227</cik0002079109:WorkingCapitalDeficit>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000556"
      unitRef="CHF">-98478340</ifrs-full:RetainedEarnings>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000559">&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zRzM5r0CnHK2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_868_zp3V7ohtEEV"&gt;Foreign Currency Transactions and Translation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The annual financial statements of the fully consolidated subsidiaries whose functional currency is not the Swiss franc are translated into the Company reporting currency, the Swiss franc, using the modified closing rate method. Assets and liabilities are translated at the exchange rate on the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income statement items are translated at the average exchange rate for the year. Equity components are translated at historical rates at the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The currency translation differences are recognized in other comprehensive income. The currency difference resulting from the translation is recognized in other comprehensive income. The cumulative currency translation differences recognized in other reserves are released to profit or loss when Company companies are deconsolidated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s reporting currency is CHF.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2025, the conversion rates between CHF and Euro used were 0.93703 Annual average exchange rate (translation of income and expenses) and 0.93050 Year-end exchange rate (translation of assets and liabilities).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2024, the conversion rates between CHF and Euro used were 0.95238 Annual average exchange rate (translation of income and expenses) and 0.93845 Year-end exchange rate (translation of assets and liabilities).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000561">&lt;p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_zqM0dOkBNZa9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86F_zhDYXl6mWI03"&gt;Fair value measurement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, other receivables, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000564">&lt;p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_zfKGIGJ41G8c" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_z9FCZ0Djhqf2"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Cash and cash equivalents comprise cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000566">&lt;p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z9IvmxzGfvPj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zp8pfsprpfc8"&gt;Property, plant and equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The office and business equipment and IT systems recognized under property, plant and equipment are reported at acquisition or production cost less accumulated depreciation and recognized impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation is calculated using the straight-line method over a useful life of 3-20 years. The expected useful lives, residual values and depreciation methods are reviewed at each reporting date and all necessary changes in estimates are adjusted by account classification prospectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfStraightLineMethodOverAUsefulLifeTableTextBlock_zntqx7zbLHni" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of material accounting policies (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BF_z1fyrKZY0aDb" style="display: none"&gt;Schedule of straight-line method over a useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Fixed Asset Class&lt;/b&gt;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Applied Useful Life&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; width: 73%; padding-left: 0.125in; text-indent: -0.125in"&gt;Furniture and fixtures&lt;/td&gt;
    &lt;td style="width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; width: 25%"&gt;&lt;span id="xdx_90C_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixturesMember_zfcFxkuRjUFl" title="Amortization Useful life"&gt;3 &#x2013; 8&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IT systems&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITSystemsMember_z8u9NbONpW98" title="Amortization Useful life"&gt;3 &#x2013; 5&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Leasehold improvements (permanently installed laboratory equipment)&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_902_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zBSahEcHMXR8" title="Amortization Useful life"&gt;8 &#x2013; 20&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A0_zBuBCgecvpai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Property, plant and equipment are derecognized at the time of disposal or when they are no longer expected to generate any further economic benefit. The gain or loss resulting from the sale or retirement of an item of property, plant and equipment is determined as the difference between the proceeds from the sale and the carrying amount of the asset and is recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The carrying amount of the Company&#x2019;s plant and equipment are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset&#x2019;s recoverable amount is estimated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <cik0002079109:ScheduleOfStraightLineMethodOverAUsefulLifeTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000568">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfStraightLineMethodOverAUsefulLifeTableTextBlock_zntqx7zbLHni" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of material accounting policies (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BF_z1fyrKZY0aDb" style="display: none"&gt;Schedule of straight-line method over a useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Fixed Asset Class&lt;/b&gt;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Applied Useful Life&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; width: 73%; padding-left: 0.125in; text-indent: -0.125in"&gt;Furniture and fixtures&lt;/td&gt;
    &lt;td style="width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; width: 25%"&gt;&lt;span id="xdx_90C_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixturesMember_zfcFxkuRjUFl" title="Amortization Useful life"&gt;3 &#x2013; 8&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IT systems&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITSystemsMember_z8u9NbONpW98" title="Amortization Useful life"&gt;3 &#x2013; 5&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Leasehold improvements (permanently installed laboratory equipment)&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_902_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zBSahEcHMXR8" title="Amortization Useful life"&gt;8 &#x2013; 20&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfStraightLineMethodOverAUsefulLifeTableTextBlock>
    <cik0002079109:AmortizationUsefulLife
      contextRef="From2025-01-012025-12-31_custom_FurnitureAndFixturesMember_custom_VeraxaBiotechAGMember"
      id="Fact000570">3 &#x2013; 8</cik0002079109:AmortizationUsefulLife>
    <cik0002079109:AmortizationUsefulLife
      contextRef="From2025-01-012025-12-31_custom_ITSystemsMember_custom_VeraxaBiotechAGMember"
      id="Fact000572">3 &#x2013; 5</cik0002079109:AmortizationUsefulLife>
    <cik0002079109:AmortizationUsefulLife
      contextRef="From2025-01-012025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      id="Fact000574">8 &#x2013; 20</cik0002079109:AmortizationUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000576">&lt;p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_zHMAVK1YDE1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_866_zNyn15AQdnwf"&gt;Intangible assets and Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other intangible assets that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation is calculated using the straight-line method over the estimated useful life. The expected useful lives, residual values and depreciation methods are reviewed at each reporting date and all necessary changes in estimates are taken into account prospectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zYz0JEYudJQ1" style="font: 10pt Times New Roman, Times, serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of material accounting policies (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8BA_zZgsGiwHTmY9" style="display: none"&gt;Schedule of estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Intangible asset class&lt;/b&gt;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Applied Useful Life&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top; width: 73%"&gt;Industrial property rights&lt;/td&gt;
    &lt;td style="width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; width: 25%"&gt;&lt;span id="xdx_901_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--IndustrialPropertyRightsMember_zjiLnHzIX8z5" title="Amortization Useful life"&gt;10 &#x2013; 20&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Capitalized development costs&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--CapitalizedDevelopmentCostsMember_zR6JVdrjwbzi" title="Amortization Useful life"&gt;3 &#x2013; 5 &lt;/span&gt;years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Technology &#x2013; patent protection rights&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TechnologyMember_zocu4V3Bs1U9" title="Amortization Useful life"&gt;20&lt;/span&gt; years, or patent protection period&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A6_zY5xQY3i3ATh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Goodwill is not amortized but is tested for impairment annually at the end of financial year and is allocated to the Company&#x2019;s cash generating units or groups of cash generating units, which represent the lowest level at which goodwill is monitored but where such a level is not larger than an operating segment. Gains and losses on the disposal of an entity include the carrying amount of goodwill related to the entity sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (a &#x201c;CGU&#x201d;). The goodwill acquired in a business combination, for the purpose of impairment testing, is allocated to a CGU that is expected to benefit from the synergies of the combination. If an indication of impairment or reversal of a previous impairment charge exists, an estimate of the recoverable amount of a CGU is calculated based on the greater of its value-in-use (&#x201c;VIU&#x201d;) and its fair value less costs of disposal (&#x201c;FVLCD&#x201d;). An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit (group of units) on a pro rata basis. An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&#x2019;s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Goodwill is carried at cost less any accumulated impairment losses. As of December&#160;31, 2025, and 2024, there is one CGU and there has been no impairment recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <cik0002079109:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000578">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zYz0JEYudJQ1" style="font: 10pt Times New Roman, Times, serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of material accounting policies (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8BA_zZgsGiwHTmY9" style="display: none"&gt;Schedule of estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Intangible asset class&lt;/b&gt;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Applied Useful Life&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top; width: 73%"&gt;Industrial property rights&lt;/td&gt;
    &lt;td style="width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; width: 25%"&gt;&lt;span id="xdx_901_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--IndustrialPropertyRightsMember_zjiLnHzIX8z5" title="Amortization Useful life"&gt;10 &#x2013; 20&lt;/span&gt; years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Capitalized development costs&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--CapitalizedDevelopmentCostsMember_zR6JVdrjwbzi" title="Amortization Useful life"&gt;3 &#x2013; 5 &lt;/span&gt;years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Technology &#x2013; patent protection rights&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--AmortizationUsefulLife_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--TechnologyMember_zocu4V3Bs1U9" title="Amortization Useful life"&gt;20&lt;/span&gt; years, or patent protection period&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <cik0002079109:AmortizationUsefulLife
      contextRef="From2025-01-012025-12-31_custom_IndustrialPropertyRightsMember_custom_VeraxaBiotechAGMember"
      id="Fact000580">10 &#x2013; 20</cik0002079109:AmortizationUsefulLife>
    <cik0002079109:AmortizationUsefulLife
      contextRef="From2025-01-012025-12-31_custom_CapitalizedDevelopmentCostsMember_custom_VeraxaBiotechAGMember"
      id="Fact000582">3 &#x2013; 5</cik0002079109:AmortizationUsefulLife>
    <cik0002079109:AmortizationUsefulLife
      contextRef="From2025-01-012025-12-31_custom_TechnologyMember_custom_VeraxaBiotechAGMember"
      id="Fact000584">20</cik0002079109:AmortizationUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000587">&lt;p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_zYrVHJ2sbCL5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_862_zuxp7husaJo9"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income tax expense represents the sum of current tax expense and deferred taxes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Current or deferred taxes are recognized in the consolidated statement of operations unless they relate to items that are recognized either in other comprehensive income or directly in equity. In this case, current and deferred taxes are also recognized in other comprehensive income or directly in equity. Deferred taxes resulting from the first-time recognition of a business combination are recognized as part of the revaluation of the net assets of the acquired Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The current tax expense is calculated on the basis of the taxable income for the year. Taxable income differs from the net loss for the year in the consolidated statement of operations due to expenses and income that are taxable or tax-deductible in later years or never. The Company&#x2019;s liability for current taxes is calculated on the basis of the tax rates applicable or soon to be applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred taxes are recognized for the differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred tax assets are generally recognized for all taxable temporary differences; deferred tax assets are recognized to the extent that it is probable that taxable profits will be available against which the losses from the reversal of deductible temporary differences can be offset. The Company does not recognize deferred tax assets and deferred tax liabilities for temporary differences arising from the initial recognition of goodwill or from a transaction that is not a business combination and, at the time of its initial recognition, affects neither the taxable result nor the result according to IFRS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The carrying amount of deferred tax assets is reviewed each year on the reporting date and reduced in value if it is no longer probable that sufficient taxable income will be available to realize the claim in full or in part.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred tax liabilities and tax assets are calculated on the basis of the expected tax rates and tax laws that are expected to apply at the time the liability is settled or the asset is realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000590">&lt;p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_zsJzt3VvgL31" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_zWjxSBcYvWub"&gt;Transactions with related parties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company has transactions with related parties (as noted in Note 1). The definition of related parties used is in accordance with IAS 24, Related Party Disclosures. The party which is considered a related party is a person or entity that is related to the entity that is preparing its consolidated financial statements. Key management personnel are identified as the key individuals having authority and responsibility for planning, directing, and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of the Company. The related party status extends to the key management of the subsidiaries to the extent they direct the operations of subsidiaries with minimal involvement from the Company&#x2019;s management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000592">&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zCmYq2jroQua" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_861_z0Tcbr7EZll6"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Leases are accounted for in accordance with IFRS 16. At contract inception, the Company determines whether an arrangement is or contains a lease by assessing if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Leases include all contracts that transfer the right to use a specified asset for a period of time in exchange for consideration, even if the right-to-use such asset is not explicitly described in the contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company recognizes right-of-use assets as of the commencement date of the lease (i.e.; as of the date on which the underlying asset is available for use by a lessee). Right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment losses and adjusted for any remeasurement of the lease liability. The right-of-use asset corresponds to the amount of the initial measurement of the lease liability, the initial direct costs incurred and the lease payments made at or before the commencement date, less any lease incentives received and the estimate of costs for dismantling or removing the underlying asset or for restoring the underlying asset or the site on which it is located. The Company&#x2019;s leases primarily include real estate and vehicle contracts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Right-of-use assets are depreciated on a straight-line basis over the useful life of the underlying asset, adjusted for impairments. The useful life of the right-of-use asset is the shorter of the asset&#x2019;s economic useful life or the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;If ownership of the underlying asset transfers to the Company at the end of the lease term or a purchase option is exercised, the depreciation will be calculated based on the expected useful life of the underlying asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On the commencement date, the Company measures the lease liabilities at the present value of the future lease payments. In determining the lease term, extension and termination options are taken into account if it is reasonably certain that they will be exercised or not exercised. The lease payments include fixed payments (including in-substance fixed payments), less any lease incentives receivable, variable lease payments that depend on an index or rate and amounts expected to be payable under residual value guarantees. The lease payments further include the exercise price of a purchase option if the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease if the lease term reflects the Company exercising an option to terminate the lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Variable lease payments, that do not depend on an index or a rate, are recognized in profit or loss in the period in which the event or condition that triggers those payments occurs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As a practical expedient, the Company has elected not to separate non-lease components from lease components, and instead accounts for each lease component and any associated non-lease components as a single lease component.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;When calculating the present value of the lease payments, the Company uses its interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases, the lessee&#x2019;s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Following the commencement date, the amount of the lease liability is increased to reflect interest and reduced to reflect the lease payments made. In addition, the carrying amount of the lease liability is remeasured in the event of changes to the lease term, changes to the lease payments (e.g.; changes in future lease payments as a result of a change in an index or a rate used to determine those payments) or in the event of a change in the assessment of an option to purchase the underlying asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company applies the exemption for short-term leases (i.e.; leases whose term from the commencement date is a maximum of twelve months and which do not include a purchase option) for all asset classes. Lease payments for short- term leases are recognized as an expense on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000595">&lt;p id="xdx_84C_eifrs-full--DisclosureOfGeneralAndAdministrativeExpenseExplanatory_z5LNP58i6OXl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_865_zFWMROG3p4G2"&gt;General and Administrative expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;General and administrative expenses primarily consist of personnel expenses, professional fees, occupancy costs, depreciation expense, insurance expense, office expenses, security expenses, travel expenses, staff training expenses, utilities expenses, and subscription and dues expenses. Personnel-related costs include stock compensation expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000597">&lt;p id="xdx_844_eifrs-full--DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_zge3QDUdIvjd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zuvzVL1GOick"&gt;Research and development expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Research and development costs consist of salary and personnel related costs and third-party costs for the Company&#x2019;s research and development activities. Personnel-related costs include stock compensation expenses. The largest component of third-party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <cik0002079109:SalesAndMarketingExpensesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000599">&lt;p id="xdx_842_ecustom--SalesAndMarketingExpensesExplanatory_zmnX6TVRmEug" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86E_z4JWQ0JE0jx3"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Sales and marketing expenses primarily consist of personnel expenses. Personnel-related costs include stock compensation expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:SalesAndMarketingExpensesExplanatory>
    <cik0002079109:ShareBasedCompensationShareAppreciationRightsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000601">&lt;p id="xdx_84D_ecustom--ShareBasedCompensationShareAppreciationRightsExplanatory_zvkU8uv2DuY" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zsMcVFgwWzN8"&gt;Share-Based Compensation &#x2013; Share Appreciation Rights (&#x201c;SARs&#x201d;)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash-settled share-based compensation benefits, including Virtual Stock Option Plans (VSOPs), Employee Stock Options (ESOPs) and Share Appreciation Rights (SARs), are provided to employees in exchange for the rendering of services. These awards entitle the holder to a future cash payment (or other Company assets) based on the value of the Company&#x2019;s equity instruments and are accounted for as liability-classified share-based payment transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The cost of these liability-classified transactions is recognized as an expense, with a corresponding liability, over the vesting period. The liability is remeasured at fair value at the end of each reporting period and at the date of settlement, with any changes in fair value recognized in profit or loss for the period. The cumulative charge to net loss is calculated based on the fair value of the award at each reporting date, the best estimate of the number of awards that are likely to vest, and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognized over the remaining vesting period, unless the award is forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</cik0002079109:ShareBasedCompensationShareAppreciationRightsExplanatory>
    <cik0002079109:CriticalAccountingEstimatesAndJudgmentsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000604">&lt;p id="xdx_847_ecustom--CriticalAccountingEstimatesAndJudgmentsExplanatory_zzzjCueTdJwb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_868_z97bHZfUyWFa"&gt;Critical Accounting Estimates and Judgments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;When applying the Company&#x2019;s accounting and valuation methods presented, management must assess facts, make estimates and judgements during the preparation of these consolidated financial statements regarding assumptions about current and future events affecting transactions and balances. These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates. The significant estimates and judgements made have been described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company measures the cost of liability classified share based payment transactions, including contingent liabilities, Virtual Stock Option Plans (VSOPs) and Employee Stock Options (ESOPs) and Employee Stock Options (ESOPs), by reference to the fair value of the equity instruments at the date at which they are granted and each subsequent reporting date. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 13.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:CriticalAccountingEstimatesAndJudgmentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000606">&lt;p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zjmANlcFfBOj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86C_zzAGdo2zb07g"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, the Company has determined that it operates as one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <cik0002079109:NewAndAmendedStandardsAndInterpretationsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000608">&lt;p id="xdx_840_ecustom--NewAndAmendedStandardsAndInterpretationsExplanatory_zeVMaFqpuwzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;span id="xdx_86F_ztj2EuHxnWS2"&gt;New and amended standards and interpretations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;New standards, amendments to published approved accounting and reporting standards and interpretations which are effective during the year&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company has applied the following standards and amendments for the first time for its annual reporting for the period commencing January&#160;1, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IAS 1, Presentation of Financial Statements - Classification of Liabilities as Current or Non-current&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendment to IFRS 16 Leases: Changes in the illustrative example related to Lease Liability in a Sale and Leaseback&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IAS 7 and IFRS 7: Supplier Finance Arrangements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IAS 21 - Lack of exchangeability&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect the current or future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Standards, amendments to published standards and interpretations that are not yet effective and have not been early adopted by the Company&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Annual improvements to IFRS Accounting Standards, Volume 11&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Contract Referencing Nature-Dependent Electricity - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Amendments to IFRS 19 &#x2013; Presentation and Disclosure in Financial Statements&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The amendments listed above have been published but are not mandatory and have not been early adopted by the Company. These amendments are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:NewAndAmendedStandardsAndInterpretationsExplanatory>
    <cik0002079109:PersonnelExpensesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000611">&lt;p id="xdx_802_ecustom--PersonnelExpensesExplanatory_zKLORq7Xydi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;3. &lt;span id="xdx_82C_zQMtphEsTq8i"&gt;Personnel expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfExpensesForEmployeeBenefitsTableTextBlock_zIjtChy1t503" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Personnel expenses (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B6_zA6YRVVv3UGh" style="display: none"&gt;Schedule of expenses for employee benefits&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20250101__20251231_z7gFZDuL6LRj" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240101__20241231_zbi5xlZOJ3d3" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;years ended&lt;br/&gt;December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--WagesAndSalaries_zHROTo87qcw5" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Salaries&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,342,552&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,106,105&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--Ifrs2SharebasedPaymentOnVirtualOptions_z9Jl56FYY3pi" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IFRS 2 - Share-based payment on virtual options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;38,556,750&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,407,873&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--Ifrs2SharebasedPaymentOnEmployeeStockOptions_zZKOaO7f6bz3" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IFRS 2 - Share-based payment on employee stock options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,106,551&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,920,321&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--SocialExpenses_zYen2ZvKTRJe" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Social expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;744,285&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;458,029&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--OtherExpenseByNature_zZaK9gNmaxB9" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Other personnel expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;77,482&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;156,885&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--OtherGainsLosses_zjSFh3uol1O5" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Total expenses for employee benefits&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,827,620&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,049,213&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A3_zBrzi2o444Ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;During 2021, an employee participation program (share-based cash remuneration based on virtual options &#x201c;VSOP&#x201d;) was adopted. As part of this program, the virtual options vest over a period of 3 years. Similar to vesting, a corresponding personnel expense and a corresponding expense and liability is recognized. The participation program provides for benefits in the event of an exit transaction or in the event of profit distributions. The term of the virtual options is a maximum of 10 years from the date of issue, and the beneficiaries must be in a non-terminated position during the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The below table represents the VSOP share activity as of December&#160;31, 2025 and 2024,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfVSOPShareActivityTableTextBlock_zUSo5nEpiv72" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Personnel expenses (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B3_zlPWXExpJJN9" style="display: none"&gt;Schedule of VSOP share activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding, beginning of the year&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--NumberOfVsopShares_iS_c20250101__20251231_zdtQ2o9TQ23l" style="width: 9%; text-align: right" title="Number of VSOP shares at beginning"&gt;1,228,679&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--NumberOfVsopShares_iS_c20240101__20241231_zjP3CYDCOzW5" style="width: 9%; text-align: right" title="Number of VSOP shares at beginning"&gt;1,267,931&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Commitments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NumberOfVsopSharesCommitments_c20250101__20251231_z6DyBwCtJ6W8" style="text-align: right" title="Number of VSOP shares, commitments"&gt;244,200&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--NumberOfVsopSharesCommitments_c20240101__20241231_zwF3bX59bwva" style="text-align: right" title="Number of VSOP shares, commitments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0641"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--NumberOfVsopSharesForfeited_c20250101__20251231_zcfXKqmCrxIg" style="text-align: right" title="Number of VSOP shares, forfeited"&gt;(50,628&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--NumberOfVsopSharesForfeited_c20240101__20241231_zDkBQZ4K41P2" style="text-align: right" title="Number of VSOP shares, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cancelled&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NumberOfVsopSharesCancelled_c20250101__20251231_zBlvnaeabwS9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of VSOP shares, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--NumberOfVsopSharesCancelled_c20240101__20241231_zVzAzOScOMsc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of VSOP shares, cancelled"&gt;(39,252&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding, end of the year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--NumberOfVsopShares_iE_c20250101__20251231_zRYvtlxtX8G6" style="text-align: right" title="Number of VSOP shares at ending"&gt;1,422,251&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--NumberOfVsopShares_iE_c20240101__20241231_zYkYurrGDGr4" style="text-align: right" title="Number of VSOP shares at ending"&gt;1,228,679&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A6_zihmDMFIh7bc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2025 there were &lt;span id="xdx_90F_ecustom--NumberOfVsopSharesIssued_iI_c20251231_zUZ1UIf89del" title="Number of VSOP shares issued"&gt;995,100&lt;/span&gt; VSOP shares that the Company has committed to issue upon completing various financing milestones.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In September&#160;2021, our board of directors established the Employee Stock Option Plan (&#x201c;ESOP&#x201d;) as a one-off plan pursuant to which select eligible participants are directly allowed to purchase a specific number of common shares at a purchase price determined by the board of directors. For the year ended December&#160;31, 2024, &lt;span id="xdx_90C_eifrs-full--NumberOfSharesIssued_iI_c20241231_zpLlXH0IBWTd" title="Number of shares issued"&gt;140,400&lt;/span&gt; shares were issued to members of management at par value, which were fully paid resulting in proceeds of CHF &lt;span id="xdx_905_eifrs-full--EmployeeBenefitsExpense_c20240101__20241231_zwErporhohvj" title="share based compensation expense"&gt;140,400&lt;/span&gt; and share-based compensation expense of CHF &lt;span id="xdx_90F_eifrs-full--AdministrativeExpense_c20240101__20241231_zEMsBLiKAoD5" title="General and administrative expenses"&gt;2,920,321&lt;/span&gt; recorded in General and administrative expenses. For the year ended December, 31, 2025, &lt;span id="xdx_90D_eifrs-full--NumberOfSharesIssued_iI_c20251231_z4upmrlPMXAi" title="Number of shares issued"&gt;347,452&lt;/span&gt; shares were issued to members of management at par value, which were fully paid resulting in proceeds of CHF &lt;span id="xdx_90E_eifrs-full--EmployeeBenefitsExpense_c20250101__20251231_zcQNqg6PnW2k" title="share based compensation expense"&gt;347,452&lt;/span&gt; and shared-based compensation expense of CHF &lt;span id="xdx_90F_eifrs-full--AdministrativeExpense_c20250101__20251231_zfkglHRFHz1a" title="General and administrative expenses"&gt;14,106,551&lt;/span&gt;. As of December&#160;31, 2025 and 2024, no options were outstanding under the ESOP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</cik0002079109:PersonnelExpensesExplanatory>
    <cik0002079109:ScheduleOfExpensesForEmployeeBenefitsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000613">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfExpensesForEmployeeBenefitsTableTextBlock_zIjtChy1t503" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Personnel expenses (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B6_zA6YRVVv3UGh" style="display: none"&gt;Schedule of expenses for employee benefits&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20250101__20251231_z7gFZDuL6LRj" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240101__20241231_zbi5xlZOJ3d3" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;years ended&lt;br/&gt;December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--WagesAndSalaries_zHROTo87qcw5" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Salaries&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,342,552&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,106,105&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--Ifrs2SharebasedPaymentOnVirtualOptions_z9Jl56FYY3pi" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IFRS 2 - Share-based payment on virtual options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;38,556,750&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,407,873&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--Ifrs2SharebasedPaymentOnEmployeeStockOptions_zZKOaO7f6bz3" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;IFRS 2 - Share-based payment on employee stock options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,106,551&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,920,321&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--SocialExpenses_zYen2ZvKTRJe" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Social expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;744,285&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;458,029&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--OtherExpenseByNature_zZaK9gNmaxB9" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Other personnel expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;77,482&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;156,885&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--OtherGainsLosses_zjSFh3uol1O5" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Total expenses for employee benefits&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,827,620&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,049,213&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfExpensesForEmployeeBenefitsTableTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000615"
      unitRef="CHF">3342552</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000616"
      unitRef="CHF">3106105</ifrs-full:WagesAndSalaries>
    <cik0002079109:Ifrs2SharebasedPaymentOnVirtualOptions
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000618"
      unitRef="CHF">38556750</cik0002079109:Ifrs2SharebasedPaymentOnVirtualOptions>
    <cik0002079109:Ifrs2SharebasedPaymentOnVirtualOptions
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000619"
      unitRef="CHF">15407873</cik0002079109:Ifrs2SharebasedPaymentOnVirtualOptions>
    <cik0002079109:Ifrs2SharebasedPaymentOnEmployeeStockOptions
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000621"
      unitRef="CHF">14106551</cik0002079109:Ifrs2SharebasedPaymentOnEmployeeStockOptions>
    <cik0002079109:Ifrs2SharebasedPaymentOnEmployeeStockOptions
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000622"
      unitRef="CHF">2920321</cik0002079109:Ifrs2SharebasedPaymentOnEmployeeStockOptions>
    <cik0002079109:SocialExpenses
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000624"
      unitRef="CHF">744285</cik0002079109:SocialExpenses>
    <cik0002079109:SocialExpenses
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000625"
      unitRef="CHF">458029</cik0002079109:SocialExpenses>
    <ifrs-full:OtherExpenseByNature
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000627"
      unitRef="CHF">77482</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000628"
      unitRef="CHF">156885</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherGainsLosses
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000630"
      unitRef="CHF">56827620</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000631"
      unitRef="CHF">22049213</ifrs-full:OtherGainsLosses>
    <cik0002079109:ScheduleOfVSOPShareActivityTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000633">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfVSOPShareActivityTableTextBlock_zUSo5nEpiv72" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Personnel expenses (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B3_zlPWXExpJJN9" style="display: none"&gt;Schedule of VSOP share activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding, beginning of the year&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--NumberOfVsopShares_iS_c20250101__20251231_zdtQ2o9TQ23l" style="width: 9%; text-align: right" title="Number of VSOP shares at beginning"&gt;1,228,679&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--NumberOfVsopShares_iS_c20240101__20241231_zjP3CYDCOzW5" style="width: 9%; text-align: right" title="Number of VSOP shares at beginning"&gt;1,267,931&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Commitments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NumberOfVsopSharesCommitments_c20250101__20251231_z6DyBwCtJ6W8" style="text-align: right" title="Number of VSOP shares, commitments"&gt;244,200&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--NumberOfVsopSharesCommitments_c20240101__20241231_zwF3bX59bwva" style="text-align: right" title="Number of VSOP shares, commitments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0641"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--NumberOfVsopSharesForfeited_c20250101__20251231_zcfXKqmCrxIg" style="text-align: right" title="Number of VSOP shares, forfeited"&gt;(50,628&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--NumberOfVsopSharesForfeited_c20240101__20241231_zDkBQZ4K41P2" style="text-align: right" title="Number of VSOP shares, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cancelled&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NumberOfVsopSharesCancelled_c20250101__20251231_zBlvnaeabwS9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of VSOP shares, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--NumberOfVsopSharesCancelled_c20240101__20241231_zVzAzOScOMsc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of VSOP shares, cancelled"&gt;(39,252&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding, end of the year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--NumberOfVsopShares_iE_c20250101__20251231_zRYvtlxtX8G6" style="text-align: right" title="Number of VSOP shares at ending"&gt;1,422,251&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--NumberOfVsopShares_iE_c20240101__20241231_zYkYurrGDGr4" style="text-align: right" title="Number of VSOP shares at ending"&gt;1,228,679&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfVSOPShareActivityTableTextBlock>
    <cik0002079109:NumberOfVsopShares
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">1228679</cik0002079109:NumberOfVsopShares>
    <cik0002079109:NumberOfVsopShares
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000637"
      unitRef="Shares">1267931</cik0002079109:NumberOfVsopShares>
    <cik0002079109:NumberOfVsopSharesCommitments
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">244200</cik0002079109:NumberOfVsopSharesCommitments>
    <cik0002079109:NumberOfVsopSharesForfeited
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">-50628</cik0002079109:NumberOfVsopSharesForfeited>
    <cik0002079109:NumberOfVsopSharesCancelled
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">-39252</cik0002079109:NumberOfVsopSharesCancelled>
    <cik0002079109:NumberOfVsopShares
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000651"
      unitRef="Shares">1422251</cik0002079109:NumberOfVsopShares>
    <cik0002079109:NumberOfVsopShares
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">1228679</cik0002079109:NumberOfVsopShares>
    <cik0002079109:NumberOfVsopSharesIssued
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">995100</cik0002079109:NumberOfVsopSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">140400</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000659"
      unitRef="CHF">140400</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000661"
      unitRef="CHF">2920321</ifrs-full:AdministrativeExpense>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">347452</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000665"
      unitRef="CHF">347452</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000667"
      unitRef="CHF">14106551</ifrs-full:AdministrativeExpense>
    <cik0002079109:DisclosureOfPropertyPlantAndEquipmentsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000670">&lt;p id="xdx_80F_ecustom--DisclosureOfPropertyPlantAndEquipmentsExplanatory_zSfrxlmQkpug" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;4. &lt;span id="xdx_826_zIZRquo0Ocjl"&gt;Property and equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The below table represents the details of the property and equipment as of December&#160;31, 2025 and December&#160;31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zP1dCa57jmr" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and equipment (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B0_z7ARi3tbAof1" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Furniture&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Machines&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Vehicles&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Assets under construction&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Leasehold improvement&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Beginning Cost at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z3dWvwvdKDRe" style="text-align: right" title="Property and equipment, beginning"&gt;635,762&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z1Mwgnt8zyD9" style="text-align: right" title="Property and equipment, beginning"&gt; 2,236,176&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zFtcZgXJUbI1" style="text-align: right" title="Property and equipment, beginning"&gt;2,027&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zYbWfYXYuUD9" style="text-align: right" title="Property and equipment, beginning"&gt;7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zvk57R1UUz5a" style="text-align: right" title="Property and equipment, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0682"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231_zpDD8Pmxvxtd" style="text-align: right" title="Property and equipment, beginning"&gt;2,881,695&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z5O2L1pZ3q65" style="text-align: right" title="Additions"&gt;27,128&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zWah31UrYNhf" style="text-align: right" title="Additions"&gt;93,749&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_znTiGl3FX3Bb" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zaU96lwgzyc4" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zmMLR5Pjsx51" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0694"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231_zobkeNi14Tn9" style="text-align: right" title="Additions"&gt;120,877&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Transfer&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zUhM46jF6G9d" style="text-align: right" title="Transfer"&gt;346&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zcHGLIUdUvpj" style="text-align: right" title="Transfer"&gt;(346&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zpPrVAc8iiZ5" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_z5kHIDNncYlc" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0704"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zFZhrFfOOm08" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransferPropertyAndEquipment_c20240101__20241231_zAqwCIOjJDC2" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0708"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Disposals&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zx2SDUY0t3e5" style="text-align: right" title="Disposals"&gt;(7&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zPdkqYi17zf4" style="text-align: right" title="Additions"&gt;(27,016&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z8U4ETh6FFUe" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zgZM8I42nQrg" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zvgb3NArBFO5" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0718"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231_zYfbTYcgePD8" style="text-align: right" title="Additions"&gt;(27,023&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;FX Effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zkcBEdczl1gd" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;4,991&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z05hUDhiNcbb" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;17,953&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z6EEz0PRPdTj" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;13&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zmXT0o1EOR3e" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0728"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zNCT6qNkbyF" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231_zNTdGGfxB5mk" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;22,957&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Ending Cost at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zYeuz7Fr4yq3" style="text-align: right" title="Property and equipment, beginning"&gt;668,220&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z6rLryBAAQT5" style="text-align: right" title="Property and equipment, beginning"&gt;2,320,516&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zMCJkQ3j6Y93" style="text-align: right" title="Property and equipment, beginning"&gt;2,040&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_z0ssxLTDAdUc" style="text-align: right" title="Property and equipment, beginning"&gt;7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zZEQEKkCmkIh" style="text-align: right" title="Property and equipment, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231_zTWuEVIUpVNc" style="text-align: right" title="Property and equipment, beginning"&gt;2,998,506&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zx2OtDppPRR3" style="text-align: right" title="Additions"&gt;70,817&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zDzr6UJQAkDk" style="text-align: right" title="Additions"&gt;144,835&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zQHCZMB6nbcd" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zoujMa4KSma4" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zLIEJURnu0Vd" style="text-align: right" title="Additions"&gt;221,523&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231_zEbNDSqMNyhg" style="text-align: right" title="Additions"&gt;437,175&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;FX Effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zsL8JcuDOMS" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;2,061&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zfGxthuHP8Sc" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;(7,917&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zfgu8zXjsoti" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;13&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zLQUeaS44fx7" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zUFm5qSxoRh7" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;(13,746&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231_z1QNhvOetgak" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;(19,589&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Ending Cost at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zgb6ax9c5PSk" style="text-align: right" title="Property and equipment, ending"&gt;741,098&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zTuXd4ip38Il" style="text-align: right" title="Property and equipment, ending"&gt;2,457,434&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zY7lw11tVQ4h" style="text-align: right" title="Property and equipment, ending"&gt;2,053&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zpzLifIQCjA5" style="text-align: right" title="Property and equipment, ending"&gt;7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zTfbRzg18as1" style="text-align: right" title="Property and equipment, ending"&gt;207,777&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231_zwUjCkpcBTtc" style="text-align: right" title="Property and equipment, ending"&gt;3,416,092&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Accumulated depreciation&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Balance at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zroPwae1KfWc" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(220,405&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z2SPXwvXdBy3" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(517,674&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zDDoVc5KlqG4" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(1,157&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_ziMf0QCZbcei" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_z7ip0jdkWLG" style="text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231_zawjpcuNVZsh" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(746,966&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Depreciation for the year&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zPCfmCsoWUN4" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(100,948&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z0D96jYIrgJc" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(188,545&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zPbmBQNOiHn3" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(255&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--DepreciationPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zrA7ZTWqnqV9" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--DepreciationPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zn1qDI6QS4p3" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231_z14Nb3uiY0u" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(289,748&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zOT93mUtK6U9" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(321,353&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zrGXRoW9nnr" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(706,219&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z1BgectA9Vq4" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(1,412&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zNVvEWLsIZi7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zWfVfmBRK0Y5" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iNS_di_c20250101__20251231_zMFBUyopn7fk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(1,036,714&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Depreciation for the year&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zLLIaMtdnOKh" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(142,718&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_ztI6cZ3hq828" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(227,677&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_znKjpAPi68Ke" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(270&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--DepreciationPropertyPlantAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zq5iasVwGP0b" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0824"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zQOpGPGKr9Sf" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(23,736&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231_znKnP1qgd4b2" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(394,401&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z05QWfIkNL9k" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(464,071&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zo3rBsywcJxc" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(933,896&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zxlMquwIw8Sa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(1,682&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zijqWARoZ8Xa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zi1xCAt1MR6a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(23,736&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231_zhMCm9AVfwuj" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(1,431,115&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Carrying Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z8dFqtAnElri" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;346,867&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z3TbUIySpTP2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,614,297&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z5qqanf2Cbjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;628&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zLB7lOtzME9j" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zSEV7pZgNVie" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PropertyAndEquipmentNet_iI_c20241231_zyUa5PoFjCw4" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,961,792&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zTC1nXF8mgQ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;277,027&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z1o8XPqgdzUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,523,538&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z5oKy4bY7Uxb" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;371&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zoeZ5YoYjs9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zOCS6HkGrV3d" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;184,041&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--PropertyAndEquipmentNet_iI_c20251231_zakCvE6mn6Dh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,984,977&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A9_zxmgEWKY9Y1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DisclosureOfPropertyPlantAndEquipmentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000672">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zP1dCa57jmr" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and equipment (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B0_z7ARi3tbAof1" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Furniture&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Machines&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Vehicles&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Assets under construction&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Leasehold improvement&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Beginning Cost at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z3dWvwvdKDRe" style="text-align: right" title="Property and equipment, beginning"&gt;635,762&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z1Mwgnt8zyD9" style="text-align: right" title="Property and equipment, beginning"&gt; 2,236,176&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zFtcZgXJUbI1" style="text-align: right" title="Property and equipment, beginning"&gt;2,027&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zYbWfYXYuUD9" style="text-align: right" title="Property and equipment, beginning"&gt;7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zvk57R1UUz5a" style="text-align: right" title="Property and equipment, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0682"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_c20240101__20241231_zpDD8Pmxvxtd" style="text-align: right" title="Property and equipment, beginning"&gt;2,881,695&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z5O2L1pZ3q65" style="text-align: right" title="Additions"&gt;27,128&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zWah31UrYNhf" style="text-align: right" title="Additions"&gt;93,749&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_znTiGl3FX3Bb" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zaU96lwgzyc4" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zmMLR5Pjsx51" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0694"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AdditionsPropertyAndEquipment_c20240101__20241231_zobkeNi14Tn9" style="text-align: right" title="Additions"&gt;120,877&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Transfer&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zUhM46jF6G9d" style="text-align: right" title="Transfer"&gt;346&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zcHGLIUdUvpj" style="text-align: right" title="Transfer"&gt;(346&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zpPrVAc8iiZ5" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_z5kHIDNncYlc" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0704"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--TransferPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zFZhrFfOOm08" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--TransferPropertyAndEquipment_c20240101__20241231_zAqwCIOjJDC2" style="text-align: right" title="Transfer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0708"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Disposals&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zx2SDUY0t3e5" style="text-align: right" title="Disposals"&gt;(7&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zPdkqYi17zf4" style="text-align: right" title="Additions"&gt;(27,016&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z8U4ETh6FFUe" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zgZM8I42nQrg" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zvgb3NArBFO5" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0718"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--DisposalsPropertyPlantAndEquipment_c20240101__20241231_zYfbTYcgePD8" style="text-align: right" title="Additions"&gt;(27,023&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;FX Effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zkcBEdczl1gd" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;4,991&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z05hUDhiNcbb" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;17,953&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z6EEz0PRPdTj" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;13&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zmXT0o1EOR3e" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0728"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zNCT6qNkbyF" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--FXEffectsPropertyAndEquipment_c20240101__20241231_zNTdGGfxB5mk" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;22,957&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Ending Cost at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zYeuz7Fr4yq3" style="text-align: right" title="Property and equipment, beginning"&gt;668,220&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z6rLryBAAQT5" style="text-align: right" title="Property and equipment, beginning"&gt;2,320,516&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zMCJkQ3j6Y93" style="text-align: right" title="Property and equipment, beginning"&gt;2,040&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_z0ssxLTDAdUc" style="text-align: right" title="Property and equipment, beginning"&gt;7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zZEQEKkCmkIh" style="text-align: right" title="Property and equipment, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iS_c20250101__20251231_zTWuEVIUpVNc" style="text-align: right" title="Property and equipment, beginning"&gt;2,998,506&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zx2OtDppPRR3" style="text-align: right" title="Additions"&gt;70,817&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zDzr6UJQAkDk" style="text-align: right" title="Additions"&gt;144,835&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zQHCZMB6nbcd" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zoujMa4KSma4" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zLIEJURnu0Vd" style="text-align: right" title="Additions"&gt;221,523&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AdditionsPropertyAndEquipment_c20250101__20251231_zEbNDSqMNyhg" style="text-align: right" title="Additions"&gt;437,175&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;FX Effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zsL8JcuDOMS" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;2,061&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zfGxthuHP8Sc" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;(7,917&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zfgu8zXjsoti" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;13&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zLQUeaS44fx7" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zUFm5qSxoRh7" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;(13,746&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FXEffectsPropertyAndEquipment_c20250101__20251231_z1QNhvOetgak" style="border-bottom: Black 1pt solid; text-align: right" title="FX Effects"&gt;(19,589&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Ending Cost at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zgb6ax9c5PSk" style="text-align: right" title="Property and equipment, ending"&gt;741,098&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zTuXd4ip38Il" style="text-align: right" title="Property and equipment, ending"&gt;2,457,434&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zY7lw11tVQ4h" style="text-align: right" title="Property and equipment, ending"&gt;2,053&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zpzLifIQCjA5" style="text-align: right" title="Property and equipment, ending"&gt;7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zTfbRzg18as1" style="text-align: right" title="Property and equipment, ending"&gt;207,777&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iE_c20250101__20251231_zwUjCkpcBTtc" style="text-align: right" title="Property and equipment, ending"&gt;3,416,092&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Accumulated depreciation&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Balance at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zroPwae1KfWc" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(220,405&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z2SPXwvXdBy3" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(517,674&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zDDoVc5KlqG4" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(1,157&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_ziMf0QCZbcei" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_z7ip0jdkWLG" style="text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20240101__20241231_zawjpcuNVZsh" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(746,966&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Depreciation for the year&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zPCfmCsoWUN4" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(100,948&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z0D96jYIrgJc" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(188,545&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zPbmBQNOiHn3" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(255&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--DepreciationPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zrA7ZTWqnqV9" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--DepreciationPropertyPlantAndEquipment_c20240101__20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zn1qDI6QS4p3" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20240101__20241231_z14Nb3uiY0u" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(289,748&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zOT93mUtK6U9" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(321,353&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zrGXRoW9nnr" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(706,219&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z1BgectA9Vq4" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(1,412&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zNVvEWLsIZi7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iS_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zWfVfmBRK0Y5" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iNS_di_c20250101__20251231_zMFBUyopn7fk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(1,036,714&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Depreciation for the year&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zLLIaMtdnOKh" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(142,718&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_ztI6cZ3hq828" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(227,677&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_znKjpAPi68Ke" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(270&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--DepreciationPropertyPlantAndEquipment_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zq5iasVwGP0b" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0824"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zQOpGPGKr9Sf" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(23,736&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_di_c20250101__20251231_znKnP1qgd4b2" style="border-bottom: Black 1pt solid; text-align: right" title="Depreciation for the year"&gt;(394,401&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z05QWfIkNL9k" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(464,071&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_zo3rBsywcJxc" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(933,896&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_zxlMquwIw8Sa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(1,682&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zijqWARoZ8Xa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(7,730&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zi1xCAt1MR6a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(23,736&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AccumulatedDepreciationPropertyPlantAndEquipment_iE_c20250101__20251231_zhMCm9AVfwuj" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;(1,431,115&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Carrying Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_z8dFqtAnElri" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;346,867&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z3TbUIySpTP2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,614,297&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z5qqanf2Cbjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;628&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zLB7lOtzME9j" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--PropertyAndEquipmentNet_iI_c20241231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zSEV7pZgNVie" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PropertyAndEquipmentNet_iI_c20241231_zyUa5PoFjCw4" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,961,792&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureMember_zTC1nXF8mgQ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;277,027&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--MachinesMember_z1o8XPqgdzUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,523,538&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--VehicleMember_z5oKy4bY7Uxb" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;371&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AssetsUnderConstructionMember_zoeZ5YoYjs9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PropertyAndEquipmentNet_iI_c20251231__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeaseholdImprovementMember_zOCS6HkGrV3d" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;184,041&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--PropertyAndEquipmentNet_iI_c20251231_zakCvE6mn6Dh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;1,984,977&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000674"
      unitRef="CHF">635762</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000676"
      unitRef="CHF">2236176</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000678"
      unitRef="CHF">2027</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000680"
      unitRef="CHF">7730</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000684"
      unitRef="CHF">2881695</ifrs-full:PropertyPlantAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000686"
      unitRef="CHF">27128</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000688"
      unitRef="CHF">93749</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000696"
      unitRef="CHF">120877</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:TransferPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000698"
      unitRef="CHF">346</cik0002079109:TransferPropertyAndEquipment>
    <cik0002079109:TransferPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000700"
      unitRef="CHF">-346</cik0002079109:TransferPropertyAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000710"
      unitRef="CHF">-7</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000712"
      unitRef="CHF">-27016</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000720"
      unitRef="CHF">-27023</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000722"
      unitRef="CHF">4991</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000724"
      unitRef="CHF">17953</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000726"
      unitRef="CHF">13</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000732"
      unitRef="CHF">22957</cik0002079109:FXEffectsPropertyAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000734"
      unitRef="CHF">668220</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000736"
      unitRef="CHF">2320516</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000738"
      unitRef="CHF">2040</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000740"
      unitRef="CHF">7730</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000744"
      unitRef="CHF">2998506</ifrs-full:PropertyPlantAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000746"
      unitRef="CHF">70817</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000748"
      unitRef="CHF">144835</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000754"
      unitRef="CHF">221523</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:AdditionsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000756"
      unitRef="CHF">437175</cik0002079109:AdditionsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000758"
      unitRef="CHF">2061</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000760"
      unitRef="CHF">-7917</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000762"
      unitRef="CHF">13</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000766"
      unitRef="CHF">-13746</cik0002079109:FXEffectsPropertyAndEquipment>
    <cik0002079109:FXEffectsPropertyAndEquipment
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000768"
      unitRef="CHF">-19589</cik0002079109:FXEffectsPropertyAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000770"
      unitRef="CHF">741098</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000772"
      unitRef="CHF">2457434</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000774"
      unitRef="CHF">2053</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000776"
      unitRef="CHF">7730</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000778"
      unitRef="CHF">207777</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000780"
      unitRef="CHF">3416092</ifrs-full:PropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000782"
      unitRef="CHF">-220405</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000784"
      unitRef="CHF">-517674</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000786"
      unitRef="CHF">-1157</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000788"
      unitRef="CHF">-7730</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000792"
      unitRef="CHF">-746966</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000794"
      unitRef="CHF">100948</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000796"
      unitRef="CHF">188545</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000798"
      unitRef="CHF">255</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000804"
      unitRef="CHF">289748</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000806"
      unitRef="CHF">-321353</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000808"
      unitRef="CHF">-706219</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000810"
      unitRef="CHF">-1412</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000812"
      unitRef="CHF">-7730</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000816"
      unitRef="CHF">1036714</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2025-01-012025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000818"
      unitRef="CHF">142718</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2025-01-012025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000820"
      unitRef="CHF">227677</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2025-01-012025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000822"
      unitRef="CHF">270</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2025-01-012025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000826"
      unitRef="CHF">23736</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000828"
      unitRef="CHF">394401</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000830"
      unitRef="CHF">-464071</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000832"
      unitRef="CHF">-933896</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000834"
      unitRef="CHF">-1682</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_AssetsUnderConstructionMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000836"
      unitRef="CHF">-7730</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000838"
      unitRef="CHF">-23736</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000840"
      unitRef="CHF">-1431115</cik0002079109:AccumulatedDepreciationPropertyPlantAndEquipment>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000842"
      unitRef="CHF">346867</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000844"
      unitRef="CHF">1614297</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000846"
      unitRef="CHF">628</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000852"
      unitRef="CHF">1961792</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_FurnitureMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000854"
      unitRef="CHF">277027</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_MachinesMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000856"
      unitRef="CHF">1523538</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_VehicleMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000858"
      unitRef="CHF">371</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_LeaseholdImprovementMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000862"
      unitRef="CHF">184041</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:PropertyAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000864"
      unitRef="CHF">1984977</cik0002079109:PropertyAndEquipmentNet>
    <cik0002079109:DisclosureOfIntangibleAssetAndGoodwillExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000866">&lt;p id="xdx_801_ecustom--DisclosureOfIntangibleAssetAndGoodwillExplanatory_zSlA0iEwBCdc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;5. &lt;span id="xdx_825_zchnwFxFJJu3"&gt;Intangible assets and goodwill&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The below table represents the details of the intangible assets and goodwill as of December&#160;31, 2025 and December&#160;31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eifrs-full--DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_zuUP287HCRee" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible assets and goodwill (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B5_zUqeLtFdHQqg" style="display: none"&gt;Schedule of intangible assets and goodwill&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;In process R&amp;amp;D (Flysin)&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Trademark rights&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Software&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Beginning Cost at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zYsOsN4uYTx9" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;22,848,728&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zhb6f3cQW3y1" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;28,498,755&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zK2Qh5ozJbQc" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;31,261,245&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zcdPgSe3MP42" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;48,857&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231_zItjybCV4wge" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;82,657,585&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Disposals&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zpPRwCIG2m9g" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zH5ZD3ihi4Pd" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0882"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zxgOGXePOI8f" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zodJL2yyGuwe" style="text-align: right" title="Disposals"&gt;(7,999&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231_zQW92FgkYx85" style="text-align: right" title="Disposals"&gt;(7,999&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;FX effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zc0iiNhGHbLc" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zxqupoFeh0m9" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zXOgbi3q7di8" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;1,272&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_z8FgiHA1eRf6" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231_zpXrtCNPf4Vi" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;1,272&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Ending Cost at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zSzYsD3bFja4" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;22,848,728&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zpJXK7MsRo8j" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;28,498,755&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zbtFDmdmOqxh" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;31,262,517&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zu75rgCcT1y" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;40,858&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231_zDF2hAsTCb1c" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;82,650,858&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zYSawMbOmjA4" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zwfj6qv0TNqh" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zAJU4x7Sopqh" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_z9SSlqmSIby" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231_zPCT87fSgx1k" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;FX effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z9jHkdaKW3Xa" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zyi9lewLYEmf" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zX3DjRZe22nb" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;816&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zz5JYBfVHRB7" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;8&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231_zTE7rFalbrYa" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;824&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Ending Cost at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z7w1extycnP7" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;22,848,728&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zV5AokhgHGea" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;28,498,755&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_z8Rqy48RFc3d" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;31,263,333&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zQishlMxqeV4" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;40,866&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231_zIorjbvbsW13" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;82,651,682&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Accumulated depreciation&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Balance at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z1yV1zdirWXf" style="text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zyt5AbwsBfq7" style="text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zMocEeIKWeu4" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(4,696,411&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zOZosIVIYxDl" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(37,253&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231_zbBn1SpDU1vi" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(4,733,664&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Amortization for the year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zopy8dEqJah6" style="text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zAJFPtvazoBk" style="text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zQiDlVJFyLei" style="text-align: right" title="Amortization for the year"&gt;(1,579,717&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zxbfUxz9AoWh" style="text-align: right" title="Amortization for the year"&gt;(7,597&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231_zGknywfdvTv3" style="text-align: right" title="Amortization for the year"&gt;(1,587,314&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;Disposals&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z0g9FJBy5tB9" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zoC0r2fUXGVi" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_z02ZxF3tpm21" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zAs7dGUVqXBb" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;4,140&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231_zxAI4o9Jeiu1" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;4,140&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zKg9FgdBV7ch" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zhS3U8dzaDgg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0972"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zsozAg7Q36F2" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(6,276,128&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zNSi8UPfqq6b" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(40,710&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231_zwmCMAdw8N7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(6,316,838&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;Amortization for the year&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zNKVmVCHE6H1" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zNBRwPONy0y8" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_ztpp3DfyeO91" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;(1,577,997&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_znfytxv4LHWi" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;(156&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231_z7Mq5yQnZpM6" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;(1,578,153&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z6EkFMLMB004" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zYvH3tAfYPij" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zk9I4xqkfKfc" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt;(7,854,125&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zWd1zOGsaaR7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt; (40,866&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231_zSM84O8nCJjb" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt; (7,894,991&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Carrying Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z6RekLd1Ptfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;22,848,728&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zl8RoP7g4pfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;28,498,755&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zHP058pFong1" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;24,986,389&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zsWPRuwJTGA5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;148&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231_zsXj7aJpA81b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;76,334,020&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zQgEkX2viXQ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;22,848,728&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zjC7WMZa8V58" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;28,498,755&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zcGLbWP2DQo4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;23,409,208&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zHZwbIYVupF5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1016"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231_z5RpXakYjhub" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;74,756,691&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8AB_zzchoKTXZq9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Patent claims, in particular the patent claims of Veraxa Biotech GmbH and the former Company ARAXA, are summarized under the heading &#x2018;Intangible asset - Trademark rights&#x2019;. The intangible asset &#x2018;Intangible&#x2013; In-Process R&amp;amp;D Flysin&#x2019; stems from the acquisition of the Company Synimmune; it is an antibody that has already successfully completed a Phase I trial.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Intangible assets are amortized on a straight-line basis, whenever possible over the term of patent protection (20 years). Amortization of intangible assets is under depreciation and amortization. Amortization begins with the commencement of use or revenue generation. In-process R&amp;amp;D is not being amortized until completed, but instead is tested for impairment annually under IAS38. The annual impairment test for goodwill did not reveal any need for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Goodwill is a result of the ARAXA acquisition prior to 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DisclosureOfIntangibleAssetAndGoodwillExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact000868">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eifrs-full--DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_zuUP287HCRee" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible assets and goodwill (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B5_zUqeLtFdHQqg" style="display: none"&gt;Schedule of intangible assets and goodwill&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;In process R&amp;amp;D (Flysin)&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Trademark rights&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Software&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Beginning Cost at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zYsOsN4uYTx9" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;22,848,728&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zhb6f3cQW3y1" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;28,498,755&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zK2Qh5ozJbQc" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;31,261,245&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zcdPgSe3MP42" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;48,857&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20240101__20241231_zItjybCV4wge" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;82,657,585&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Disposals&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zpPRwCIG2m9g" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zH5ZD3ihi4Pd" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0882"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zxgOGXePOI8f" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zodJL2yyGuwe" style="text-align: right" title="Disposals"&gt;(7,999&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--DisposalsIntangibleAssetsAndGoodwill_c20240101__20241231_zQW92FgkYx85" style="text-align: right" title="Disposals"&gt;(7,999&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;FX effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zc0iiNhGHbLc" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zxqupoFeh0m9" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zXOgbi3q7di8" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;1,272&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_z8FgiHA1eRf6" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20240101__20241231_zpXrtCNPf4Vi" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;1,272&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Ending Cost at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zSzYsD3bFja4" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;22,848,728&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zpJXK7MsRo8j" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;28,498,755&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zbtFDmdmOqxh" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;31,262,517&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_987_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zu75rgCcT1y" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;40,858&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--IntangibleAssetsAndGoodwill_iS_c20250101__20251231_zDF2hAsTCb1c" style="text-align: right" title="Intangible assets and goodwill, beginning"&gt;82,650,858&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zYSawMbOmjA4" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zwfj6qv0TNqh" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zAJU4x7Sopqh" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_z9SSlqmSIby" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AdditionsIntangibleAssetsAndGoodwill_c20250101__20251231_zPCT87fSgx1k" style="text-align: right" title="Additions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;FX effects&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z9jHkdaKW3Xa" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zyi9lewLYEmf" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zX3DjRZe22nb" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;816&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zz5JYBfVHRB7" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;8&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--FXEffectsIntangibleAssetsAndGoodwill_c20250101__20251231_zTE7rFalbrYa" style="border-bottom: Black 1pt solid; text-align: right" title="FX effects"&gt;824&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Ending Cost at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z7w1extycnP7" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;22,848,728&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zV5AokhgHGea" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;28,498,755&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_z8Rqy48RFc3d" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;31,263,333&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zQishlMxqeV4" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;40,866&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--IntangibleAssetsAndGoodwill_iE_c20250101__20251231_zIorjbvbsW13" style="text-align: right" title="Intangible assets and goodwill, ending"&gt;&lt;b&gt;82,651,682&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Accumulated depreciation&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Balance at 12/31/2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z1yV1zdirWXf" style="text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zyt5AbwsBfq7" style="text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zMocEeIKWeu4" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(4,696,411&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zOZosIVIYxDl" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(37,253&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20240101__20241231_zbBn1SpDU1vi" style="text-align: right" title="Accumulated depreciation at beginning"&gt;(4,733,664&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Amortization for the year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zopy8dEqJah6" style="text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zAJFPtvazoBk" style="text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zQiDlVJFyLei" style="text-align: right" title="Amortization for the year"&gt;(1,579,717&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zxbfUxz9AoWh" style="text-align: right" title="Amortization for the year"&gt;(7,597&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20240101__20241231_zGknywfdvTv3" style="text-align: right" title="Amortization for the year"&gt;(1,587,314&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;Disposals&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z0g9FJBy5tB9" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zoC0r2fUXGVi" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_z02ZxF3tpm21" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zAs7dGUVqXBb" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;4,140&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AccumulatedDepreciationDisposals_c20240101__20241231_zxAI4o9Jeiu1" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals"&gt;4,140&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zKg9FgdBV7ch" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zhS3U8dzaDgg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0972"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zsozAg7Q36F2" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(6,276,128&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zNSi8UPfqq6b" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(40,710&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iS_c20250101__20251231_zwmCMAdw8N7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at beginning"&gt;(6,316,838&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;Amortization for the year&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zNKVmVCHE6H1" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zNBRwPONy0y8" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_ztpp3DfyeO91" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;(1,577,997&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_znfytxv4LHWi" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;(156&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AmortizationIntangibleAssetsAndGoodwill_c20250101__20251231_z7Mq5yQnZpM6" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization for the year"&gt;(1,578,153&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z6EkFMLMB004" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zYvH3tAfYPij" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zk9I4xqkfKfc" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt;(7,854,125&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zWd1zOGsaaR7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt; (40,866&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AccumulatedDepreciationIntangibleAssetsAndGoodwill_iE_c20250101__20251231_zSM84O8nCJjb" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation at ending"&gt;&lt;b&gt; (7,894,991&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Carrying Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_z6RekLd1Ptfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;22,848,728&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zl8RoP7g4pfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;28,498,755&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zHP058pFong1" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;24,986,389&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zsWPRuwJTGA5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;148&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20241231_zsXj7aJpA81b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;76,334,020&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt"&gt;&lt;b&gt;at 12/31/2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--GoodwillsMember_zQgEkX2viXQ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;22,848,728&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--InProcessRAndDFlysinMember_zjC7WMZa8V58" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;28,498,755&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TrademarkRightsMember_zcGLbWP2DQo4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;23,409,208&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--SoftwareMember_zHZwbIYVupF5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1016"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#x20a3;&lt;/b&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--IntangibleAssetsAndGoodwillNet_iI_c20251231_z5RpXakYjhub" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets and goodwill net"&gt;&lt;b&gt;74,756,691&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000870"
      unitRef="CHF">22848728</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000872"
      unitRef="CHF">28498755</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000874"
      unitRef="CHF">31261245</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000876"
      unitRef="CHF">48857</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000878"
      unitRef="CHF">82657585</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000886"
      unitRef="CHF">-7999</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000888"
      unitRef="CHF">-7999</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000894"
      unitRef="CHF">1272</cik0002079109:FXEffectsIntangibleAssetsAndGoodwill>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000898"
      unitRef="CHF">1272</cik0002079109:FXEffectsIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000900"
      unitRef="CHF">22848728</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000902"
      unitRef="CHF">28498755</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000904"
      unitRef="CHF">31262517</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000906"
      unitRef="CHF">40858</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000908"
      unitRef="CHF">82650858</ifrs-full:IntangibleAssetsAndGoodwill>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000924"
      unitRef="CHF">816</cik0002079109:FXEffectsIntangibleAssetsAndGoodwill>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000926"
      unitRef="CHF">8</cik0002079109:FXEffectsIntangibleAssetsAndGoodwill>
    <cik0002079109:FXEffectsIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000928"
      unitRef="CHF">824</cik0002079109:FXEffectsIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000930"
      unitRef="CHF">22848728</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000932"
      unitRef="CHF">28498755</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000934"
      unitRef="CHF">31263333</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000936"
      unitRef="CHF">40866</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000938"
      unitRef="CHF">82651682</ifrs-full:IntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000944"
      unitRef="CHF">-4696411</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000946"
      unitRef="CHF">-37253</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000948"
      unitRef="CHF">-4733664</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000954"
      unitRef="CHF">-1579717</cik0002079109:AmortizationIntangibleAssetsAndGoodwill>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000956"
      unitRef="CHF">-7597</cik0002079109:AmortizationIntangibleAssetsAndGoodwill>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000958"
      unitRef="CHF">-1587314</cik0002079109:AmortizationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationDisposals
      contextRef="From2024-01-012024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000966"
      unitRef="CHF">4140</cik0002079109:AccumulatedDepreciationDisposals>
    <cik0002079109:AccumulatedDepreciationDisposals
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000968"
      unitRef="CHF">4140</cik0002079109:AccumulatedDepreciationDisposals>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000974"
      unitRef="CHF">-6276128</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000976"
      unitRef="CHF">-40710</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000978"
      unitRef="CHF">-6316838</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000984"
      unitRef="CHF">-1577997</cik0002079109:AmortizationIntangibleAssetsAndGoodwill>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000986"
      unitRef="CHF">-156</cik0002079109:AmortizationIntangibleAssetsAndGoodwill>
    <cik0002079109:AmortizationIntangibleAssetsAndGoodwill
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000988"
      unitRef="CHF">-1578153</cik0002079109:AmortizationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000994"
      unitRef="CHF">-7854125</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000996"
      unitRef="CHF">-40866</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact000998"
      unitRef="CHF">-7894991</cik0002079109:AccumulatedDepreciationIntangibleAssetsAndGoodwill>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2024-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001000"
      unitRef="CHF">22848728</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2024-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001002"
      unitRef="CHF">28498755</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2024-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001004"
      unitRef="CHF">24986389</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2024-12-31_custom_SoftwareMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001006"
      unitRef="CHF">148</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001008"
      unitRef="CHF">76334020</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2025-12-31_custom_GoodwillsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001010"
      unitRef="CHF">22848728</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2025-12-31_custom_InProcessRAndDFlysinMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001012"
      unitRef="CHF">28498755</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2025-12-31_custom_TrademarkRightsMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001014"
      unitRef="CHF">23409208</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <cik0002079109:IntangibleAssetsAndGoodwillNet
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001018"
      unitRef="CHF">74756691</cik0002079109:IntangibleAssetsAndGoodwillNet>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001021">&lt;p id="xdx_802_eifrs-full--DisclosureOfLeasesExplanatory_zwPnSnarJBu6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;6. &lt;span id="xdx_821_zpKfBA2C0m05"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company leases office space, factory facilities and storage space. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Currently, the Company holds two leases requiring recognition of a right-of-use asset for the lease term. Lease liabilities are the Company&#x2019;s obligation to make the lease payments arising from a lease. As the Company&#x2019;s lease does not provide an implicit rate, the Company&#x2019;s lease liabilities are measured on a discounted basis using the Company&#x2019;s incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For the year ended December&#160;31, 2025, the Company&#x2019;s total cash outflow for leases was CHF &lt;span id="xdx_90E_eifrs-full--CashOutflowForLeases_c20250101__20251231_zjZmdfIszYEg" title="Cash outflow for leases"&gt;188,745&lt;/span&gt;. This consisted of CHF &lt;span id="xdx_90C_ecustom--PaymentOfPrincipalPortionOfLeaseLiabilities_c20250101__20251231_zEXHg4HMmGT" title="Payment of principal portion of lease liabilities"&gt;164,640&lt;/span&gt; for the principal portion of lease liabilities, presented within financing activities, and CHF &lt;span id="xdx_908_eifrs-full--InterestExpenseOnLeaseLiabilities_c20250101__20251231_z149mJRNd9Ua" title="Interest paid on lease liabilities."&gt;24,105&lt;/span&gt; for interest paid on lease liabilities. Additionally, during the year, the Company recognized non-cash additions to right-of-use assets and lease liabilities amounting to CHF &lt;span id="xdx_903_ecustom--RightofuseAssetsAndLeaseLiabilities_iI_c20251231_zCc4POxOANOf" title="Right-of-use assets and lease liabilities"&gt;440,802&lt;/span&gt; in connection with a newly acquired lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company&#x2019;s leases at December&#160;31, 2025 and December&#160;31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_z5Lr0wnAdxS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: middle; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BA_z2u0uYNlokqf" style="display: none"&gt;Schedule of weighted-average discount rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="text-align: left; vertical-align: bottom; padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: middle; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average remaining lease term&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; width: 15%"&gt;&lt;span id="xdx_90A_ecustom--WeightedAverageRemainingLeaseTerm_c20250101__20251231_zudLebidDKOe" title="Weighted average remaining lease term"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; width: 15%"&gt;&lt;span id="xdx_901_ecustom--WeightedAverageRemainingLeaseTerm_c20240101__20241231_z6ZFRnBk9Y5h" title="Weighted average remaining lease term"&gt;5.0 years&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: middle; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average discount rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageDiscountRate_iI_dp_c20251231_zGCI4PTT3z14" title="Weighted average discount rate"&gt;3.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageDiscountRate_iI_dp_c20241231_zsobWvuf8qe2" title="Weighted average discount rate"&gt;3.0&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A0_zUAQxPS5abW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The following table summarizes the maturities of the Company&#x2019;s leases at December&#160;31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_zMtiTprHNf5c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B1_zIKXCBD67wA1" style="display: none"&gt;Schedule of summarizes the maturities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20251231_zok0ZRcmpSZi" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--OneYearMember_zDGzXAOJoir1" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;291,276&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--TwoYearsMember_zKQyUNiQRzhk" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;296,938&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--ThreeYearsMember_zB2gBnEsgKgf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;2028&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;305,846&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--FourYearsMember_zZYNeGPdlYGb" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;2029&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;315,022&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TotalExpectedLeasePayments_iI_z0wvplRvi3F7" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Total expected lease payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,209,082&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LessImputedInterest_iI_zE5lqB3Yji8i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68,434&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--LeaseLiabilities_iI_zhBRmAVBxucd" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Total lease liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,140,648&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentLeaseLiabilities_iNI_di_zlUqsSQyFRZ1" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less: current lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(257,095&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--NoncurrentLeaseLiabilities_iI_zHmGtvP8b7vd" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Non-current lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;883,553&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A3_zuHr1BdwYzpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</ifrs-full:DisclosureOfLeasesExplanatory>
    <ifrs-full:CashOutflowForLeases
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001023"
      unitRef="CHF">188745</ifrs-full:CashOutflowForLeases>
    <cik0002079109:PaymentOfPrincipalPortionOfLeaseLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001025"
      unitRef="CHF">164640</cik0002079109:PaymentOfPrincipalPortionOfLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001027"
      unitRef="CHF">24105</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <cik0002079109:RightofuseAssetsAndLeaseLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001029"
      unitRef="CHF">440802</cik0002079109:RightofuseAssetsAndLeaseLiabilities>
    <cik0002079109:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001031">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_z5Lr0wnAdxS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: middle; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BA_z2u0uYNlokqf" style="display: none"&gt;Schedule of weighted-average discount rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;th style="text-align: left; vertical-align: bottom; padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"&gt;&#160;&lt;/th&gt;
    &lt;th style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="text-align: left; vertical-align: middle; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average remaining lease term&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; width: 15%"&gt;&lt;span id="xdx_90A_ecustom--WeightedAverageRemainingLeaseTerm_c20250101__20251231_zudLebidDKOe" title="Weighted average remaining lease term"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; width: 15%"&gt;&lt;span id="xdx_901_ecustom--WeightedAverageRemainingLeaseTerm_c20240101__20241231_z6ZFRnBk9Y5h" title="Weighted average remaining lease term"&gt;5.0 years&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF"&gt;
    &lt;td style="text-align: left; vertical-align: middle; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average discount rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageDiscountRate_iI_dp_c20251231_zGCI4PTT3z14" title="Weighted average discount rate"&gt;3.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageDiscountRate_iI_dp_c20241231_zsobWvuf8qe2" title="Weighted average discount rate"&gt;3.0&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock>
    <cik0002079109:WeightedAverageRemainingLeaseTerm
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001033">4.0 years</cik0002079109:WeightedAverageRemainingLeaseTerm>
    <cik0002079109:WeightedAverageRemainingLeaseTerm
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001035">5.0 years</cik0002079109:WeightedAverageRemainingLeaseTerm>
    <cik0002079109:WeightedAverageDiscountRate
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Pure">0.030</cik0002079109:WeightedAverageDiscountRate>
    <cik0002079109:WeightedAverageDiscountRate
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001039"
      unitRef="Pure">0.030</cik0002079109:WeightedAverageDiscountRate>
    <cik0002079109:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001041">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_zMtiTprHNf5c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B1_zIKXCBD67wA1" style="display: none"&gt;Schedule of summarizes the maturities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20251231_zok0ZRcmpSZi" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--OneYearMember_zDGzXAOJoir1" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;291,276&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--TwoYearsMember_zKQyUNiQRzhk" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;296,938&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--ThreeYearsMember_zB2gBnEsgKgf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;2028&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;305,846&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FutureMaturitiesLeasePayments_iI_hifrs-full--MaturityAxis__custom--FourYearsMember_zZYNeGPdlYGb" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;2029&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;315,022&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TotalExpectedLeasePayments_iI_z0wvplRvi3F7" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Total expected lease payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,209,082&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LessImputedInterest_iI_zE5lqB3Yji8i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68,434&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--LeaseLiabilities_iI_zhBRmAVBxucd" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Total lease liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,140,648&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentLeaseLiabilities_iNI_di_zlUqsSQyFRZ1" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less: current lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(257,095&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--NoncurrentLeaseLiabilities_iI_zHmGtvP8b7vd" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Non-current lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;883,553&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock>
    <cik0002079109:FutureMaturitiesLeasePayments
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_OneYearMember"
      decimals="0"
      id="Fact001043"
      unitRef="CHF">291276</cik0002079109:FutureMaturitiesLeasePayments>
    <cik0002079109:FutureMaturitiesLeasePayments
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_TwoYearsMember"
      decimals="0"
      id="Fact001045"
      unitRef="CHF">296938</cik0002079109:FutureMaturitiesLeasePayments>
    <cik0002079109:FutureMaturitiesLeasePayments
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_ThreeYearsMember"
      decimals="0"
      id="Fact001047"
      unitRef="CHF">305846</cik0002079109:FutureMaturitiesLeasePayments>
    <cik0002079109:FutureMaturitiesLeasePayments
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember_custom_FourYearsMember"
      decimals="0"
      id="Fact001049"
      unitRef="CHF">315022</cik0002079109:FutureMaturitiesLeasePayments>
    <cik0002079109:TotalExpectedLeasePayments
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001051"
      unitRef="CHF">1209082</cik0002079109:TotalExpectedLeasePayments>
    <cik0002079109:LessImputedInterest
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001053"
      unitRef="CHF">-68434</cik0002079109:LessImputedInterest>
    <ifrs-full:LeaseLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001055"
      unitRef="CHF">1140648</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001057"
      unitRef="CHF">257095</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001059"
      unitRef="CHF">883553</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001062">&lt;p id="xdx_808_eifrs-full--DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_zV4j5b9WLWz9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;7. &lt;span id="xdx_82B_zbbDOEqoPftj"&gt;Accrued expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfAccruedExpensesTableTextBlock_zq3nNdQTjXR1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued expenses (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B3_zBxJqRRbujHf" style="display: none"&gt;Schedule of accrued expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20251231_zJGMkFTXLlgc" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20241231_z6EDHlzNHePa" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PersonnelExpenses_iI_zL0wG2VhEDKk" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Personnel expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;459,669&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;253,718&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TaxProvisionIncl.EmissionLeviesOnCapitalBand_iI_zboQzt7MMV98" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Tax provision (incl. emission levies on capital band)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;535,548&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;427,592&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--XlifeShareLendingAccrual_iI_z6quPuPsEtm4" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Xlife share lending accrual&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,189,037&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,001,878&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--Other_iI_zzX0wkbUg9o8" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Other&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;491,369&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;119,162&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedExpenses_iI_z7wpinKOGoDk" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Total accrued expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,675,623&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,802,350&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
    <cik0002079109:ScheduleOfAccruedExpensesTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001064">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfAccruedExpensesTableTextBlock_zq3nNdQTjXR1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued expenses (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B3_zBxJqRRbujHf" style="display: none"&gt;Schedule of accrued expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20251231_zJGMkFTXLlgc" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20241231_z6EDHlzNHePa" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PersonnelExpenses_iI_zL0wG2VhEDKk" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Personnel expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;459,669&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;253,718&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TaxProvisionIncl.EmissionLeviesOnCapitalBand_iI_zboQzt7MMV98" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Tax provision (incl. emission levies on capital band)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;535,548&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;427,592&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--XlifeShareLendingAccrual_iI_z6quPuPsEtm4" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Xlife share lending accrual&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,189,037&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,001,878&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--Other_iI_zzX0wkbUg9o8" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Other&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;491,369&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;119,162&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedExpenses_iI_z7wpinKOGoDk" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Total accrued expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,675,623&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,802,350&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</cik0002079109:ScheduleOfAccruedExpensesTableTextBlock>
    <cik0002079109:PersonnelExpenses
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001066"
      unitRef="CHF">459669</cik0002079109:PersonnelExpenses>
    <cik0002079109:PersonnelExpenses
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001067"
      unitRef="CHF">253718</cik0002079109:PersonnelExpenses>
    <cik0002079109:TaxProvisionIncl.EmissionLeviesOnCapitalBand
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001069"
      unitRef="CHF">535548</cik0002079109:TaxProvisionIncl.EmissionLeviesOnCapitalBand>
    <cik0002079109:TaxProvisionIncl.EmissionLeviesOnCapitalBand
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001070"
      unitRef="CHF">427592</cik0002079109:TaxProvisionIncl.EmissionLeviesOnCapitalBand>
    <cik0002079109:XlifeShareLendingAccrual
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001072"
      unitRef="CHF">1189037</cik0002079109:XlifeShareLendingAccrual>
    <cik0002079109:XlifeShareLendingAccrual
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001073"
      unitRef="CHF">1001878</cik0002079109:XlifeShareLendingAccrual>
    <cik0002079109:Other
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001075"
      unitRef="CHF">491369</cik0002079109:Other>
    <cik0002079109:Other
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001076"
      unitRef="CHF">119162</cik0002079109:Other>
    <cik0002079109:AccruedExpenses
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001078"
      unitRef="CHF">2675623</cik0002079109:AccruedExpenses>
    <cik0002079109:AccruedExpenses
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001079"
      unitRef="CHF">1802350</cik0002079109:AccruedExpenses>
    <cik0002079109:DisclosureOfIncomeTaxesRecognizedInTheIncomeStatementExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001081">&lt;p id="xdx_800_ecustom--DisclosureOfIncomeTaxesRecognizedInTheIncomeStatementExplanatory_zcNibUphmPTg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;8. &lt;span id="xdx_82A_ztd3iZwSoID6"&gt;Income taxes recognized in the income statement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Current taxes are calculated on the basis of an average income tax rate of 31% on the profits generated. This expected average tax rate corresponds to the expected tax rate in Germany, as this is where the operating activities take place.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfOperatingActivitiesTableTextBlock_zg1lNXzepF0d" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes recognized in the income statement (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B4_zjrHuT8rOWo5" style="display: none"&gt;Schedule of operating activities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20250101__20251231_zDHPqstGpOha" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20240101__20241231_z81nrkCqF6n1" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="border-bottom: Black 1pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;b&gt;in CHF&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Current taxes&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_zIvM74qPhc1i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Income tax income/expense in the current financial year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Deferred taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--DeferredTaxExpenseIncome_zZ8CG7oexqZ6" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;Recognized deferred (tax expense)/tax income&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;392,603&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,774&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_zflyIm0GYHuh" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt"&gt;&lt;b&gt;Reported tax income for the current period&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392,603&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;620,774&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8AA_zojCoFoagrE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;No income taxes were recognized directly in equity or in other comprehensive income in the financial year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The tax expense/income for the financial year can be reconciled to the profit/loss for the period as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfTaxExpenseIncomeForTheFinancialYearTableTextBlock_zv9svWjhdLIi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes recognized in the income statement (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zcPnBAU9PYwa" style="display: none"&gt;Schedule of tax expense income for the financial year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20251231_zalE3U5lw224" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zXUjIbkbxoAf" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;in CHF&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EarningsBeforeIncomeTaxes_zCY3HLrPGnDf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Earnings before income taxes&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;(67,006,593&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt; (28,753,745&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_zyt2dUKXpLWh" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Income tax expense at a tax rate of 31%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20,772,044&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt; 8,913,661&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AmortizationOfDeferredTaxAssetsDueToDerecognition_zESCAQCximB5" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Amortization of deferred tax assets due to derecognition&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_z9hofkXDySnf" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Effects of non-tax-deductible expenses and income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(12,336,984&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,420,625&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectsOfResultsForWhichNoDeferredTaxesWereRecognized_zY4soJR7eW5b" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Effects of results for which no deferred taxes were recognized&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,523,688&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,666,379&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectsOfLossesForWhichDeferredTaxAssetsWereRecognized_zlfdYF1Q2s98" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Effects of losses for which deferred tax assets were recognized&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--AdjustmentsForDeferredTaxOfPriorPeriods_z3kRxXa1bdjk" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Tax rate differences&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(428,768&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(205,883&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--OtherComponentsOfDeferredTaxExpenseIncome_zvolpUYvEbRj" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Tax amount recognized in the income statement&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;482,603&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;620,774&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A6_zar16E0eagJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</cik0002079109:DisclosureOfIncomeTaxesRecognizedInTheIncomeStatementExplanatory>
    <cik0002079109:ScheduleOfOperatingActivitiesTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001083">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfOperatingActivitiesTableTextBlock_zg1lNXzepF0d" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes recognized in the income statement (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B4_zjrHuT8rOWo5" style="display: none"&gt;Schedule of operating activities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20250101__20251231_zDHPqstGpOha" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20240101__20241231_z81nrkCqF6n1" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="border-bottom: Black 1pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;b&gt;in CHF&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Current taxes&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_zIvM74qPhc1i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Income tax income/expense in the current financial year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Deferred taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--DeferredTaxExpenseIncome_zZ8CG7oexqZ6" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt"&gt;Recognized deferred (tax expense)/tax income&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;392,603&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,774&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_zflyIm0GYHuh" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt"&gt;&lt;b&gt;Reported tax income for the current period&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392,603&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;620,774&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfOperatingActivitiesTableTextBlock>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001088"
      unitRef="CHF">392603</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001089"
      unitRef="CHF">620774</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001091"
      unitRef="CHF">392603</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001092"
      unitRef="CHF">620774</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <cik0002079109:ScheduleOfTaxExpenseIncomeForTheFinancialYearTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001094">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfTaxExpenseIncomeForTheFinancialYearTableTextBlock_zv9svWjhdLIi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes recognized in the income statement (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zcPnBAU9PYwa" style="display: none"&gt;Schedule of tax expense income for the financial year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20251231_zalE3U5lw224" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zXUjIbkbxoAf" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;in CHF&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EarningsBeforeIncomeTaxes_zCY3HLrPGnDf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Earnings before income taxes&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;(67,006,593&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt; (28,753,745&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_zyt2dUKXpLWh" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Income tax expense at a tax rate of 31%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20,772,044&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt; 8,913,661&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AmortizationOfDeferredTaxAssetsDueToDerecognition_zESCAQCximB5" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Amortization of deferred tax assets due to derecognition&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_z9hofkXDySnf" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Effects of non-tax-deductible expenses and income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(12,336,984&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,420,625&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectsOfResultsForWhichNoDeferredTaxesWereRecognized_zY4soJR7eW5b" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Effects of results for which no deferred taxes were recognized&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,523,688&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,666,379&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectsOfLossesForWhichDeferredTaxAssetsWereRecognized_zlfdYF1Q2s98" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Effects of losses for which deferred tax assets were recognized&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--AdjustmentsForDeferredTaxOfPriorPeriods_z3kRxXa1bdjk" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Tax rate differences&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(428,768&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(205,883&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--OtherComponentsOfDeferredTaxExpenseIncome_zvolpUYvEbRj" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Tax amount recognized in the income statement&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;482,603&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;620,774&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfTaxExpenseIncomeForTheFinancialYearTableTextBlock>
    <cik0002079109:EarningsBeforeIncomeTaxes
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001096"
      unitRef="CHF">-67006593</cik0002079109:EarningsBeforeIncomeTaxes>
    <cik0002079109:EarningsBeforeIncomeTaxes
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001097"
      unitRef="CHF">-28753745</cik0002079109:EarningsBeforeIncomeTaxes>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001099"
      unitRef="CHF">20772044</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001100"
      unitRef="CHF">8913661</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001105"
      unitRef="CHF">-12336984</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001106"
      unitRef="CHF">-5420625</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <cik0002079109:EffectsOfResultsForWhichNoDeferredTaxesWereRecognized
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001108"
      unitRef="CHF">-7523688</cik0002079109:EffectsOfResultsForWhichNoDeferredTaxesWereRecognized>
    <cik0002079109:EffectsOfResultsForWhichNoDeferredTaxesWereRecognized
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001109"
      unitRef="CHF">-2666379</cik0002079109:EffectsOfResultsForWhichNoDeferredTaxesWereRecognized>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001114"
      unitRef="CHF">-428768</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001115"
      unitRef="CHF">-205883</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:OtherComponentsOfDeferredTaxExpenseIncome
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001117"
      unitRef="CHF">482603</ifrs-full:OtherComponentsOfDeferredTaxExpenseIncome>
    <ifrs-full:OtherComponentsOfDeferredTaxExpenseIncome
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001118"
      unitRef="CHF">620774</ifrs-full:OtherComponentsOfDeferredTaxExpenseIncome>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001121">&lt;p id="xdx_80B_eifrs-full--DisclosureOfDeferredTaxesExplanatory_zI4HDD3P7XA8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;9. &lt;span id="xdx_82D_zotG4FAglGve"&gt;Deferred taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Deferred tax assets were not recognized with regard to the following items, as it is not yet possible to estimate whether taxable income will be available in the future against which the Company can use the deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_zBnWDKVja0qj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Deferred taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BE_z6AbPxDf7uJf" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20251231_zYgt8OEulpg" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_zykD5yYbRKZ7" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;in CHF&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TaxLossesSwitzerland_zc2Q7WyZfbhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax losses (Switzerland)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,610,769&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;11,163,549&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--TaxLossesGermany_zBaJnSH68qfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Tax losses (Germany)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;34,639,558&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;25,153,116&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TotalUnrecognizedDeferredTaxAssetsExpiringUntil2028_zcfc2bN7WgPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total unrecognized deferred tax assets (expiring until 2028)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;54,250,327&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36,316,665&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--TaxEffectOfTaxLosses_zChp5Ny70yc9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Possible tax effect&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,817,601&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,197,629&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20251231_zd5NqiquwUW6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20241231_zEWqZjmYL6Y5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--CapitalIncreaseExpenses_iI_z7oHwM0e8M8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Capital increase expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,639,197&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,397,446&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DeferredTaxAssets_iNI_di_zx1J2LHUSHDd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Balancing&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;(1,639,197&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;(1,397,446&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--NetDeferredTaxAssets_iI_zqRKp4ygeFr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Balance sheet recognition of deferred tax assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1143"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1144"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20251231_zqxMHEbJPFKa" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20241231_zFtF3ZtAIaFh" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Deferred tax liabilities&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IntangibleAssetsFromAdditionVeraxaBiotechGmbh_iI_zctM8PNDpZ6a" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Intangible assets from addition Veraxa Biotech GmbH&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(9,652,055&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(9,652,055&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IntangibleAssetsFromAdditionSynimmuneGmbh_iI_zdvxbfeR06Ma" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Intangible assets from addition Synimmune GmbH&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(8,840,889&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(8,840,889&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AmortizationOfIntangibleAssetsDeferredTaxLiabilities_iI_z8lOrCAF4HZf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Amortization of intangible assets&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,413,015&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,930,412&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--GrossAmountOfDeferredTaxLiabilities_iI_zDLtJkgbAw04" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Gross amount of deferred tax liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(16,079,929&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(16,562,532&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--NetDeferredTaxLiabilities_iI_zfOFfKZKrUMd" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Balancing&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,639,197&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,397,446&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--DeferredTaxLiabilities_iNI_di_z4fx7kRYYeog" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Balance sheet recognition of deferred tax liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(14,440,732&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(15,165,086&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8AB_zcBab12Qdv2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <cik0002079109:ScheduleOfDeferredTaxAssetsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001123">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfDeferredTaxAssetsTableTextBlock_zBnWDKVja0qj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Deferred taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BE_z6AbPxDf7uJf" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20251231_zYgt8OEulpg" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_zykD5yYbRKZ7" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;in CHF&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TaxLossesSwitzerland_zc2Q7WyZfbhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax losses (Switzerland)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,610,769&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;11,163,549&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--TaxLossesGermany_zBaJnSH68qfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Tax losses (Germany)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;34,639,558&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;25,153,116&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TotalUnrecognizedDeferredTaxAssetsExpiringUntil2028_zcfc2bN7WgPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total unrecognized deferred tax assets (expiring until 2028)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;54,250,327&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36,316,665&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--TaxEffectOfTaxLosses_zChp5Ny70yc9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Possible tax effect&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,817,601&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,197,629&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20251231_zd5NqiquwUW6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20241231_zEWqZjmYL6Y5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--CapitalIncreaseExpenses_iI_z7oHwM0e8M8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Capital increase expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,639,197&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,397,446&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DeferredTaxAssets_iNI_di_zx1J2LHUSHDd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Balancing&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;(1,639,197&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;(1,397,446&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--NetDeferredTaxAssets_iI_zqRKp4ygeFr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Balance sheet recognition of deferred tax assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1143"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1144"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20251231_zqxMHEbJPFKa" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20241231_zFtF3ZtAIaFh" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Deferred tax liabilities&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IntangibleAssetsFromAdditionVeraxaBiotechGmbh_iI_zctM8PNDpZ6a" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Intangible assets from addition Veraxa Biotech GmbH&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(9,652,055&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(9,652,055&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IntangibleAssetsFromAdditionSynimmuneGmbh_iI_zdvxbfeR06Ma" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Intangible assets from addition Synimmune GmbH&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(8,840,889&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(8,840,889&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AmortizationOfIntangibleAssetsDeferredTaxLiabilities_iI_z8lOrCAF4HZf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Amortization of intangible assets&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,413,015&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,930,412&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--GrossAmountOfDeferredTaxLiabilities_iI_zDLtJkgbAw04" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Gross amount of deferred tax liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(16,079,929&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(16,562,532&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--NetDeferredTaxLiabilities_iI_zfOFfKZKrUMd" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Balancing&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,639,197&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,397,446&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--DeferredTaxLiabilities_iNI_di_z4fx7kRYYeog" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Balance sheet recognition of deferred tax liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(14,440,732&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(15,165,086&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfDeferredTaxAssetsTableTextBlock>
    <cik0002079109:TaxLossesSwitzerland
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001125"
      unitRef="CHF">19610769</cik0002079109:TaxLossesSwitzerland>
    <cik0002079109:TaxLossesSwitzerland
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001126"
      unitRef="CHF">11163549</cik0002079109:TaxLossesSwitzerland>
    <cik0002079109:TaxLossesGermany
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001128"
      unitRef="CHF">34639558</cik0002079109:TaxLossesGermany>
    <cik0002079109:TaxLossesGermany
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001129"
      unitRef="CHF">25153116</cik0002079109:TaxLossesGermany>
    <cik0002079109:TotalUnrecognizedDeferredTaxAssetsExpiringUntil2028
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001131"
      unitRef="CHF">54250327</cik0002079109:TotalUnrecognizedDeferredTaxAssetsExpiringUntil2028>
    <cik0002079109:TotalUnrecognizedDeferredTaxAssetsExpiringUntil2028
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001132"
      unitRef="CHF">36316665</cik0002079109:TotalUnrecognizedDeferredTaxAssetsExpiringUntil2028>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001134"
      unitRef="CHF">16817601</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001135"
      unitRef="CHF">10197629</ifrs-full:TaxEffectOfTaxLosses>
    <cik0002079109:CapitalIncreaseExpenses
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001137"
      unitRef="CHF">1639197</cik0002079109:CapitalIncreaseExpenses>
    <cik0002079109:CapitalIncreaseExpenses
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001138"
      unitRef="CHF">1397446</cik0002079109:CapitalIncreaseExpenses>
    <ifrs-full:DeferredTaxAssets
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001140"
      unitRef="CHF">1639197</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001141"
      unitRef="CHF">1397446</ifrs-full:DeferredTaxAssets>
    <cik0002079109:IntangibleAssetsFromAdditionVeraxaBiotechGmbh
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001146"
      unitRef="CHF">-9652055</cik0002079109:IntangibleAssetsFromAdditionVeraxaBiotechGmbh>
    <cik0002079109:IntangibleAssetsFromAdditionVeraxaBiotechGmbh
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001147"
      unitRef="CHF">-9652055</cik0002079109:IntangibleAssetsFromAdditionVeraxaBiotechGmbh>
    <cik0002079109:IntangibleAssetsFromAdditionSynimmuneGmbh
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001149"
      unitRef="CHF">-8840889</cik0002079109:IntangibleAssetsFromAdditionSynimmuneGmbh>
    <cik0002079109:IntangibleAssetsFromAdditionSynimmuneGmbh
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001150"
      unitRef="CHF">-8840889</cik0002079109:IntangibleAssetsFromAdditionSynimmuneGmbh>
    <cik0002079109:AmortizationOfIntangibleAssetsDeferredTaxLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001152"
      unitRef="CHF">2413015</cik0002079109:AmortizationOfIntangibleAssetsDeferredTaxLiabilities>
    <cik0002079109:AmortizationOfIntangibleAssetsDeferredTaxLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001153"
      unitRef="CHF">1930412</cik0002079109:AmortizationOfIntangibleAssetsDeferredTaxLiabilities>
    <cik0002079109:GrossAmountOfDeferredTaxLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001155"
      unitRef="CHF">-16079929</cik0002079109:GrossAmountOfDeferredTaxLiabilities>
    <cik0002079109:GrossAmountOfDeferredTaxLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001156"
      unitRef="CHF">-16562532</cik0002079109:GrossAmountOfDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001158"
      unitRef="CHF">1639197</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001159"
      unitRef="CHF">1397446</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001161"
      unitRef="CHF">14440732</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001162"
      unitRef="CHF">15165086</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001164">&lt;p id="xdx_80B_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_z3Xdc9eGN3sf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;10. &lt;span id="xdx_825_zDIWmwKkrPG6"&gt;Share capital&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The shares have a nominal value of CHF 1.00, each carry voting rights and are entitled to dividends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfVotingRightsAndAreEntitledToDividendsTableTextBlock_zJf7QJqtNX2i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BB_z2nhzhwgybPk" style="display: none"&gt;Schedule of carry voting rights&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Share capital balance as of beginning of year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--IssuedCapital_iS_c20250101__20251231_z7JTGmQ6dTDc" style="text-align: right" title="Share capital balance as of year end"&gt;14,182,189&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--IssuedCapital_iS_c20240101__20241231_zCMU2W1h0RA6" style="text-align: right" title="Share capital balance as of year end"&gt;13,409,213&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Changes in the reporting year&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ChangesInReportingYear_c20250101__20251231_zwtaj0qzRm32" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Changes in the reporting year"&gt;568,878&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ChangesInReportingYear_c20240101__20241231_zYg2LWrlr0o6" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Changes in the reporting year"&gt;772,976&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Share capital balance as of year end&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IssuedCapital_iE_c20250101__20251231_zI95lZmjxTEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share capital balance as of year end"&gt;14,751,067&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--IssuedCapital_iE_c20240101__20241231_zu6nr8enK5G9" style="border-bottom: Black 2.5pt double; text-align: right" title="Share capital balance as of year end"&gt;14,182,189&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8AE_zLPGY8n0NPGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other reserves includes foreign currency translation reserves.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfForeignCurrencyTranslationReservesTableTextBlock_zgdneQXPTSUg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zGAbPmN6Ad63" style="display: none"&gt;Schedule of foreign currency translation reserves&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_z4oFTGD1xmW2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zIu3YqLrK8ng" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Remaining authorized share capital&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--CapitalBandArticle3b_iI_zlQecmLJvYQ9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Capital band (Article 3b)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,115,039&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,683,918&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ConditionalShareCapitalArticle3a_iI_zFP5VhtZnnp5" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Conditional share capital (Article 3a)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,000,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,000,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A1_ziuGdpD6mt65" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <cik0002079109:ScheduleOfVotingRightsAndAreEntitledToDividendsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001166">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfVotingRightsAndAreEntitledToDividendsTableTextBlock_zJf7QJqtNX2i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BB_z2nhzhwgybPk" style="display: none"&gt;Schedule of carry voting rights&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Share capital balance as of beginning of year&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--IssuedCapital_iS_c20250101__20251231_z7JTGmQ6dTDc" style="text-align: right" title="Share capital balance as of year end"&gt;14,182,189&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98B_eifrs-full--IssuedCapital_iS_c20240101__20241231_zCMU2W1h0RA6" style="text-align: right" title="Share capital balance as of year end"&gt;13,409,213&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Changes in the reporting year&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ChangesInReportingYear_c20250101__20251231_zwtaj0qzRm32" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Changes in the reporting year"&gt;568,878&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ChangesInReportingYear_c20240101__20241231_zYg2LWrlr0o6" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Changes in the reporting year"&gt;772,976&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Share capital balance as of year end&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--IssuedCapital_iE_c20250101__20251231_zI95lZmjxTEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share capital balance as of year end"&gt;14,751,067&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--IssuedCapital_iE_c20240101__20241231_zu6nr8enK5G9" style="border-bottom: Black 2.5pt double; text-align: right" title="Share capital balance as of year end"&gt;14,182,189&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfVotingRightsAndAreEntitledToDividendsTableTextBlock>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001168"
      unitRef="CHF">14182189</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2023-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001170"
      unitRef="CHF">13409213</ifrs-full:IssuedCapital>
    <cik0002079109:ChangesInReportingYear
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001172"
      unitRef="CHF">568878</cik0002079109:ChangesInReportingYear>
    <cik0002079109:ChangesInReportingYear
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001174"
      unitRef="CHF">772976</cik0002079109:ChangesInReportingYear>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001176"
      unitRef="CHF">14751067</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001178"
      unitRef="CHF">14182189</ifrs-full:IssuedCapital>
    <cik0002079109:ScheduleOfForeignCurrencyTranslationReservesTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001180">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfForeignCurrencyTranslationReservesTableTextBlock_zgdneQXPTSUg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zGAbPmN6Ad63" style="display: none"&gt;Schedule of foreign currency translation reserves&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_z4oFTGD1xmW2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zIu3YqLrK8ng" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Remaining authorized share capital&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--CapitalBandArticle3b_iI_zlQecmLJvYQ9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Capital band (Article 3b)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,115,039&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,683,918&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ConditionalShareCapitalArticle3a_iI_zFP5VhtZnnp5" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Conditional share capital (Article 3a)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,000,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,000,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfForeignCurrencyTranslationReservesTableTextBlock>
    <cik0002079109:CapitalBandArticle3b
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001182"
      unitRef="Shares">4115039</cik0002079109:CapitalBandArticle3b>
    <cik0002079109:CapitalBandArticle3b
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001183"
      unitRef="Shares">4683918</cik0002079109:CapitalBandArticle3b>
    <cik0002079109:ConditionalShareCapitalArticle3a
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001185"
      unitRef="Shares">7000000</cik0002079109:ConditionalShareCapitalArticle3a>
    <cik0002079109:ConditionalShareCapitalArticle3a
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001186"
      unitRef="Shares">7000000</cik0002079109:ConditionalShareCapitalArticle3a>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001189">&lt;p id="xdx_801_eifrs-full--DisclosureOfRelatedPartyExplanatory_zctVTQHIeT5l" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;11. &lt;span id="xdx_825_zm1vidAy1UW4"&gt;Transactions with related parties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Company Consulting Services Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On September 1, 2022, the Company entered into a consulting services agreement with Xlife Sciences AG, one of their shareholders. Pursuant to the agreement, the Company agreed to pay Xlife Sciences AG a monthly fee in exchange for strategic and business development consulting services. The agreement remains in effect until terminated by either party in accordance with its terms. During the fiscal years ended December 31, 2025 and 2024, Veraxa paid Xlife Sciences AG an aggregate amount of CHF &lt;span id="xdx_90E_ecustom--AggregateAmount_c20250101__20251231_zTtYoHf059ck" title="Aggregate amount"&gt;360,000 &lt;/span&gt;and CHF &lt;span id="xdx_909_ecustom--AggregateAmount_c20240101__20241231_zikKD7RxFDDf" title="Aggregate amount"&gt;600,000&lt;/span&gt;, respectively, under this arrangement. As of December&#160;31, 2025 and 2024, no amounts were payable under this agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Company Share Lending Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On October&#160;1, 2024, the Company entered into a share lending agreement with Xlife Sciences AG, one of their shareholders, for a fixed term ending on June&#160;30, 2026. Under the terms of the agreement, Xlife Sciences AG agreed to lend the Company &lt;span id="xdx_90C_ecustom--OrdinaryShares_iI_c20241001_z417ZY2m0Dlc" title="Ordinary shares"&gt;1,000,000 &lt;/span&gt;of our ordinary shares. In consideration for the share loan, the Company agreed to pay Xlife Sciences AG a fee equal to 3.5% of the aggregate market value of the loaned shares over the duration of the agreement. As of December&#160;31, 2025, there were &lt;span id="xdx_903_ecustom--OwedShares_iI_c20251231_zyrKgushc9ul" title="Owned shares"&gt;23,242 &lt;/span&gt;shares owed to Xlife Sciences AG which are not settled as of December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Unsecured Loan Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On September&#160;15, 2025, the Company also entered into an unsecured loan agreement with Xlife Sciences AG, for a principal amount of CHF &lt;span id="xdx_905_ecustom--PrincipalAmount_iI_c20250915_zCN17Dth2nwg" title="Principal amount"&gt;1,000,000&lt;/span&gt;. The loan was set to mature on December&#160;31, 2025 and was subsequently extended to a mature on September&#160;30, 2026, at which time the principal must be repaid in a single lump sum. The debt bears a fixed interest rate of 2.5% per annum, payable monthly, which is subject to adjustment if the tax-recognized interest rate for foreign currency loans published by the FTA exceeds 2.5%. Xlife Sciences AG retains the right to accelerate the debt and demand immediate repayment for good cause, including uncured payment defaults or a material deterioration in the Company&#x2019;s financial circumstances that puts the fulfillment of the agreement at risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Loans to or from related companies and persons are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfLoansToOrFromRelatedCompaniesTableTextBlock_zAObNFtakWkh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Transactions with related parties (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of Loans to or from related companies&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20251231_zNgZbWicaibc" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20241231_zoULX9GKyMrl" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--OtherReceivables_iI_zCIekenyuCq6" style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other receivables - Xlife&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;45,789&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OtherReceivablesRelatedPartyVeraxaBiotechHoldingAg_iI_zvuqUsbCt7d8" style="background-color: White; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other receivables - related party (Veraxa Biotech Holding AG)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,856&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--CurrentInterestPayable_iI_zDRJy7VGbPu7" style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Notes payable - Xlife&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1210"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CurrentPrepayments_iI_z2WSLAhpxfy8" style="background-color: White; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Prepaid benefit receipt&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1212"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,369&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <cik0002079109:AggregateAmount
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001191"
      unitRef="CHF">360000</cik0002079109:AggregateAmount>
    <cik0002079109:AggregateAmount
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001193"
      unitRef="CHF">600000</cik0002079109:AggregateAmount>
    <cik0002079109:OrdinaryShares
      contextRef="AsOf2024-10-01_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001195"
      unitRef="Shares">1000000</cik0002079109:OrdinaryShares>
    <cik0002079109:OwedShares
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">23242</cik0002079109:OwedShares>
    <cik0002079109:PrincipalAmount
      contextRef="AsOf2025-09-15_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001199"
      unitRef="CHF">1000000</cik0002079109:PrincipalAmount>
    <cik0002079109:ScheduleOfLoansToOrFromRelatedCompaniesTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001201">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfLoansToOrFromRelatedCompaniesTableTextBlock_zAObNFtakWkh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Transactions with related parties (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of Loans to or from related companies&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20251231_zNgZbWicaibc" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20241231_zoULX9GKyMrl" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--OtherReceivables_iI_zCIekenyuCq6" style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other receivables - Xlife&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;45,789&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OtherReceivablesRelatedPartyVeraxaBiotechHoldingAg_iI_zvuqUsbCt7d8" style="background-color: White; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other receivables - related party (Veraxa Biotech Holding AG)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,856&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--CurrentInterestPayable_iI_zDRJy7VGbPu7" style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Notes payable - Xlife&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1210"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CurrentPrepayments_iI_z2WSLAhpxfy8" style="background-color: White; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Prepaid benefit receipt&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1212"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,369&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</cik0002079109:ScheduleOfLoansToOrFromRelatedCompaniesTableTextBlock>
    <ifrs-full:OtherReceivables
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001203"
      unitRef="CHF">45789</ifrs-full:OtherReceivables>
    <cik0002079109:OtherReceivablesRelatedPartyVeraxaBiotechHoldingAg
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001206"
      unitRef="CHF">8856</cik0002079109:OtherReceivablesRelatedPartyVeraxaBiotechHoldingAg>
    <ifrs-full:CurrentInterestPayable
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001209"
      unitRef="CHF">1000000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:CurrentPrepayments
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001213"
      unitRef="CHF">4369</ifrs-full:CurrentPrepayments>
    <cik0002079109:DisclosuresOnFinancialInstrumentsCapitalRiskManagementExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001215">&lt;p id="xdx_800_ecustom--DisclosuresOnFinancialInstrumentsCapitalRiskManagementExplanatory_zfy42ij5hqEb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;12. &lt;span id="xdx_821_z1cOFk7nYQ23"&gt;Disclosures on financial instruments Capital risk management&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company manages its capital with the aim of ensuring that the Company can operate under the going concern assumption and at the same time maximizing the income of the Company&#x2019;s stakeholders by optimizing the ratio of equity to debt. The Company&#x2019;s capital structure consists of net debt and the Company&#x2019;s equity. This is made up of the equivalent value of issued shares, the capital reserve and the balance sheet carry-forward. The Company is not subject to any externally imposed capital requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Liquidity risk management&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Ultimately, responsibility for liquidity risk management lies with the Board of Directors, which has developed an appropriate concept for managing short, medium and long-term financing and liquidity requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Market risks&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="text-decoration: underline"&gt;Currency risks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Changes in exchange rates can lead to losses in the value of financial instruments and to adverse changes in future cash flows from planned transactions. Due to the current focus of the Company&#x2019;s business on Switzerland and Germany, there are currently primarily&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Currency risks from the CHF to EUR exchange rate. Based on the transactions planned to date and the existing financial instruments, the effect of an exchange rate change of +/- 10% is expected to be around +/-300,000 estimated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="text-decoration: underline"&gt;Interest rate risks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Interest rate risks exist due to potential changes in market interest rates and can lead to a change in the fair value of fixed interest financial instruments and fluctuations in interest payments for variable-interest financial instruments. The following table shows that there is currently no significant interest rate risk for the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="text-decoration: underline"&gt;Cluster risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company holds its cash and cash equivalents at various commercial banks with at least an A rating.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Categories of financial instruments:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialInstrumentsTableTextBlock_zmZzFGoGnTg4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Disclosures on financial instruments Capital risk management (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B3_zYJBVhiQgXm3" style="display: none"&gt;Schedule of financial instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20251231_zi4FcArcb6T" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_zYC7YSro2Le3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Financial assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--CashAndCashEquivalents_iI_z30cODTnYYZ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,613,989&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;5,362,638&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--FinancialAssetsAtAmortisedCost_iI_zvyIXTC8F33a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Financial assets measured at amortized cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,270,594&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;243,688&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20251231_zar8mid2NO6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20241231_zoCzOoHRwvpc" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Financial liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--FinancialLiabilitiesAtAmortisedCost_iI_z20HXVMiJxk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Financial liabilities measured at amortized cost&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,681,092&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;587,389&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWgPlVGfGLC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DisclosuresOnFinancialInstrumentsCapitalRiskManagementExplanatory>
    <cik0002079109:ScheduleOfFinancialInstrumentsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001218">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialInstrumentsTableTextBlock_zmZzFGoGnTg4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Disclosures on financial instruments Capital risk management (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B3_zYJBVhiQgXm3" style="display: none"&gt;Schedule of financial instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20251231_zi4FcArcb6T" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_zYC7YSro2Le3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Financial assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--CashAndCashEquivalents_iI_z30cODTnYYZ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,613,989&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;5,362,638&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--FinancialAssetsAtAmortisedCost_iI_zvyIXTC8F33a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Financial assets measured at amortized cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,270,594&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;243,688&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cik0002079109:ScheduleOfFinancialInstrumentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001220"
      unitRef="CHF">1613989</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001221"
      unitRef="CHF">5362638</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001223"
      unitRef="CHF">1270594</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001224"
      unitRef="CHF">243688</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="AsOf2025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001226"
      unitRef="CHF">2681092</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="AsOf2024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001227"
      unitRef="CHF">587389</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001229">&lt;p id="xdx_80B_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zJVrXJpCFuJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;13. &lt;span id="xdx_829_zd4XjPqtygze"&gt;Fair value measurement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;A fair value measurement of a non-financial asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The carrying amounts of the financial assets and financial liabilities approximate their fair values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The fair values of cash and cash equivalents, prepaid assets, accounts payable and accrued expenses are estimated to approximate the carrying values as of December&#160;31, 2025 and 2024, due to the short maturities of such instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis on December&#160;31, 2025 and December&#160;31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOnARecurringBasisTableTextBlock_zmzNo4q8xEHi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair value measurement (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B1_zfhFPj3bIOR5" style="display: none"&gt;Schedule of liabilities that are measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;SARs &lt;br/&gt; (Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;SARs liability, January&#160;1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_z6d0Os5BUoC5" style="width: 9%; text-align: right" title="Fair value liability, beginning"&gt;17,784,920&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Share based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensations_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zPhBgxtytL2a" style="text-align: right" title="Share based compensation"&gt;7,248,741&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--FairValueAdjustment_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_z2H28OaRWrKb" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;8,159,132&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;SARs liability, December&#160;31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zoxyUbMpwU4g" style="text-align: right" title="Fair value liability, beginning"&gt;33,192,793&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Share based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensations_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zKfeLJPhlSMi" style="text-align: right" title="Share based compensation"&gt;15,795,532&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--FairValueAdjustment_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_z5dKHqfONnod" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;22,761,218&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;SARs liability, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FinancialLiabilitiesAtFairValue_iE_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zvXztfLYQdH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value liability, ending"&gt;71,749,543&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Contingent liability&lt;br/&gt; (Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Contingent liability, January&#160;1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zF5PofvHbN3j" style="width: 9%; text-align: right" title="Fair value liability, beginning"&gt;1,625,167&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--FairValueAdjustment_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zbTsSFs9Adyi" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;474,538&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Contingent liability, December&#160;31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zxb8UJeyzg7d" style="text-align: right" title="Fair value liability, beginning"&gt;2,099,705&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FairValueAdjustment_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zqFDjzo0xyV1" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;799,168&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Contingent liability, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FinancialLiabilitiesAtFairValue_iE_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zpJrxo0NPTX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value liability, ending"&gt;2,898,873&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A7_zzrys6KfD4U5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Below are the key assumptions used in valuing the SARs and contingent liability:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfSARsAndContingentLiabilityTableTextBlock_zh1p9tjnPDgh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair value measurement (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BA_zXK2wKUTEsgf" style="display: none"&gt;Schedule of assumptions used in valuing the SARs and contingent liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Stock Price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--StockPrice_c20250101__20251231_zJzxLIB30zvb" title="Stock price"&gt;54.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--StockPrice_c20240101__20241231_zlRhQjAaV4L7" title="Stock price"&gt;36.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_dp_c20250101__20251231_zchYcKfL8Jgk" title="Volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1264"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_dp_c20240101__20241231_zpN8wbesLgq" title="Volatility"&gt;75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Risk free rate of return&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20250101__20251231_zw1A6vB5ri69" title="Risk free rate of retturn"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20240101__20241231_z8oJ5KsYb3d3" title="Risk free rate of retturn"&gt;4.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--DescriptionOfExpectedLifeOfWarrant_dtY_c20240101__20241231_zxf2MQod9hIg" title="Expected term (in years)"&gt;1.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; 

&lt;p id="xdx_8A7_zxdijoZa1Bee" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;There were no transfers between Levels 1, 2 or 3 during the years ended December&#160;31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2025, the Company utilized the most recent observable stock purchase price from arm&#x2019;s-length transactions involving the Company&#x2019;s common stock to estimate the fair value of its common stock and stock options. Management determined that the latest transaction price represented the best available indicator of fair value as it reflected contemporaneous market participant assumptions and pricing obtained in connection with third-party equity financings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2024, the Company utilized a third-party valuation specialist to calculate the fair value of Veraxa&#x2019;s options and common stock. Veraxa&#x2019;s options were valued using an intrinsic value calculation where the value of each option was calculated as the fair value of common stock less the exercise price, weighted between a &#x201c;stay private&#x201d; scenario and a &#x201c;DeSPAC&#x201d; scenario.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The &#x201c;stay private&#x201d; scenario was calculated using both an income approach (i. e. discounted cash flow method) and a market approach (i.e. a market roll-forward of the implied (back solved) equity value based on latest third-party financings from August&#160;23, 2024). Some of the more significant assumptions utilized in the discounted cash flow method included projected revenues, probability of commercial success, and the discount rate. The fair value using the discounted cash flow method was determined using an estimated weighted average cost of capital of &lt;span id="xdx_90D_ecustom--WeightedAverageCostOfCapital_dp_c20250101__20251231_zRCBrg0eLjsk" title="Weighted average cost of capital"&gt;25.5&lt;/span&gt;% in the &#x201c;stay-private&#x201d; scenario, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. As of December&#160;31, 2025, there was no change to approach for stay private scenario.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The &#x201c;DeSPAC&#x201d; scenario was calculated using the DeSPAC term sheet or non-binding letter of interest (&#x201c;LOI&#x201d;) dated February&#160;28, 2025, noting that this letter was known or knowable as of December&#160;31, 2024. As of December&#160;31, 2025 the valuation was updated for the DeSPAC signing of the Business Combination and probability of the DeSPAC occurring based off market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;This fair value measurement was based on significant inputs not observable in the market and thus represent Level 3 fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <cik0002079109:ScheduleOfFairValueOnARecurringBasisTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001232">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfFairValueOnARecurringBasisTableTextBlock_zmzNo4q8xEHi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair value measurement (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B1_zfhFPj3bIOR5" style="display: none"&gt;Schedule of liabilities that are measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;SARs &lt;br/&gt; (Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;SARs liability, January&#160;1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_z6d0Os5BUoC5" style="width: 9%; text-align: right" title="Fair value liability, beginning"&gt;17,784,920&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Share based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensations_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zPhBgxtytL2a" style="text-align: right" title="Share based compensation"&gt;7,248,741&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--FairValueAdjustment_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_z2H28OaRWrKb" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;8,159,132&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;SARs liability, December&#160;31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zoxyUbMpwU4g" style="text-align: right" title="Fair value liability, beginning"&gt;33,192,793&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Share based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensations_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zKfeLJPhlSMi" style="text-align: right" title="Share based compensation"&gt;15,795,532&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--FairValueAdjustment_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_z5dKHqfONnod" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;22,761,218&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;SARs liability, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--FinancialLiabilitiesAtFairValue_iE_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--SARsLiabilityMember_zvXztfLYQdH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value liability, ending"&gt;71,749,543&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Contingent liability&lt;br/&gt; (Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Contingent liability, January&#160;1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zF5PofvHbN3j" style="width: 9%; text-align: right" title="Fair value liability, beginning"&gt;1,625,167&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--FairValueAdjustment_c20240101__20241231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zbTsSFs9Adyi" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;474,538&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Contingent liability, December&#160;31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--FinancialLiabilitiesAtFairValue_iS_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zxb8UJeyzg7d" style="text-align: right" title="Fair value liability, beginning"&gt;2,099,705&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Fair value adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--FairValueAdjustment_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zqFDjzo0xyV1" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"&gt;799,168&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Contingent liability, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--FinancialLiabilitiesAtFairValue_iE_c20250101__20251231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--Level3OfFairValuesHierarchyMember__ifrs-full--ClassesOfLiabilitiesAxis__custom--ContingentLiabilityMember_zpJrxo0NPTX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value liability, ending"&gt;2,898,873&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfFairValueOnARecurringBasisTableTextBlock>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AsOf2023-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001234"
      unitRef="CHF">17784920</ifrs-full:FinancialLiabilitiesAtFairValue>
    <cik0002079109:ShareBasedCompensations
      contextRef="From2024-01-012024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001236"
      unitRef="CHF">7248741</cik0002079109:ShareBasedCompensations>
    <cik0002079109:FairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001238"
      unitRef="CHF">8159132</cik0002079109:FairValueAdjustment>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AsOf2024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001240"
      unitRef="CHF">33192793</ifrs-full:FinancialLiabilitiesAtFairValue>
    <cik0002079109:ShareBasedCompensations
      contextRef="From2025-01-012025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001242"
      unitRef="CHF">15795532</cik0002079109:ShareBasedCompensations>
    <cik0002079109:FairValueAdjustment
      contextRef="From2025-01-012025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001244"
      unitRef="CHF">22761218</cik0002079109:FairValueAdjustment>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AsOf2025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_SARsLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001246"
      unitRef="CHF">71749543</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AsOf2023-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001248"
      unitRef="CHF">1625167</ifrs-full:FinancialLiabilitiesAtFairValue>
    <cik0002079109:FairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001250"
      unitRef="CHF">474538</cik0002079109:FairValueAdjustment>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AsOf2024-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001252"
      unitRef="CHF">2099705</ifrs-full:FinancialLiabilitiesAtFairValue>
    <cik0002079109:FairValueAdjustment
      contextRef="From2025-01-012025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001254"
      unitRef="CHF">799168</cik0002079109:FairValueAdjustment>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AsOf2025-12-31_custom_Level3OfFairValuesHierarchyMember_custom_ContingentLiabilityMember_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001256"
      unitRef="CHF">2898873</ifrs-full:FinancialLiabilitiesAtFairValue>
    <cik0002079109:ScheduleOfSARsAndContingentLiabilityTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001258">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfSARsAndContingentLiabilityTableTextBlock_zh1p9tjnPDgh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair value measurement (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BA_zXK2wKUTEsgf" style="display: none"&gt;Schedule of assumptions used in valuing the SARs and contingent liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Stock Price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--StockPrice_c20250101__20251231_zJzxLIB30zvb" title="Stock price"&gt;54.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--StockPrice_c20240101__20241231_zlRhQjAaV4L7" title="Stock price"&gt;36.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_dp_c20250101__20251231_zchYcKfL8Jgk" title="Volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1264"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_dp_c20240101__20241231_zpN8wbesLgq" title="Volatility"&gt;75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Risk free rate of return&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20250101__20251231_zw1A6vB5ri69" title="Risk free rate of retturn"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20240101__20241231_z8oJ5KsYb3d3" title="Risk free rate of retturn"&gt;4.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--DescriptionOfExpectedLifeOfWarrant_dtY_c20240101__20241231_zxf2MQod9hIg" title="Expected term (in years)"&gt;1.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; 

</cik0002079109:ScheduleOfSARsAndContingentLiabilityTableTextBlock>
    <cik0002079109:StockPrice
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001260"
      unitRef="CHFShares">54.60</cik0002079109:StockPrice>
    <cik0002079109:StockPrice
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001262"
      unitRef="CHFShares">36.44</cik0002079109:StockPrice>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.75</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001270"
      unitRef="Pure">0.042</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <cik0002079109:DescriptionOfExpectedLifeOfWarrant
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001272">P1Y</cik0002079109:DescriptionOfExpectedLifeOfWarrant>
    <cik0002079109:WeightedAverageCostOfCapital
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001275"
      unitRef="Pure">0.255</cik0002079109:WeightedAverageCostOfCapital>
    <cik0002079109:DisclosureOfLossPerShareExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001277">&lt;p id="xdx_805_ecustom--DisclosureOfLossPerShareExplanatory_zbnj52nWMPbh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;14. &lt;span id="xdx_82B_zfO8rfOpA4Ul"&gt;Loss per share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For the years ended December&#160;31, 2025 and 2024, basic and diluted loss per share are identical, as the inclusion of all potential ordinary shares would be antidilutive due to the loss incurred for the periods. The following table sets forth the computation of basic and diluted loss per share:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfBasicAndDilutedLossPerShareTableTextBlock_zJTwDx7cZ9bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Loss per share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B5_zfnlDQ2FRn98" style="display: none"&gt;Schedule of antidilutive due to the loss incurred for the periods&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20251231_z8WJddDQhJDl" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240101__20241231_z7Hk2HkEUJT2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NumeratorAbstract_iB_zgUdh5ZuaYX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_zGRMVsRzRQce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Net loss available to common shareholders&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(66,613,990&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,132,971&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DenominatorAbstract_iB_zEPKaTbAin11" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average common shares outstanding used in computing loss per share available to common stockholders, basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_909_ecustom--WeightedaverageSharesOutstandingBasic_c20250101__20251231_zhYzUQsxxhhl" title="Weighted-average shares outstanding, basic"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_903_ecustom--WeightedaverageSharesOutstandingDiluted_c20250101__20251231_z5FHyEmAwCCh" title="Weighted-average shares outstanding, diluted"&gt;14,474,974&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_90B_ecustom--WeightedaverageSharesOutstandingBasic_c20240101__20241231_zOtPcVroZWZ5" title="Weighted-average shares outstanding, basic"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_908_ecustom--WeightedaverageSharesOutstandingDiluted_c20240101__20241231_zjFit2DDwDdj" title="Weighted-average shares outstanding, diluted"&gt;14,051,547&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_90D_eifrs-full--BasicEarningsLossPerShare_c20250101__20251231_zFGd1LqfQ6F" title="Basic earnings per share"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_902_eifrs-full--DilutedEarningsLossPerShare_c20250101__20251231_zj2MxA557Vv3" title="Diluted earnings per share"&gt;(4.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_90C_eifrs-full--BasicEarningsLossPerShare_c20240101__20241231_zj8JNNq3z7Ga" title="Basic earnings per share"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_c20240101__20241231_zUp9WF2hBTCg" title="Diluted earnings per share"&gt;(2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As of December&#160;31, 2025 and 2024, no options were outstanding under the ESOP (Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</cik0002079109:DisclosureOfLossPerShareExplanatory>
    <cik0002079109:ScheduleOfBasicAndDilutedLossPerShareTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001279">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfBasicAndDilutedLossPerShareTableTextBlock_zJTwDx7cZ9bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Loss per share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B5_zfnlDQ2FRn98" style="display: none"&gt;Schedule of antidilutive due to the loss incurred for the periods&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20251231_z8WJddDQhJDl" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240101__20241231_z7Hk2HkEUJT2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NumeratorAbstract_iB_zgUdh5ZuaYX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_zGRMVsRzRQce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Net loss available to common shareholders&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(66,613,990&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,132,971&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DenominatorAbstract_iB_zEPKaTbAin11" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average common shares outstanding used in computing loss per share available to common stockholders, basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_909_ecustom--WeightedaverageSharesOutstandingBasic_c20250101__20251231_zhYzUQsxxhhl" title="Weighted-average shares outstanding, basic"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_903_ecustom--WeightedaverageSharesOutstandingDiluted_c20250101__20251231_z5FHyEmAwCCh" title="Weighted-average shares outstanding, diluted"&gt;14,474,974&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_90B_ecustom--WeightedaverageSharesOutstandingBasic_c20240101__20241231_zOtPcVroZWZ5" title="Weighted-average shares outstanding, basic"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_908_ecustom--WeightedaverageSharesOutstandingDiluted_c20240101__20241231_zjFit2DDwDdj" title="Weighted-average shares outstanding, diluted"&gt;14,051,547&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_90D_eifrs-full--BasicEarningsLossPerShare_c20250101__20251231_zFGd1LqfQ6F" title="Basic earnings per share"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_902_eifrs-full--DilutedEarningsLossPerShare_c20250101__20251231_zj2MxA557Vv3" title="Diluted earnings per share"&gt;(4.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_90C_eifrs-full--BasicEarningsLossPerShare_c20240101__20241231_zj8JNNq3z7Ga" title="Basic earnings per share"&gt;&lt;span class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVCBPRiBMT1NTIEFORCBPVEhFUiBDT01QUkVIRU5TSVZFIExPU1MA" id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_c20240101__20241231_zUp9WF2hBTCg" title="Diluted earnings per share"&gt;(2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cik0002079109:ScheduleOfBasicAndDilutedLossPerShareTableTextBlock>
    <cik0002079109:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001284"
      unitRef="CHF">-66613990</cik0002079109:NetIncomeLossAvailableToCommonStockholderBasic>
    <cik0002079109:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001285"
      unitRef="CHF">-28132971</cik0002079109:NetIncomeLossAvailableToCommonStockholderBasic>
    <cik0002079109:WeightedaverageSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001290"
      unitRef="Shares">14474974</cik0002079109:WeightedaverageSharesOutstandingBasic>
    <cik0002079109:WeightedaverageSharesOutstandingDiluted
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001292"
      unitRef="Shares">14474974</cik0002079109:WeightedaverageSharesOutstandingDiluted>
    <cik0002079109:WeightedaverageSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001294"
      unitRef="Shares">14051547</cik0002079109:WeightedaverageSharesOutstandingBasic>
    <cik0002079109:WeightedaverageSharesOutstandingDiluted
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001296"
      unitRef="Shares">14051547</cik0002079109:WeightedaverageSharesOutstandingDiluted>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001298"
      unitRef="CHFShares">-4.60</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001300"
      unitRef="CHFShares">-4.60</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001302"
      unitRef="CHFShares">-2.00</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001304"
      unitRef="CHFShares">-2.00</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DisclosureOfCommitmentsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001306">&lt;p id="xdx_80E_eifrs-full--DisclosureOfCommitmentsExplanatory_zB8mLvRxtVJa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;15. &lt;span id="xdx_82F_z9XrSimUbkD5"&gt;Commitments and contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In the opinion of the Executive team, the Company did not have any contingencies as of December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

 

 

</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001309">&lt;p id="xdx_806_eifrs-full--DisclosureOfEntitysReportableSegmentsExplanatory_z3m0NTrse5Pk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;16. &lt;span id="xdx_828_z0qWrDx37oj2"&gt;Segment disclosures&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company operates in one reportable segment, focused on the research and development of products for the aging population. This segment is identified based on how the Company&#x2019;s chief operating decision maker (CODM) reviews performance and allocates resources.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The financial results of the Company&#x2019;s single segment are measured based on: research and development (R&amp;amp;D) expenses, including personnel costs, clinical trials, and regulatory filings; grant funding and partnership revenue, when applicable; general and administrative cost, which support operational infrastructure; finance costs, including loan interest and transaction fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As per IFRS 8 guidance and the July&#160;2024 IFRIC agenda decision, the Company discloses material income and expense items that contribute to the assessment of segment performance, even if they are not separately reviewed by the CODM.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--ScheduleOfDisclosesMaterialIncomeAndExpenseTableTextBlock_z2aNBvODkssb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment disclosures (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BA_zJyKEIqnYHok" style="display: none"&gt;&#160;Schedule of contribute to the assessment of segment performance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20251231_zpHn9fnUMji" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240101__20241231_zT1LixrWKQZ2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the &lt;br/&gt; years ended &lt;br/&gt; December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_zvDh7rIZ11B9" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;23,426&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--CostOfSales_iN_di_zhZvXS2z97V7" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cost of goods sold&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,965&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--GrossProfit_pp0d_zdn616d0Eo1j" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Gross profit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,461&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--GeneralAndAdministrativeExpense_iN_pp0d_di_zR8aVKwJGICi" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(46,922,232&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17,095,133&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--ResearchAndDevelopmentExpense_iN_pp0d_di_zK4ibLezpXB" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(10,264,123&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,310,608&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--SalesAndMarketingExpense_iN_pp0d_di_zHTcG9RUG5Eg" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Sales and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,948,456&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,635,658&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DepreciationAndAmortisationExpenses_iN_pp0d_di_zWYzChGQ53Of" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Depreciation and amortization expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,097,225&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,876,482&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--OperatingLoss_pp0d_zWYWd7Komdcl" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Operating loss&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(66,216,575&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,917,881&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; 

</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <cik0002079109:ScheduleOfDisclosesMaterialIncomeAndExpenseTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001311">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--ScheduleOfDisclosesMaterialIncomeAndExpenseTableTextBlock_z2aNBvODkssb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment disclosures (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8BA_zJyKEIqnYHok" style="display: none"&gt;&#160;Schedule of contribute to the assessment of segment performance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20251231_zpHn9fnUMji" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240101__20241231_zT1LixrWKQZ2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the &lt;br/&gt; years ended &lt;br/&gt; December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_zvDh7rIZ11B9" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;23,426&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--CostOfSales_iN_di_zhZvXS2z97V7" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cost of goods sold&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,965&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--GrossProfit_pp0d_zdn616d0Eo1j" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Gross profit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,461&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--GeneralAndAdministrativeExpense_iN_pp0d_di_zR8aVKwJGICi" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(46,922,232&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17,095,133&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--ResearchAndDevelopmentExpense_iN_pp0d_di_zK4ibLezpXB" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(10,264,123&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,310,608&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--SalesAndMarketingExpense_iN_pp0d_di_zHTcG9RUG5Eg" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Sales and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,948,456&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,635,658&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DepreciationAndAmortisationExpenses_iN_pp0d_di_zWYzChGQ53Of" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Depreciation and amortization expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,097,225&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,876,482&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--OperatingLoss_pp0d_zWYWd7Komdcl" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;Operating loss&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(66,216,575&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#x20a3;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,917,881&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</cik0002079109:ScheduleOfDisclosesMaterialIncomeAndExpenseTableTextBlock>
    <ifrs-full:Revenue
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001313"
      unitRef="CHF">23426</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001316"
      unitRef="CHF">7965</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001319"
      unitRef="CHF">15461</ifrs-full:GrossProfit>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001322"
      unitRef="CHF">46922232</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001323"
      unitRef="CHF">17095133</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001325"
      unitRef="CHF">10264123</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001326"
      unitRef="CHF">6310608</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001328"
      unitRef="CHF">6948456</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001329"
      unitRef="CHF">3635658</ifrs-full:SalesAndMarketingExpense>
    <cik0002079109:DepreciationAndAmortisationExpenses
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001331"
      unitRef="CHF">2097225</cik0002079109:DepreciationAndAmortisationExpenses>
    <cik0002079109:DepreciationAndAmortisationExpenses
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001332"
      unitRef="CHF">1876482</cik0002079109:DepreciationAndAmortisationExpenses>
    <cik0002079109:OperatingLoss
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001334"
      unitRef="CHF">-66216575</cik0002079109:OperatingLoss>
    <cik0002079109:OperatingLoss
      contextRef="From2024-01-012024-12-31_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001335"
      unitRef="CHF">-28917881</cik0002079109:OperatingLoss>
    <cik0002079109:DisclosureOfEventsOccurringAfterTheReportingDateExplanatory
      contextRef="From2025-01-012025-12-31_custom_VeraxaBiotechAGMember"
      id="Fact001337">&lt;p id="xdx_806_ecustom--DisclosureOfEventsOccurringAfterTheReportingDateExplanatory_zgL9mGQQb6H1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;17. &lt;span id="xdx_82C_zIt2WmwmRU2k"&gt;Events Occurring After the Reporting Date&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The consolidated financial statements were authorized for issue by the board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were issued, and determined that the following subsequent events required disclosure in the accompanying consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;High Trail Financing Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On May 27, 2026, SPAC, PubCo and High Trail Capital LP (&#x201c;&lt;b&gt;HTC&lt;/b&gt;&#x201d;) executed a Securities Purchase Agreement in respect of a private placement of a senior secured note in the principal amount of $&lt;span id="xdx_90E_ecustom--PrincipalAmount_iI_c20260527_zmHt2m96XAzg" title="Principal amount"&gt;27,500,000&lt;/span&gt; (the &#x201c;&lt;b&gt;Note&lt;/b&gt;&#x201d;) and a four-year warrant for an aggregate exercise price of $&lt;span id="xdx_904_ecustom--AggregateExercisePrice_iI_pn3n3_dm_c20260527_zcGe7SXNrZAf" title="Aggregate exercise price"&gt;27.5&lt;/span&gt; million, with an initial exercise price of $&lt;span id="xdx_904_ecustom--InitialExercisePrice_iI_c20260527_zOIzF1enq9od" title="Initial exercise price"&gt;11.50&lt;/span&gt; per share (with customary anti-dilution protections) (the &#x201c;&lt;b&gt;HTC Financing&lt;/b&gt;&#x201d;). The closing of the HTC Financing occurred on June&#160;15, 2026. The term of the Note is 15 months, amortizing monthly beginning six months after the closing of the HTC Financing. At PubCo&#x2019;s sole option and subject to customary conditions, any amortization payment may be made in cash, in registered-for-resale shares of common stock, or a combination thereof. The Note is a senior secured obligation of PubCo, secured by all PubCo assets and ranking senior to all other PubCo obligations. Funding occurred concurrently with the closing of the HTC Financing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt; 

 



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;LPC Purchase Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 27, 2026, Voyager, PubCo and Lincoln Park Capital Fund, LLC (&#x201c;&lt;b&gt;Lincoln Park&lt;/b&gt;&#x201d;) entered into a purchase agreement (the &#x201c;&lt;b&gt;LPC Purchase Agreement&lt;/b&gt;&#x201d;) and a related registration rights agreement (together, the &#x201c;&lt;b&gt;LPC Agreements&lt;/b&gt;&#x201d;), pursuant to which Lincoln Park committed to purchase, at PubCo&#x2019;s sole direction from time to time over a 24-month period, up to an aggregate of $50,000,000 of PubCo Ordinary Shares at market-based purchase prices, subject to certain conditions and limitations, including a 4.99% beneficial ownership cap (increasable to 9.99% upon 61 days&#x2019; prior written notice) (the &#x201c;&lt;b&gt;LPC Financing&lt;/b&gt;&#x201d;). As consideration for Lincoln Park&#x2019;s commitment, PubCo shall issue to Lincoln Park $750,000 of PubCo Ordinary Shares (the &#x201c;&lt;b&gt;Commitment Shares&lt;/b&gt;&#x201d;), subject to the occurrence of the Merger Closing. PubCo has the right to terminate the LPC Purchase Agreement at any time after the commencement date with one business day&#x2019;s prior written notice to Lincoln Park, at no cost or penalty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;CF&amp;amp;CO Fee Modification Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 27, 2026, Voyager, PubCo and Cantor Fitzgerald
&amp;amp; Co. (&#x201c;&lt;b&gt;CF&amp;amp;CO&lt;/b&gt;&#x201d;) executed a Fee Modification Agreement (the &#x201c;&lt;b&gt;Fee Modification Agreement&lt;/b&gt;&#x201d;),
pursuant to which the parties agreed to modify the payment terms of the $12,045,000 deferred underwriting commission (the &#x201c;&lt;b&gt;Original
Deferred Fee&lt;/b&gt;&#x201d;) owed to CF&amp;amp;CO under the Underwriting Agreement dated August 8, 2024 (the &#x201c;&lt;b&gt;CF&amp;amp;CO Fee Modification&lt;/b&gt;&#x201d;).
Under the Fee Modification Agreement, the Original Deferred Fee was replaced with a modified deferred fee consisting of (i) a cash fee
of $1,000,000 ($500,000 payable at the Closing and $500,000 payable on or prior to the one-year anniversary of the Closing) and (ii)
$7,000,000 in shares of PubCo common stock (the &#x201c;&lt;b&gt;CF&amp;amp;CO Fee Shares&lt;/b&gt;&#x201d;), payable in two tranches ($2,300,000 no later
than 30 days following the Closing and $4,700,000 no later than 90 days following the Closing), with the number of CF&amp;amp;CO Fee Shares
determined based on the greater of $10.00 per share and the five-day VWAP preceding the applicable registration statement filing date.
The CF&amp;amp;CO Fee Shares are subject to a lock-up period ending on the earlier of 12 months after the Closing or the consummation of
a subsequent transaction resulting in a liquidity event for stockholders. In the event of a default by PubCo under the Fee Modification
Agreement, CF&amp;amp;CO may elect to receive the entire Original Deferred Fee in cash, less amounts previously paid or the fair market value
of any freely tradeable CF&amp;amp;CO Fee Shares previously received.&lt;/p&gt;



</cik0002079109:DisclosureOfEventsOccurringAfterTheReportingDateExplanatory>
    <cik0002079109:PrincipalAmount
      contextRef="AsOf2026-05-27_custom_VeraxaBiotechAGMember"
      decimals="0"
      id="Fact001339"
      unitRef="CHF">27500000</cik0002079109:PrincipalAmount>
    <cik0002079109:AggregateExercisePrice
      contextRef="AsOf2026-05-27_custom_VeraxaBiotechAGMember"
      decimals="-3"
      id="Fact001341"
      unitRef="CHF">27500000</cik0002079109:AggregateExercisePrice>
    <cik0002079109:InitialExercisePrice
      contextRef="AsOf2026-05-27_custom_VeraxaBiotechAGMember"
      decimals="INF"
      id="Fact001343"
      unitRef="CHFShares">11.50</cik0002079109:InitialExercisePrice>
</xbrl>
